# EDGAR Filing Document

**Accession Number:** 0001418076
**File Stem:** 0001193125-25-264654
**Filing Date:** 2025-11
**Character Count:** 362007
**Document Hash:** d34ddcc7e221bef8c9359aa39d037e46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-264654.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001193125-25-264654

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 87

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SLR Investment Corp.
- **CENTRAL INDEX KEY:** 0001418076

**ORGANIZATION NAME:**
- **EIN:** 261381340
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 814-00754
- **FILM NUMBER:** 251448978

**BUSINESS ADDRESS:**
- **STREET 1:** 500 PARK AVENUE
- **STREET 2:** 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (212) 993-1670

**MAIL ADDRESS:**
- **STREET 1:** 500 PARK AVENUE
- **STREET 2:** 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Solar Capital Ltd.
- **DATE OF NAME CHANGE:** 20071109

?xml version='1.0' encoding='ASCII'? 10-Q

[**<u>**Table of Contents**</u>**](#toc_page)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM** 10-Q

------

☒ **Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**For the Quarter Ended** **September 30,** 2025

☐ **Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Commission File Number:** 814-00754

------

SLR INVESTMENT CORP.

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| Maryland | 26-1381340 |
| **(State of Incorporation)** | **(I.R.S. Employer**<br>**Identification No.)** |
| 500 Park Avenue<br>New York**,** N.Y**.** | 10022 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(**212**)** 993-1670

**(Registrant's telephone number, including area code)** 

------

**Securities registered pursuant to Section 12(b) of the Act:** 

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading**<br>**Symbol(s)** | **Name of Each Exchange**<br>**on Which Registered** |
| Common Stock, par value $0.01 per share | SLRC | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No☒

The number of shares of the registrant's Common Stock, $0.01 par value, outstanding as of October 31, 2025 was 54,554,634.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025** 

**TABLE OF CONTENTS** 

---

| | | |
|:---|:---|:---|
|  |  | **PAGE** |
| [**<u>PART I. FINANCIAL INFORMATION</u>**](#part_i) | [**<u>PART I. FINANCIAL INFORMATION</u>**](#part_i) |  |
| Item 1. | [<u>Financial Statements</u>](#item1_i) |  |
|  | [<u>Consolidated Statements of Assets and Liabilities as of September 30, 2025 (unaudited) and December 31, 2024</u>](#stmt_of_assets_and_liabilities) | 3 |
|  | [<u>Consolidated Statements of Operations for the three and nine months ended September 30, 2025 (unaudited) and the three and nine months ended September 30, 2024 (unaudited)</u>](#statements_of_operations_unaudited) | 4 |
|  | [<u>Consolidated Statements of Changes in Net Assets for the three and nine months ended September 30, 2025 (unaudited) and the three and nine months ended September 30, 2024 (unaudited)</u>](#changes_in_net_assets_unaudited) | 5 |
|  | [<u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 (unaudited) and the nine months ended September 30, 2024 (unaudited)</u>](#cash_flows_unaudited) | 6 |
|  | [<u>Consolidated Schedule of Investments as of September 30, 2025 (unaudited)</u>](#soi_march31_unaudited) | 7 |
|  | [<u>Consolidated Schedule of Investments as of December 31, 2024</u>](#soi_dec31_unaudited) | 15 |
|  | [<u>Notes to Consolidated Financial Statements (unaudited)</u>](#notes_to_cons_financial_stmt_unaudited) | 23 |
|  | [<u>Report of Independent Registered Public Accounting Firm</u>](#report_independent_reg_public_accou_firm) | 47 |
| Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#mda) | 48 |
| Item 3. | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#item_3) | 69 |
| Item 4. | [<u>Controls and Procedures</u>](#item_4) | 70 |
| [**<u>PART II. OTHER INFORMATION</u>**](#partii_other_information) | [**<u>PART II. OTHER INFORMATION</u>**](#partii_other_information) |  |
| Item 1. | [<u>Legal Proceedings</u>](#item1_ii) | 71 |
| Item 1A. | [<u>Risk Factors</u>](#item1a_ii) | 71 |
| Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item2_ii) | 71 |
| Item 3. | [<u>Defaults Upon Senior Securities</u>](#item3_ii) | 71 |
| Item 4. | [<u>Mine Safety Disclosures</u>](#item4_ii) | 71 |
| Item 5. | [<u>Other Information</u>](#item5_ii) | 71 |
| Item 6. | [<u>Exhibits</u>](#item6_ii) | 72 |
|  | [<u>Signatures</u>](#signatures) | 73 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART I. FINANCIAL INFORMATION** 

In this Quarterly Report, "Company," "we," "us," and "our" refer to SLR Investment Corp. unless the context states otherwise.

**Item 1. Financial Statements** 

**SLR INVESTMENT CORP.** 

**CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES** 

**(in thousands, except share and per share amounts)** 

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025<br>(unaudited)** | **December 31,<br>2024** |
| **Assets** |  |  |
| Investments at fair value: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies less than 5% owned (cost: $1,119,909 and $1,019,357, respectively) | $1124029 | $1027457 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies 5% to 25% owned (cost: $107,962 and $103,655, respectively) | 94843 | 89945 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies more than 25% owned (cost: $910,367 and $916,554, respectively) | 886421 | 888232 |
| Cash | 21421 | 16761 |
| Cash equivalents (cost: $373,030 and $397,510, respectively) | 373030 | 397510 |
| Dividends receivable | 15807 | 15375 |
| Interest receivable | 13035 | 11993 |
| Receivable for investments sold | 122 | 1573 |
| Prepaid expenses and other assets | 1184 | 571 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $2529892 | $2449417 |
| **Liabilities** |  |  |
| Debt ($1,147,436 and $1,041,093 face amounts, respectively, reported net of<br> unamortized debt issuance costs of $8,474 and $9,399, respectively. See note 7) | $1138962 | $1031694 |
| Payable for investments and cash equivalents purchased | 373335 | 397510 |
| Management fee payable (see note 3) | 7977 | 7739 |
| Performance-based incentive fee payable (see note 3) | 5391 | 5920 |
| Interest payable (see note 7) | 6762 | 7836 |
| Administrative services payable (see note 3) | 1757 | 3332 |
| Other liabilities and accrued expenses | 2421 | 2460 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | $1536605 | $1456491 |
| Commitments and contingencies (see note 9) |  |  |
| **Net Assets** |  |  |
| Common stock, par value $0.01 per share, 200,000,000 and 200,000,000 common shares<br> authorized, respectively, and 54,554,634 and 54,554,634 shares issued and<br> outstanding, respectively | $546 | $546 |
| Paid-in capital in excess of par | 1117606 | 1117606 |
| Accumulated distributable net loss | (124865) | (125226) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total net assets** | $993287 | $992926 |
| **Net Asset Value Per Share** | $18.21 | $18.20 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)** 

**(in thousands, except share and per share amounts)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| **INVESTMENT INCOME:** |  |  |  |  |
| Interest: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies less than 5% owned | $31711 | $41068 | $90047 | $122087 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies 5% to 25% owned | 1263 | 926 | 3730 | 2613 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies more than 25% owned | 3253 | 3379 | 9675 | 10023 |
| Dividends: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies 5% to 25% owned | 806 | 91 | 2362 | 91 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies more than 25% owned | 16174 | 12487 | 51770 | 37196 |
| Other income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies less than 5% owned | 3669 | 1688 | 6169 | 4446 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies more than 25% owned | 116 | 132 | 330 | 392 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investment income | 56992 | 59771 | 164083 | 176848 |
| **EXPENSES:** |  |  |  |  |
| Management fees (see note 3) | 7977 | 7893 | 23250 | 23650 |
| Performance-based incentive fees (see note 3) | 5403 | 6077 | 16326 | 18097 |
| Interest and other credit facility expenses (see note 7) | 18684 | 18913 | 51266 | 55280 |
| Administrative services expense (see note 3) | 1456 | 1392 | 4320 | 4144 |
| Other general and administrative expenses | 1859 | 1189 | 3616 | 3290 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 35379 | 35464 | 98778 | 104461 |
| Performance-based incentive fees waived (see note 3) | (13) | (41) | (35) | (131) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net expenses | 35366 | 35423 | 98743 | 104330 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net investment income | $21626 | $24348 | $65340 | $72518 |
| **REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS AND<br> CASH EQUIVALENTS:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gain (loss) on investments and cash equivalents (companies less than 5% owned) | $1323 | $(2748) | $1136 | $(2508) |
| Net change in unrealized gain (loss) on investments and cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies less than 5% owned | (2599) | (4027) | (3978) | (480) |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies 5% to 25% owned | 2533 | 3411 | 589 | 3412 |
| &nbsp;&nbsp;&nbsp;&nbsp;Companies more than 25% owned | 422 | 1065 | 4376 | 206 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized gain (loss) on investments and cash equivalents | 356 | 449 | 987 | 3138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments and cash equivalents | 1679 | (2299) | 2123 | 630 |
| **NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS** | $23305 | $22049 | $67463 | $73148 |
| **EARNINGS PER SHARE (see note 5)** | $0.43 | $0.40 | $1.24 | $1.34 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS (unaudited)** 

**(in thousands, except share amounts)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| **Increase (decrease) in net assets resulting from operations:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income | $21626 | $24348 | $65340 | $72518 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gain (loss) | 1323 | (2748) | 1136 | (2508) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized gain (loss) | 356 | 449 | 987 | 3138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase in net assets resulting from operations | 23305 | 22049 | 67463 | 73148 |
| **Distributions to stockholders:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;From net investment income | (21626) | (22367) | (65340) | (67102) |
| &nbsp;&nbsp;&nbsp;&nbsp;From return of capital | (741) |  | (1762) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net distributions to stockholders | (22367) | (22367) | (67102) | (67102) |
| Total increase (decrease) in net assets | 938 | (318) | 361 | 6046 |
| Net assets at beginning of period | 992349 | 993003 | 992926 | 986639 |
| Net assets at end of period | $993287 | $992685 | $993287 | $992685 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)** 

**(in thousands)** 

---

| | | |
|:---|:---|:---|
|  | **Nine months ended** | **Nine months ended** |
|  | **September 30, 2025** | **September 30, 2024** |
| **Cash Flows from Operating Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net increase in net assets resulting from operations** | $67463 | $73148 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net increase in net assets resulting from operations to <br> net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net realized (gain) loss on investments and cash equivalents | (1136) | 2508 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized (gain) loss on investments | (987) | (3138) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred financing costs/market discount amortization | 2269 | 2823 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net accretion of discount on investments | (5217) | (7251) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Increase) decrease in operating assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of investments | (803720) | (322116) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from disposition of investments | 715678 | 416342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization of payment-in-kind income | (5393) | (6064) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collections of payment-in-kind income | 1116 | 2457 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivable for investments sold | 1451 | (332) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest receivable | (1042) | 575 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends receivable | (432) | (383) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (613) | (163) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Increase (decrease) in operating liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payable for investments and cash equivalents purchased | (24175) | (9596) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management fee payable | 238 | (134) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance-based incentive fee payable | (529) | 172 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative services expense payable | (1575) | 533 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest payable | (1074) | (1232) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities and accrued expenses | (39) | (922) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Cash Provided by (Used in) Operating Activities** | (57717) | 147227 |
| **Cash Flows from Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash distributions paid | (67102) | (67102) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from unsecured borrowings | 174100 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayment of unsecured borrowings | (85000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from secured borrowings | 631056 | 333611 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayment of secured borrowings | (615157) | (412257) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Cash Provided by (Used in) Financing Activities** | 37897 | (145748) |
| **NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS** | (19820) | 1479 |
| **CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD** | 414271 | 344154 |
| **CASH AND CASH EQUIVALENTS AT END OF PERIOD** | $394451 | $345633 |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $50071 | $53689 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash purchase and disposition of investments |  | 27254 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited)** 

**September 30, 2025** 

**(in thousands, except share/unit amounts)** 

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(7)</sup> | **Floor** | **Interest<br>Rate**<sup>(1)</sup> | **Acquisition<br>Date** | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value** |
| **Senior Secured Loans — 126.0%** |  |  |  |  |  |  |  |  |  |
| <u>First Lien Bank Debt/Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| 33Across Inc. | Media | P+232 | 8.50% | 10.57% | 1/2024 | 10/2025 | $2152 | $2152 | $2152 |
| Alkeme Intermediary Holdings, LLC(16) | Insurance | S+500 | 1.00% | 9.00% | 9/2023 | 5/2027 | 17427 | 17144 | 17427 |
| All States Ag Parts, LLC(16) | Trading Companies & Distributors | S+650<sup>(12)</sup> | 1.00% | 10.76% | 4/2022 | 9/2026 | 2081 | 2071 | 2081 |
| BayMark Health Services, Inc.(16) | Health Care Providers & Services | S+500 | 1.00% | 9.26% | 4/2022 | 6/2027 | 8138 | 8010 | 7731 |
| Bayside Opco, LLC(24) | Health Care Providers & Services | S+725 | 1.00% | 11.40% | 5/2023 | 5/2026 | 19770 | 19770 | 19770 |
| Bayside Parent, LLC(24) | Health Care Providers & Services | S+1000<sup>(11)</sup> | 1.00% | 14.15% | 5/2023 | 5/2026 | 6691 | 6691 | 6691 |
| BDG Media, Inc. | Media | P+525 | 5.50% | 12.50% | 7/2022 | 7/2026 | 6339 | 6339 | 6339 |
| Blazing Star Parent, LLC(16) | Consumer Staples Distribution & Retail | S+700 | 1.00% | 11.20% | 8/2025 | 8/2030 | 16395 | 16154 | 16149 |
| CC SAG Holdings Corp.(Spectrum Automotive)(16) | Diversified Consumer Services | S+525 | 0.75% | 9.41% | 6/2021 | 6/2028 | 28830 | 28524 | 28830 |
| Clifford Loan Ventures, LLC & Clifford Preferred Ventures Holdings LLC(3) | Capital Markets | S+700<sup>(11)</sup> | 1.00% | 11.28% | 9/2025 | 9/2028 | 30000 | 29486 | 29475 |
| Copper River Seafoods, Inc. | Food Products | P+200 |  | 9.25% | 12/2023 | 4/2028 | 7453 | 7453 | 7453 |
| CVAUSA Management, LLC(16) | Health Care Providers & Services | S+525 | 1.00% | 9.39% | 5/2023 | 5/2029 | 18678 | 18459 | 18678 |
| DeepIntent, Inc. | Media | P+135 | 3.90% | 8.60% | 12/2023 | 9/2030 | 2383 | 2383 | 2383 |
| Enhanced Permanent Capital, LLC(3) | Capital Markets | S+650 | 1.00% | 10.94% | 12/2020 | 6/2026 | 55106 | 54797 | 55106 |
| EyeSouth Eye Care Holdco LLC(16) | Health Care Providers & Services | S+550 | 1.00% | 9.76% | 10/2022 | 10/2029 | 2228 | 2175 | 2228 |
| FE Advance, LLC & Sonic ACA Advance LLC(16) | Financial Services | S+650 | 1.00% | 10.79% | 7/2024 | 7/2027 | 20894 | 20614 | 20894 |
| Fertility (ITC) Investment Holdco, LLC | Health Care Providers & Services | S+650 | 1.00% | 10.62% | 1/2023 | 1/2029 | 22197 | 21780 | 22197 |
| Human Interest Inc.(16) | Professional Services | S+625 | 1.00% | 10.53% | 6/2022 | 7/2027 | 20104 | 20224 | 20104 |
| iCIMS, Inc.(16) | Software | S+575 | 0.75% | 10.06% | 8/2022 | 8/2028 | 25809 | 25583 | 25809 |
| Infillion Inc. | Professional Services | P+175 |  | 9.00% | 5/2025 | 4/2028 | 19288 | 19288 | 19288 |
| Insight Investments Holdings, LLC | Financial Services | S+625 | 1.00% | 10.55% | 6/2025 | 7/2026 | 25000 | 24907 | 25000 |
| Kingsbridge Holdings, LLC(2) | Multi-Sector Holdings | S+700 | 1.00% | 11.45% | 12/2018 | 12/2027 | 100500 | 100332 | 100500 |
| Logix Holding Company, LLC(16) | Communications Equipment | S+750<sup>(14)</sup> | 1.00% | 11.83% | 9/2018 | 12/2028 | 10393 | 10393 | 10393 |
| Luxury Asset Capital, LLC(16) | Consumer Finance | S+675 | 1.00% | 11.14% | 7/2022 | 7/2027 | 30500 | 30244 | 30500 |
| Lyneer Staffing Solutions, LLC | Professional Services | P+100 |  | 8.25% | 4/2025 | 4/2028 | 34057 | 34057 | 34057 |
| Maxor Acquisition, Inc.(16) | Health Care Providers & Services | S+600 | 1.00% | 10.26% | 3/2023 | 3/2029 | 19074 | 18716 | 19074 |
| NS and Associates LLC | Consumer Staples Distribution & Retail | S+525 | 1.00% | 9.50% | 8/2025 | 8/2030 | 8096 | 7978 | 7975 |
| One Touch Direct, LLC | Commercial Services & Supplies | P+75 | 4.00% | 8.00% | 12/2023 | 3/2027 | 4694 | 4694 | 4694 |
| ONS MSO, LLC(16) | Health Care Providers & Services | S+625 | 1.00% | 10.56% | 2/2023 | 7/2028 | 27631 | 27117 | 27631 |
| Pinnacle Fertility, Inc. | Health Care Providers & Services | S+500 | 0.75% | 9.27% | 3/2025 | 3/2028 | 981 | 948 | 981 |
| Plastic Management, LLC(16) | Health Care Providers & Services | S+500 | 1.00% | 9.00% | 4/2022 | 8/2027 | 22228 | 21761 | 22228 |
| Quantcast Corporation | Commercial Services & Supplies | S+525 | 2.00% | 9.42% | 6/2024 | 6/2029 | 8463 | 8376 | 8463 |
| RQM+ Corp.(16) | Life Sciences Tools & Services | S+675<sup>(23)</sup> | 1.00% | 11.01% | 8/2021 | 8/2029 | 24128 | 23849 | 21715 |
| Sherwood Management Co., Inc. | Specialty Retail | S+500 | 2.00% | 9.43% | 3/2025 | 3/2030 | 8161 | 8087 | 8161 |
| Shoes for Crews Global, LLC | Diversified Consumer Services | S+650<sup>(26)</sup> | 1.00% | 10.78% | 6/2024 | 6/2029 | 3421 | 3421 | 3421 |
| Sightly Enterprises, Inc. | Media | P+475 | 6.00% | 12.00% | 1/2024 | 12/2026 | 3809 | 3809 | 3809 |
| SLR Healthcare ABL (2)(3)(21) | Financial Services | S+650 |  | 10.73% | 6/2025 | 3/2026 | 1800 | 1800 | 1800 |
| Southern Lifting and Hoisting, LLC | Transportation Infrastructure | P+25 | 6.00% | 7.50% | 1/2025 | 1/2027 | 26935 | 26935 | 26935 |
| Southern Orthodontic Partners Management, LLC(16) | Health Care Providers & Services | S+550 | 1.00% | 9.50% | 6/2022 | 7/2026 | 32906 | 32674 | 32906 |
| Southern Transport LLC | Transportation Infrastructure | P+25 | 6.00% | 7.50% | 1/2025 | 1/2027 | 14408 | 14408 | 14408 |
| SPAR Marketing Force, Inc. | Media | P+190 |  | 9.15% | 12/2023 | 10/2025 | 13100 | 13100 | 13100 |
| Stella & Chewy's, LLC(16) | Consumer Staples Distribution & Retail | S+525 | 2.00% | 9.42% | 3/2025 | 3/2028 | 11978 | 11821 | 11978 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

**(in thousands, except share/unit amounts)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(7)</sup> | **Floor** | **Interest<br>Rate**<sup>(1)</sup> | **Acquisition<br>Date** | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value** |
| **Senior Secured Loans (continued)** |  |  |  |  |  |  |  |  |  |
| Streamland Media Holdings LLC | Professional Services | S+400 |  | 8.17% | 5/2025 | 5/2030 | $7563 | $7491 | $7563 |
| SunMed Group Holdings, LLC(16) | Health Care Equipment & Supplies | S+550 | 0.75% | 9.91% | 6/2021 | 6/2028 | 14713 | 14518 | 14713 |
| TAUC Management, LLC(16) | Health Care Providers & Services | S+700<sup>(27)</sup> | 1.00% | 11.15% | 4/2022 | 2/2027 | 6060 | 5962 | 5454 |
| The Townsend Company, LLC(16) | Commercial Services & Supplies | S+500 | 1.00% | 9.00% | 8/2023 | 8/2030 | 14064 | 13787 | 14064 |
| Tilley Distribution, Inc.(16) | Trading Companies & Distributors | S+600 | 1.00% | 10.15% | 4/2022 | 12/2026 | 3811 | 3748 | 3735 |
| TPC 2022, LLC | Capital Markets | S+650 | 1.00% | 10.79% | 12/2024 | 12/2027 | 20000 | 19846 | 20000 |
| United Digestive MSO Parent, LLC(16) | Health Care Providers & Services | S+575 | 1.00% | 9.75% | 3/2023 | 3/2029 | 9835 | 9637 | 9835 |
| Urology Management Holdings, Inc.(16) | Health Care Providers & Services | S+550 | 1.00% | 9.66% | 2/2023 | 6/2027 | 11818 | 11655 | 11818 |
| Velocity One, LLC | Aerospace & Defense | S+425 | 2.00% | 8.42% | 6/2025 | 6/2030 | 5250 | 5188 | 5250 |
| Western Veterinary Partners LLC(16) | Diversified Consumer Services | S+525 | 1.00% | 9.25% | 1/2024 | 10/2027 | 25947 | 25655 | 25947 |
| Wilbur-Ellis Holdings II, LLC | Fertilizer & Agricultural Chemicals | S+400 | 1.00% | 8.27% | 6/2025 | 6/2030 | 21786 | 21786 | 21786 |
| WMD Funding, LLC(11) | Financial Services |  |  | 11.50% | 12/2024 | 7/2031 | 20886 | 20886 | 20886 |
| Total First Lien Bank Debt/ Senior Secured Loans |  |  |  |  |  |  |  | $918683 | $921565 |
| <u>First Lien Life Science Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| Arcutis Biotherapeutics, Inc.(3) | Pharmaceuticals | S+595 | 2.50% | 10.20% | 12/2021 | 8/2029 | $33425 | $34936 | $36600 |
| Ardelyx, Inc.(3) | Pharmaceuticals | S+400<sup>(25)</sup> | 4.70% | 8.70% | 2/2022 | 7/2028 | 46398 | 47026 | 47094 |
| Centinel Spine, LLC(16) | Health Care Equipment & Supplies | S+530 | 4.35% | 9.65% | 2/2025 | 3/2030 | 22460 | 22389 | 22965 |
| Cerapedics, Inc. | Biotechnology | S+620 | 2.75% | 10.45% | 12/2022 | 1/2028 | 36156 | 36677 | 38833 |
| Cogent Biosciences, Inc.(3)(16) | Biotechnology | S+475 | 4.15% | 9.00% | 6/2025 | 6/2030 | 18717 | 18627 | 18623 |
| Meditrina, Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.75% | 12/2022 | 12/2027 | 3788 | 3908 | 4069 |
| OmniGuide Holdings, Inc. (13) | Health Care Equipment & Supplies | S+580 | 5.31% | 11.11% | 7/2018 | 5/2026 | 28665 | 30755 | 27948 |
| SPR Therapeutics, Inc. | Health Care Technology | S+515 | 4.00% | 9.40% | 1/2024 | 2/2029 | 7299 | 7338 | 7573 |
| Vapotherm, Inc.(24) | Health Care Equipment & Supplies | S+600 | 4.50% | 10.50% | 2/2022 | 9/2027 | 13782 | 14325 | 14357 |
| Total First Lien Life Science Senior Secured Loans |  |  |  |  |  |  |  | $215981 | $218062 |
| <u>Second Lien Asset-Based Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| AMF Levered II, LLC | Financial Services | S+705 | 1.00% | 11.39% | 12/2021 | 8/2028 | $29925 | $29774 | $29925 |
| FGI Worldwide LLC (16) | Financial Services | S+650 | 1.00% | 10.67% | 4/2023 | 4/2028 | 8206 | 8087 | 8206 |
| nFusion Capital Finance, LLC | Financial Services | S+725 | 1.00% | 11.54% | 7/2025 | 7/2028 | 35000 | 34586 | 34563 |
| Pasadena Private Lending Inc.(3) | Financial Services | S+750 | 1.00% | 11.77% | 12/2024 | 4/2028 | 12736 | 12604 | 12736 |
| WALCO Funding, LLC | Financial Services | S+785 | 1.00% | 12.01% | 6/2025 | 12/2028 | 20377 | 20047 | 20377 |
| Total Second Lien Asset-Backed Senior Secured Loans |  |  |  |  |  |  |  | $105098 | $105807 |
| <u>Second Lien Bank Debt / Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| RD Holdco, Inc.\*\* (2) | Diversified Consumer Services | S+975<sup>(11)</sup> | 1.00% |  | 12/2013 | 10/2026 | $18199 | $10272 | $5802 |
| **Total Senior Secured Loans** |  |  |  |  |  |  |  | $**1250034** | $**1251236** |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

**(in thousands, except share/unit amounts)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Interest<br>Rate**<sup>(1)</sup> | **Acquisition<br>Date** | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value** |
| **Equipment Financing — 12.3%** |  |  |  |  |  |  |  |
| A&A Crane and Rigging, LLC (10) | Commercial Services & Supplies | 7.78% | 3/2023 | 3/2028 | $43 | $43 | $43 |
| Air Methods Corporation (10) | Passenger Airlines | 7.08-7.13% | 11/2021 | 11/2026 | 2144 | 2155 | 2144 |
| Boart Longyear Company (10) | Metals & Mining | 8.31-9.06% | 5/2020 | 1/2026-10/2026 | 384 | 384 | 384 |
| Bowman Energy Solutions, LLC (10) | Commercial Services & Supplies | 7.42% | 7/2022 | 7/1/2026 | 39 | 39 | 39 |
| CKD Holdings, Inc. (10) | Ground Transportation | 8.10-8.60% | 9/2022 | 3/2026-9/2027 | 1068 | 1068 | 1068 |
| Complete Equipment Rentals, LLC (10) | Commercial Services & Supplies | 6.75-7.15% | 3/2023 | 4/2028-6/2028 | 1310 | 1298 | 1288 |
| Dongwon Autopart Technology Inc. (10) | Automobile Components | 7.96% | 2/2021 | 1/2026 | 170 | 170 | 170 |
| Double S Industrial Contractors, Inc. (10) | Commercial Services & Supplies | 8.60% | 7/2023 | 8/2027 | 63 | 63 | 63 |
| Environmental Protection & Improvement Company, LLC (10) | Ground Transportation | 8.25% | 9/2020 | 10/2027 | 3180 | 3188 | 3180 |
| First American Commercial Bancorp, Inc. (10) | Financial Services | 7.50-9.00% | 10/2021 | 10/2026-3/2027 | 993 | 993 | 993 |
| Hawkeye Contracting Company, LLC (10) | Construction & Engineering | 10.50% | 10/2021 | 11/2025 | 66 | 66 | 66 |
| No Limit Construction Services, LLC (10) | Commercial Services & Supplies | 7.73% | 5/2023 | 6/2028 | 77 | 77 | 77 |
| Rayzor's Edge LLC (10) | Diversified Consumer Services | 7.69-8.27% | 5/2023 | 5/2030-6/2030 | 553 | 553 | 553 |
| RH Land Construction, LLC & Harbor Dredging LA, Inc. (10) | Construction & Engineering | 8.08% | 5/2023 | 5/2026 | 34 | 34 | 34 |
| Rotten Rock Hardscaping & Tree Service (10) | Diversified Consumer Services | 8.21% | 12/2022 | 12/2027 | 123 | 123 | 123 |
| SLR Equipment Finance (2)(9)(17) | Multi-Sector Holdings | 8.50% | 12/2024 | 7/2026 | 7500 | 7500 | 7500 |
| Smiley Lifting Solutions, LLC(10) | Commercial Services & Supplies | 7.82-8.61% | 6/2022 | 9/2026-6/2030 | 4592 | 4592 | 4592 |
| The Smedley Company & Smedley Services, Inc. (10) | Commercial Services & Supplies | 4.07% | 7/2017 | 1/2028 | 705 | 705 | 668 |
| Trinity Equipment, Inc. (10) | Commercial Services & Supplies | 8.78-8.93% | 5/2023 | 5/2028 | 883 | 883 | 883 |
| Trinity Equipment Rentals, Inc. (10) | Commercial Services & Supplies | 7.93% | 10/2021 | 11/2026-12/2026 | 66 | 66 | 66 |
| U.S. Crane & Rigging, LLC (10) | Commercial Services & Supplies | 8.73% | 12/2022 | 9/2028 | 632 | 632 | 632 |
| Wind River Environmental, LLC (10) | Diversified Consumer Services | 8.43% | 7/2019 | 10/2025 | 7 | 7 | 7 |
| Worldwide Flight Services, Inc. (10) | Transportation Infrastructure | 8.32-9.93% | 9/2022 | 9/2027-8/2028 | 1986 | 2007 | 1986 |
| Zamborelli Enterprises Pacific Southern Foundation (10) | Diversified Consumer Services | 8.91% | 12/2022 | 1/2027 | 264 | 265 | 264 |
|  |  |  |  |  | **Shares/Units** |  |  |
| SLR Equipment Finance Equity Interests (2)(9)(17)\* | Multi-Sector Holdings |  | 7/2017 |  | 200 | 145000 | 95000 |
| **Total Equipment Financing** |  |  |  |  |  | $**171911** | $**121823** |
| **Preferred Equity – 3.2%** |  |  |  |  |  |  |  |
| SOINT, LLC (2)(3)(4) | Aerospace & Defense | 0.00% | 6/2012 | 6/2027 |  | $4600 | $959 |
| Veronica Holdings, LLC (Vapotherm)(24) | Health Care Equipment & Supplies | 9.00%<sup>(11)</sup> | 9/2024 |  | 13055991 | 30131 | 31197 |
| **Total Preferred Equity** |  |  |  |  |  | $**34731** | $**32156** |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

**(in thousands, except share/unit amounts)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Acquisition<br>Date** | **Shares/Units** | **Cost** | **Fair<br>Value** |
| **Common Equity/Equity<br> Interests/Warrants—70.5\%** |  |  |  |  |  |
| Assertio Holdings, Inc. (8)\* | Pharmaceuticals | 7/2023 | 12510 | $51 | $11 |
| Bayside Parent, LLC (24)\* | Health Care Providers & Services | 5/2023 | 6526 | 11411 | 10183 |
| CardioFocus, Inc. Warrants \* | Health Care Equipment & Supplies | 3/2017 | 90 | 51 |  |
| Centrexion Therapeutics, Inc. Warrants \* | Pharmaceuticals | 6/2019 | 289102 | 136 | 27 |
| Conventus Orthopaedics, Inc. Warrants \* | Health Care Equipment & Supplies | 6/2016 | 157500 | 65 |  |
| Delphinus Medical Technologies, Inc. Warrants \* | Health Care Equipment & Supplies | 8/2017 | 444388 | 74 | 69 |
| Essence Group Holdings Corporation<br> (Lumeris) Warrants \* | Health Care Technology | 3/2017 | 260000 | 129 |  |
| KBH Topco LLC (Kingsbridge) (2)(5)(18) | Multi-Sector Holdings | 11/2020 | 78750000 | 145434 | 172000 |
| Meditrina, Inc. Warrants \* | Health Care Equipment & Supplies | 12/2022 | 44049 | 33 | 27 |
| OmniGuide Holdings, Inc. Warrants\* | Health Care Equipment & Supplies | 9/2025 | 2625000 | 11 | 11 |
| RD Holdco, Inc. (Rug Doctor) (2)\* | Diversified Consumer Services | 12/2013 | 231177 | 15683 |  |
| RD Holdco, Inc. (Rug Doctor) Class B (2)\* | Diversified Consumer Services | 12/2013 | 522 | 5216 |  |
| Senseonics Holdings, Inc. (3)(8)\* | Health Care Equipment & Supplies | 7/2019 | 469353 | 235 | 205 |
| Shoes for Crews Holdings, LLC | Diversified Consumer Services | 6/2024 | 1884 | 2759 | 2040 |
| SLR-AMI Topco Blocker, LLC (15)(24)\* | Broadline Retail | 6/2023 |  | 25304 | 12006 |
| SLR Business Credit (2)(3)(19) | Diversified Financial Services | 4/2022 | 100 | 111583 | 133000 |
| SLR Credit Solutions (2)(3)(20) | Diversified Financial Services | 12/2012 | 280303 | 280737 | 284000 |
| SLR Healthcare ABL (2)(3)(21) | Diversified Financial Services | 4/2022 | 32839 | 34335 | 37500 |
| SLR Senior Lending Program LLC (2)(3)(22) | Asset Management & Custody Banks | 12/2022 |  | 47875 | 48360 |
| Venus Concept Ltd. Warrants\* (f/k/a<br> Restoration Robotics) | Health Care Equipment & Supplies | 5/2018 | 36 | 110 |  |
| Veronica Holdings, LLC (Vapotherm)(24)\* | Health Care Equipment & Supplies | 9/2024 | 293203 | 330 | 639 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Common Equity/Equity Interests/Warrants** |  |  |  | $**681562** | $**700078** |
| &nbsp;&nbsp;&nbsp;**Total Investments (6) — 212.0%** |  |  |  | $**2138238** | $**2105293** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Acquisition<br>Date** | **Maturity<br>Date** | **Par Amount** | **Cost** | **Fair Value** |
| **Cash Equivalents —37.5%** |  |  |  |  |  |  |
| U.S. Treasury Bill (4.02% yield) | Government | 9/2025 | 11/2025 | $375000 | $373030 | $373030 |
| &nbsp;&nbsp;&nbsp;**Total Investments & Cash Equivalents — 249.5%** |  |  |  |  | $**2511268** | $**2478323** |
| &nbsp;&nbsp;&nbsp;Liabilities in Excess of Other Assets — (149.5%) |  |  |  |  |  | (1485036) |
| &nbsp;&nbsp;&nbsp;**Net Assets — 100.0%** |  |  |  |  |  | $**993287** |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

**(in thousands, except share/unit amounts)**

(1)Floating rate debt investments typically bear interest at a rate determined by reference to the Secured Overnight Financing Rate ("SOFR" or "S") or the prime index rate ("PRIME" or "P"), and which typically reset monthly, quarterly or semi-annually. For each debt investment, we have provided the current rate of interest, or in the case of leases the current implied yield, in effect as of September 30, 2025.

(2)Denotes investments in which we are deemed to exercise a controlling influence over the management or policies of a company, as defined in the Investment Company Act of 1940, as amended (the "1940 Act"), due to beneficially owning, either directly or through one or more controlled companies, more than 25% of the outstanding voting securities of the investment. Transactions during the nine months ended September 30, 2025 in these controlled investments are as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name of Issuer** | **Fair Value at<br>December 31,<br>2024** | **Gross<br>Additions** | **Gross<br>Reductions** | **Realized<br>Loss** | **Change in<br>Unrealized<br>Gain<br>(Loss)** | **Fair Value at<br>September 30, 2025** | **Interest/<br>Dividend/<br>Other<br>Income** |
| Equipment Operating Leases, LLC | $2812 | $— | $2884 | $— | $72 | $— | $104 |
| Kingsbridge Holdings, LLC | 100500 |  |  |  | (49) | 100500 | 8780 |
| KBH Topco, LLC (Kingsbridge) | 152071 | 4514 |  |  | 15415 | 172000 | 14803 |
| Loyer Capital LLC | 7361 |  | 7500 |  | 139 |  | 406 |
| RD Holdco, Inc. (Rug Doctor, common equity) |  |  |  |  |  |  |  |
| RD Holdco, Inc. (Rug Doctor, class B) |  |  |  |  |  |  |  |
| RD Holdco, Inc. (debt) | 7827 |  | 2025 |  |  | 5802 |  |
| SLR Business Credit (revolver) |  | 15500 | 15500 |  |  |  | 9 |
| SLR Business Credit | 125370 |  |  |  | 7630 | 133000 | 10950 |
| SLR Credit Solutions | 288250 |  |  |  | (4250) | 284000 | 16900 |
| SLR Equipment Finance (equity) | 107600 |  |  |  | (12600) | 95000 |  |
| SLR Equipment Finance (debt) | 3000 | 15100 | 10600 |  |  | 7500 | 226 |
| SLR Healthcare ABL | 37850 |  |  |  | (350) | 37500 | 4967 |
| SLR Healthcare ABL (revolver) | 4000 | 76800 | 79000 |  |  | 1800 | 150 |
| SLR Senior Lending Program LLC | 49091 |  |  |  | (731) | 48360 | 4480 |
| SOINT, LLC | 2500 |  | 641 |  | (900) | 959 |  |
|  | $888232 | $111914 | $118150 | $— | $4376 | $886421 | $61775 |

---

The change in fair value in the table above may not roll across due to the recognition of accretion income, which is included in interest income.

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

**(in thousands, except share/unit amounts)**

(3)Indicates assets that the Company believes may not represent "qualifying assets" under Section 55(a) of the 1940 Act. If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of September 30, 2025, on a fair value basis, non-qualifying assets in the Company's portfolio represented 27.9% of the total assets of the Company.

(4)The Company's investment in SOINT, LLC includes a one dollar investment in common shares.

(5)Kingsbridge Holdings, LLC is held through KBH Topco LLC, a Delaware corporation.

(6)Aggregate net unrealized appreciation for U.S. federal income tax purposes is $8,612; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $125,437 and $116,825, respectively, based on a tax cost of $2,096,681. Unless otherwise noted, all of the Company's investments are pledged as collateral against the borrowings outstanding on the Credit Facility (as defined below) (see note 7 to the consolidated financial statements). The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). These investments are generally subject to certain limitations on resale, and may be deemed to be "restricted securities" under the Securities Act. All investments are Level 3 unless otherwise indicated.

(7)Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor.

(8)Denotes a Level 1 investment.

(9)SLR Equipment Finance is held through NEFCORP LLC, a wholly-owned consolidated taxable subsidiary, and NEFPASS LLC, a wholly-owned consolidated subsidiary.

(10)Indicates an investment that is wholly held by the Company through NEFPASS LLC.

(11)Interest is paid in kind ("PIK").

(12)Spread is S+600 cash / 0.50% PIK.

(13)OmniGuide Holdings, Inc., Domain Surgical, Inc. and OmniGuide, Inc. are co-borrowers.

(14)Spread is S+475 cash / 2.75% PIK.

(15)Through this entity and other intermediate entities, the Company owns approximately 5.7% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former Amerimark Interactive, LLC.

(16)Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SUNS SPV LLC. Such investments are pledged as collateral under the Senior Secured Revolving SPV Credit Facility (the "SPV Credit Facility") (see note 7 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.

(17)See note 12 to the consolidated financial statements.

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

**(in thousands, except share/unit amounts)**

(18)See note 13 to the consolidated financial statements.

(19)See note 15 to the consolidated financial statements.

(20)See note 11 to the consolidated financial statements.

(21)See note 14 to the consolidated financial statements.

(22)See note 17 to the consolidated financial statements.

(23)Spread is S+200 cash / 4.75% PIK.

(24)Denotes investments in which we are an "Affiliated Person" but do not exercise a controlling influence, as defined in the 1940 Act, due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment. Transactions during the nine months ended September 30, 2025 in these affiliated investments are as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name of Issuer** | **Fair Value at<br>December 31,<br>2024** | **Gross<br>Additions** | **Gross<br>Reductions** | **Realized<br>Gain<br>(Loss)** | **Change in<br>Unrealized<br>Gain<br>(Loss)** | **Fair Value at<br>September 30, 2025** | **Interest/ Dividend<br>Income** |
| Bayside Opco, LLC | $19905 | $— | $135 | $— | $— | $19770 | $1771 |
| Bayside Parent, LLC (loan) | 6008 | 683 |  |  |  | 6691 | 683 |
| Bayside Parent, LLC (equity) | 7179 |  |  |  | 3003 | 10183 |  |
| SLR-AMI Topco Blocker, LLC | 12778 | 1219 |  |  | (1991) | 12006 |  |
| Vapotherm, Inc. | 14254 |  |  |  | (75) | 14357 | 1276 |
| Veronica Holdings, LLC (preferred equity) | 29182 | 2014 |  |  | (348) | 31197 | 2362 |
| Veronica Holdings, LLC (common equity) | 639 |  |  |  |  | 639 |  |
|  | $89945 | $3916 | $135 | $— | $589 | $94843 | $6092 |

---

The change in fair value in the table above may not roll across due to the recognition of accretion income, which is included in interest income.

(25)Certain tranches have a spread of S+795, certain tranches have a spread of S+425 and certain tranches have a spread of S+400.

(26)Certain tranches have a spread of S+650 and certain tranches have a spread of S+700 (5.00% PIK/2.00% cash).

(27)Spread is S+600 cash / 1.00% PIK.

\* Non-income producing security.

\*\* Investment is on non-accrual status.

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (unaudited) (continued)**

**September 30, 2025** 

---

| | |
|:---|:---|
| **Industry Classification** | **Percentage of Total<br>Investments (at fair value) as<br>of September 30, 2025** |
| Financial Services (includes SLR Credit Solutions, SLR Business Credit and SLR Healthcare ABL) | 29.9% |
| Multi-Sector Holdings (includes Kingsbridge Holdings, LLC and SLR Equipment Finance) | 17.8% |
| Health Care Providers & Services | 10.3% |
| Health Care Equipment & Supplies | 5.5% |
| Capital Markets | 5.0% |
| Pharmaceuticals | 4.0% |
| Professional Services | 3.8% |
| Diversified Consumer Services | 3.2% |
| Biotechnology | 2.7% |
| Asset Management & Custody Banks | 2.3% |
| Transportation Infrastructure | 2.1% |
| Consumer Staples Distribution & Retail | 1.7% |
| Commercial Services & Supplies | 1.7% |
| Consumer Finance | 1.5% |
| Media | 1.3% |
| Software | 1.2% |
| Fertilizers & Agricultural Chemicals | 1.0% |
| Life Sciences Tools & Services | 1.0% |
| Insurance | 0.8% |
| Broadline Retail | 0.6% |
| Communications Equipment | 0.5% |
| Specialty Retail | 0.4% |
| Health Care Technology | 0.4% |
| Food Products | 0.4% |
| Aerospace & Defense | 0.3% |
| Trading Companies & Distributors | 0.3% |
| Ground Transportation | 0.2% |
| Passenger Airlines | 0.1% |
| Metals & Mining | 0.0% |
| Automobile Components | 0.0% |
| Construction & Engineering | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Investments | 100.0% |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(7)</sup> | **Floor** | **Interest<br>Rate**<sup>(1)</sup> | **Acquisition<br>Date** | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value** |
| **Senior Secured Loans — 112.5%** |  |  |  |  |  |  |  |  |  |
| <u>First Lien Bank Debt/Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| 33Across Inc. | Media | P+232 | 8.50% | 10.82% | 1/2024 | 10/2025 | $2774 | $2774 | $2774 |
| Aegis Toxicology Sciences Corporation(16) | Health Care Providers & Services | S+550 | 1.00% | 10.28% | 5/2018 | 5/2025 | 13122 | 13075 | 13122 |
| Alkeme Intermediary Holdings, LLC(16) | Insurance | S+575 | 1.00% | 10.08% | 9/2023 | 10/2026 | 16886 | 16531 | 16886 |
| All States Ag Parts, LLC(16) | Trading Companies & Distributors | S+600 | 1.00% | 10.59% | 4/2022 | 9/2026 | 2034 | 2016 | 2034 |
| BayMark Health Services, Inc.(16) | Health Care Providers & Services | S+500 | 1.00% | 9.59% | 4/2022 | 6/2027 | 8180 | 7999 | 8180 |
| Bayside Opco, LLC(24) | Health Care Providers & Services | S+725 | 1.00% | 11.73% | 5/2023 | 5/2026 | 19905 | 19905 | 19905 |
| Bayside Parent, LLC(24) | Health Care Providers & Services | S+1000<sup>(11)</sup> | 1.00% | 14.48% | 5/2023 | 5/2026 | 6008 | 6008 | 6008 |
| BDG Media, Inc. | Media | P+525 | 5.50% | 12.75% | 7/2022 | 7/2025 | 6249 | 6249 | 6249 |
| CC SAG Holdings Corp.(Spectrum Automotive)(16) | Diversified Consumer Services | S+525 | 0.75% | 9.58% | 6/2021 | 6/2028 | 30202 | 29814 | 30202 |
| Copper River Seafoods, Inc. | Food Products | P+275 |  | 10.25% | 12/2023 | 4/2025 | 5088 | 5088 | 5088 |
| CVAUSA Management, LLC(16) | Health Care Providers & Services | S+650 | 1.00% | 10.84% | 5/2023 | 5/2029 | 17191 | 16771 | 17191 |
| DeepIntent, Inc. | Media | P+185 | 5.25% | 9.35% | 12/2023 | 9/2027 | 37746 | 37746 | 37746 |
| Enhanced Permanent Capital, LLC(3) | Capital Markets | S+700 | 1.00% | 11.97% | 12/2020 | 12/2025 | 44578 | 44220 | 44578 |
| EyeSouth Eye Care Holdco LLC | Health Care Providers & Services | S+550 | 1.00% | 9.96% | 10/2022 | 10/2029 | 9625 | 9383 | 9625 |
| FE Advance, LLC | Diversified Financial Services | S+650 | 1.00% | 10.86% | 7/2024 | 7/2027 | 20894 | 20517 | 20894 |
| Fertility (ITC) Investment Holdco, LLC | Health Care Providers & Services | S+650 | 1.00% | 11.74% | 1/2023 | 1/2029 | 22368 | 21871 | 22368 |
| Foundation Consumer Brands, LLC(16) | Personal Products | S+625 | 1.00% | 10.89% | 2/2021 | 2/2027 | 25058 | 24691 | 25058 |
| Human Interest Inc. | Internet Software & Services | S+735 | 1.00% | 11.90% | 6/2022 | 7/2027 | 20104 | 20104 | 20104 |
| iCIMS, Inc. | Software | S+575 | 0.75% | 10.38% | 8/2022 | 8/2028 | 32245 | 31887 | 32245 |
| Kaseya, Inc.(16) | Software | S+550<sup>(14)</sup> | 0.75% | 9.83% | 6/2022 | 6/2029 | 24702 | 24445 | 24702 |
| Kingsbridge Holdings, LLC(2) | Multi-Sector Holdings | S+700 | 1.00% | 11.71% | 12/2018 | 12/2027 | 100500 | 100283 | 100500 |
| Logix Holding Company, LLC(16) | Communications Equipment | P+475 | 1.00% | 12.25% | 9/2018 | 3/2025 | 14009 | 13933 | 13449 |
| Luxury Asset Capital, LLC(16) | Thrifts & Mortgage Finance | S+675 | 1.00% | 11.42% | 7/2022 | 7/2027 | 30500 | 30149 | 30500 |
| Maxor Acquisition, Inc.(16) | Health Care Providers & Services | S+600 | 1.00% | 10.44% | 3/2023 | 3/2029 | 21195 | 20755 | 21195 |
| One Touch Direct, LLC | Commercial Services & Supplies | P+75 | 4.00% | 8.25% | 12/2023 | 3/2026 | 1030 | 1030 | 1030 |
| ONS MSO, LLC(16) | Health Care Providers & Services | S+625 | 1.00% | 10.84% | 2/2023 | 7/2026 | 27772 | 27317 | 27772 |
| Peter C. Foy & Associates Insurance Services, LLC(16) | Insurance | S+550<sup>(28)</sup> | 0.75% | 9.83% | 4/2022 | 11/2028 | 16706 | 16508 | 16706 |
| Plastic Management, LLC(16) | Health Care Providers & Services | S+500 | 1.00% | 9.43% | 4/2022 | 8/2027 | 16965 | 16471 | 16965 |
| Quantcast Corporation | Commercial Services & Supplies | S+525 | 2.00% | 11.75% | 6/2024 | 6/2029 | 10502 | 10380 | 10502 |
| Retina Midco, Inc.(16) | Health Care Providers & Services | S+575 | 1.00% | 10.35% | 12/2023 | 1/2026 | 27301 | 26985 | 27847 |
| RQM+ Corp.(16) | Life Sciences Tools & Services | S+675<sup>(23)</sup> | 1.00% | 11.34% | 8/2021 | 8/2029 | 23398 | 23201 | 22462 |
| RxSense Holdings LLC(16) | Diversified Consumer Services | S+500 | 1.00% | 9.69% | 4/2022 | 3/2026 | 2628 | 2582 | 2628 |
| Shoes for Crews Global, LLC | Diversified Consumer Services | S+650<sup>(26)</sup> | 1.00% | 11.17% | 6/2024 | 6/2029 | 3398 | 3398 | 3398 |
| Sightly Enterprises, Inc. | Media | P+475 | 6.00% | 12.25% | 1/2024 | 12/2026 | 4813 | 4813 | 4813 |
| SLR Healthcare ABL(2)(3)(21) | Diversified Financial Services | S+650 |  | 10.81% | 12/2024 | 12/2025 | 4000 | 4000 | 4000 |
| Southern Orthodontic Partners Management, LLC(16) | Health Care Providers & Services | S+525 | 1.00% | 9.58% | 6/2022 | 7/2026 | 33158 | 32731 | 33158 |
| SPAR Marketing Force, Inc. | Media | P+190 |  | 9.40% | 12/2023 | 10/2025 | 9251 | 9251 | 9251 |
| SunMed Group Holdings, LLC(16) | Health Care Equipment & Supplies | S+550 | 0.75% | 10.19% | 6/2021 | 6/2028 | 14828 | 14584 | 14828 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(7)</sup> | **Floor** | **Interest<br>Rate**<sup>(1)</sup> | **Acquisition<br>Date** | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value** |
| **Senior Secured Loans (continued)** |  |  |  |  |  |  |  |  |  |
| TAUC Management, LLC(16) | Health Care Providers & Services | S+700<sup>(27)</sup> | 1.00% | 11.48% | 4/2022 | 2/2027 | $7002 | $6829 | $6302 |
| The Townsend Company, LLC(16) | Commercial Services & Supplies | S+500 | 1.00% | 9.36% | 8/2023 | 8/2030 | 19775 | 19275 | 19587 |
| Tilley Distribution, Inc.(16) | Trading Companies & Distributors | S+600 | 1.00% | 10.48% | 4/2022 | 12/2026 | 3688 | 3590 | 3615 |
| TPC 2022, LLC | Capital Markets | S+650 | 1.00% | 10.88% | 12/2024 | 12/2027 | 20000 | 19802 | 19800 |
| United Digestive MSO Parent, LLC(16) | Health Care Providers & Services | S+575 | 1.00% | 10.08% | 3/2023 | 3/2029 | 9956 | 9723 | 9956 |
| Urology Management Holdings, Inc. | Health Care Providers & Services | S+550 | 1.00% | 9.83% | 2/2023 | 6/2027 | 11909 | 11683 | 11909 |
| UVP Management, LLC | Health Care Providers & Services | S+625 | 1.00% | 10.73% | 9/2023 | 9/2025 | 13653 | 13518 | 13653 |
| Western Veterinary Partners LLC(16) | Diversified Consumer Services | S+500 | 1.00% | 9.33% | 1/2024 | 10/2027 | 23515 | 23215 | 23515 |
| WMD Funding, LLC(11) | Diversified Financial Services |  |  | 11.50% | 12/2024 | 7/2031 | 18330 | 18330 | 18330 |
| Total First Lien Bank Debt/ Senior Secured Loans |  |  |  |  |  |  |  | $845430 | $852630 |
| <u>First Lien Life Science Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| Arcutis Biotherapeutics, Inc.(3) | Pharmaceuticals | S+595 | 2.50% | 10.47% | 12/2021 | 8/2029 | $33425 | $34531 | $35263 |
| Ardelyx, Inc.(3) | Pharmaceuticals | S+400<sup>(25)</sup> | 4.70% | 8.70% | 2/2022 | 7/2028 | 39750 | 40033 | 40247 |
| Cerapedics, Inc. | Biotechnology | S+620 | 2.75% | 10.72% | 12/2022 | 1/2028 | 36156 | 36498 | 37889 |
| Meditrina, Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 10.02% | 12/2022 | 12/2027 | 5051 | 5111 | 5127 |
| OmniGuide Holdings, Inc. (13) | Health Care Equipment & Supplies | S+580 | 5.31% | 11.11% | 7/2018 | 11/2025 | 24500 | 26044 | 24622 |
| Outset Medical, Inc.(16) | Health Care Equipment & Supplies | S+515 | 2.75% | 9.67% | 11/2022 | 11/2027 | 44727 | 45353 | 46405 |
| SPR Therapeutics, Inc. | Health Care Technology | S+515 | 4.00% | 9.67% | 1/2024 | 2/2029 | 4866 | 4872 | 5021 |
| Vapotherm, Inc.(24) | Health Care Equipment & Supplies | S+600 | 4.50% | 10.52% | 2/2022 | 9/2027 | 13782 | 14147 | 14254 |
| Total First Lien Life Science Senior Secured Loans |  |  |  |  |  |  |  | $206589 | $208828 |
| <u>Second Lien Asset-Based Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| AMF Levered II, LLC | Diversified Financial Services | S+705 | 1.00% | 11.67% | 12/2021 | 8/2028 | $29925 | $29741 | $29925 |
| FGI Worldwide LLC (3)(16) | Diversified Financial Services | S+650 | 1.00% | 10.86% | 4/2023 | 4/2028 | 8206 | 8058 | 8206 |
| Pasadena Private Lending Inc.(3) | Diversified Financial Services | S+750 | 1.00% | 11.88% | 12/2024 | 4/2028 | 9825 | 9703 | 9702 |
| Total Second Lien Asset-Backed Senior Secured Loans |  |  |  |  |  |  |  | $47502 | $47833 |
| <u>Second Lien Bank Debt / Senior Secured Loans</u> |  |  |  |  |  |  |  |  |  |
| RD Holdco, Inc.\*\* (2) | Diversified Consumer Services | S+975<sup>(11)</sup> | 1.00% |  | 12/2013 | 10/2026 | $18228 | $12297 | $7827 |
| **Total Senior Secured Loans** |  |  |  |  |  |  |  | $**1111818** | $**1117118** |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Interest<br>Rate**<sup>(1)</sup> | **Acquisition<br>Date** | **Maturity<br>Date** | **Par Amount** | **Cost** | **Fair<br>Value** |
| **Equipment Financing — 18.2%** |  |  |  |  |  |  |  |
| A&A Crane and Rigging, LLC (10) | Commercial Services & Supplies | 7.78% | 3/2023 | 3/2028 | $54 | $54 | $54 |
| Aero Operating LLC (10) | Commercial Services & Supplies | 8.47-9.09% | 2/2021 | 3/2025-11/2026 | 259 | 258 | 259 |
| AFG Dallas III, LLC (10) | Diversified Consumer Services | 10.00-11.29% | 8/2022 | 8/2026-3/2027 | 743 | 743 | 743 |
| Air Methods Corporation (10) | Airlines | 7.08-7.13% | 11/2021 | 11/2026 | 2569 | 2591 | 2569 |
| Boart Longyear Company (10) | Metals & Mining | 8.31-9.77% | 5/2020 | 4/2025-10/2026 | 997 | 997 | 997 |
| Bowman Energy Solutions, LLC (10) | Commercial Services & Supplies | 7.42% | 7/2022 | 7/1/2026 | 73 | 73 | 73 |
| Carolina's Contracting, LLC (10) | Diversified Consumer Services | 8.40-8.72% | 3/2023 | 3/2028-5/2028 | 2912 | 2932 | 2912 |
| CKD Holdings, Inc. (10) | Road & Rail | 8.10-8.60% | 9/2022 | 3/2026-9/2027 | 1816 | 1816 | 1816 |
| Clubcorp Holdings, Inc. (10) | Hotels, Restaurants & Leisure | 9.36-13.01% | 5/2021 | 4/2025-5/2028 | 4550 | 4550 | 4550 |
| Complete Equipment Rentals, LLC (10) | Commercial Services & Supplies | 6.75-7.15% | 3/2023 | 4/2028-6/2028 | 1467 | 1450 | 1442 |
| Dongwon Autopart Technology Inc. (10) | Auto Components | 7.96% | 2/2021 | 1/2026 | 658 | 661 | 658 |
| Double S Industrial Contractors, Inc. (10) | Commercial Services & Supplies | 8.60% | 7/2023 | 8/2027 | 85 | 85 | 85 |
| Drillers Choice, Inc. (10) | Commercial Services & Supplies | 8.00-10.08% | 10/2022 | 11/2027-6/2029 | 1089 | 1091 | 1089 |
| Environmental Protection & Improvement Company, LLC (10) | Road & Rail | 8.25% | 9/2020 | 10/2027 | 3798 | 3811 | 3798 |
| Equipment Operating Leases, LLC (2)(12) | Multi-Sector Holdings | 8.37% | 4/2018 | 4/2025 | 2884 | 2884 | 2812 |
| Extreme Steel Crane & Rigging, LLC (10) | Commercial Services & Supplies | 9.52% | 3/2023 | 3/2027 | 613 | 617 | 613 |
| First American Commercial Bancorp, Inc. (10) | Diversified Financial Services | 7.50-9.00% | 10/2021 | 10/2026-3/2027 | 1566 | 1567 | 1566 |
| First National Capital, LLC (10) | Diversified Financial Services | 9.00% | 11/2021 | 7/2026 | 3340 | 3340 | 3340 |
| GMT Corporation (10) | Machinery | 10.71% | 10/2018 | 1/2026 | 2496 | 2497 | 2496 |
| Hawkeye Contracting Company, LLC (10) | Construction & Engineering | 10.50% | 10/2021 | 11/2025 | 347 | 347 | 347 |
| HTI Logistics Corporation (10) | Commercial Services & Supplies | 9.94% | 11/2018 | 9/2025 | 53 | 53 | 51 |
| International Automotive Components Group, North America, Inc. (10) | Auto Components | 7.95% | 6/2021 | 6/2025 | 1001 | 1002 | 1001 |
| Loc Performance Products, LLC (10) | Machinery | 10.50% | 12/2022 | 6/2027 | 477 | 477 | 477 |
| Loyer Capital LLC (2)(12) | Multi-Sector Holdings | 8.73-11.52% | 5/2019 | 5/2026-9/2026 | 7500 | 7500 | 7361 |
| Miranda Logistics Enterprise, Inc. (10) | Construction & Engineering | 7.69% | 4/2023 | 4/2028 | 628 | 628 | 628 |
| Mountain Air Helicopters, Inc. (10) | Commercial Services & Supplies | 10.00% | 7/2017 | 2/2025 | 114 | 114 | 114 |
| Nimble Crane LLC (10) | Commercial Services & Supplies | 9.18% | 7/2023 | 7/2028 | 762 | 762 | 762 |
| No Limit Construction Services, LLC (10) | Commercial Services & Supplies | 7.73% | 5/2023 | 6/2028 | 95 | 95 | 95 |
| PCX Aerostructures LLC (10) | Aerospace & Defense | 9.32% | 11/2022 | 12/2028 | 1931 | 1931 | 1931 |
| Rango, Inc. (10) | Commercial Services & Supplies | 9.33% | 9/2019 | 4/2025 | 101 | 101 | 99 |
| Rayzor's Edge LLC (10) | Diversified Consumer Services | 7.69-8.27% | 5/2023 | 5/2030-6/2030 | 624 | 624 | 624 |
| RH Land Construction, LLC & Harbor Dredging LA, Inc. (10) | Construction & Engineering | 8.08% | 5/2023 | 5/2026 | 69 | 69 | 69 |
| Rotten Rock Hardscaping & Tree Service (10) | Diversified Consumer Services | 8.21% | 12/2022 | 12/2027 | 159 | 159 | 159 |
| Signet Marine Corporation (10) | Transportation Infrastructure | 8.50% | 10/2022 | 6/2029 | 10291 | 10319 | 10291 |
| SLR Equipment Finance (2)(9)(17) | Multi-Sector Holdings | 8.50% | 12/2024 | 12/2025 | 3000 | 3000 | 3000 |
| Smiley Lifting Solutions, LLC(10) | Commercial Services & Supplies | 7.82-8.61% | 6/2022 | 9/2026-6/2030 | 5195 | 5195 | 5195 |
| ST Coaches, LLC (10) | Road & Rail | 8.50% | 7/2017 | 1/2025 | 520 | 520 | 520 |
| Star Coaches Inc. (10) | Road & Rail | 8.42% | 3/2018 | 4/2025 | 1719 | 1719 | 1633 |
| Superior Transportation, Inc. (10) | Road & Rail | 10.22-10.63% | 7/2017 | 1/2026 | 1346 | 1346 | 1346 |
| The Smedley Company & Smedley Services, Inc. (10) | Commercial Services & Supplies | 4.07% | 7/2017 | 1/2028 | 970 | 970 | 901 |
| Trinity Equipment, Inc. (10) | Commercial Services & Supplies | 8.78-8.93% | 5/2023 | 5/2028 | 1085 | 1085 | 1085 |
| Trinity Equipment Rentals, Inc. (10) | Commercial Services & Supplies | 7.94-7.95% | 10/2021 | 11/2026-12/2026 | 136 | 136 | 136 |
| U.S. Crane & Rigging, LLC (10) | Commercial Services & Supplies | 8.73% | 12/2022 | 9/2028 | 766 | 766 | 766 |
| Wind River Environmental, LLC (10) | Diversified Consumer Services | 8.43% | 7/2019 | 10/2025 | 72 | 72 | 72 |
| Womble Company, Inc. (10) | Energy Equipment & Services | 9.11% | 12/2019 | 1/2025 | 17 | 17 | 17 |
| Worldwide Flight Services, Inc. (10) | Transportation Infrastructure | 8.32-9.93% | 9/2022 | 9/2027-8/2028 | 2465 | 2495 | 2465 |
| Zamborelli Enterprises Pacific Southern Foundation (10) | Diversified Consumer Services | 8.91% | 12/2022 | 1/2027 | 399 | 401 | 399 |
|  |  |  |  |  | **Shares/Units** |  |  |
| SLR Equipment Finance Equity Interests (2)(9)(17)\* | Multi-Sector Holdings |  | 7/2017 |  | 200 | 145000 | 107600 |
| **Total Equipment Financing** |  |  |  |  |  | $**218920** | $**181016** |
| **Preferred Equity – 3.2%** |  |  |  |  |  |  |  |
| SOINT, LLC (2)(3)(4) | Aerospace & Defense | 0.00% | 6/2012 | 6/2025 |  | $5241 | $2500 |
| Veronica Holdings, LLC (Vapotherm)(24) | Health Care Equipment & Supplies | 9.00%<sup>(11)</sup> | 9/2024 |  | 13055991 | 27769 | 29182 |
| **Total Preferred Equity** |  |  |  |  |  | $**33010** | $**31682** |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Acquisition<br>Date** | **Shares/<br>Units** | **Cost** | **Fair<br>Value** |
| **Common Equity/Equity<br> Interests/Warrants—68.1%** |  |  |  |  |  |
| Assertio Holdings, Inc. (8)\* | Pharmaceuticals | 7/2023 | 12510 | $51 | $11 |
| Bayside Parent, LLC (24)\* | Health Care Providers & Services | 5/2023 | 6526 | 11411 | 7179 |
| CardioFocus, Inc. Warrants \* | Health Care Equipment & Supplies | 3/2017 | 90 | 51 |  |
| Centrexion Therapeutics, Inc. Warrants \* | Pharmaceuticals | 6/2019 | 289102 | 136 | 47 |
| Conventus Orthopaedics, Inc. Warrants \* | Health Care Equipment & Supplies | 6/2016 | 157500 | 65 |  |
| Delphinus Medical Technologies, Inc. Warrants \* | Health Care Equipment & Supplies | 8/2017 | 444388 | 74 | 84 |
| Essence Group Holdings Corporation<br> (Lumeris) Warrants \* | Health Care Technology | 3/2017 | 260000 | 129 | 131 |
| KBH Topco LLC (Kingsbridge) (2)(5)(18) | Multi-Sector Holdings | 11/2020 | 76125000 | 140920 | 152071 |
| Meditrina, Inc. Warrants \* | Health Care Equipment & Supplies | 12/2022 | 44049 | 33 | 31 |
| RD Holdco, Inc. (Rug Doctor) (2)\* | Diversified Consumer Services | 12/2013 | 231177 | 15683 |  |
| RD Holdco, Inc. (Rug Doctor) Class B (2)\* | Diversified Consumer Services | 12/2013 | 522 | 5216 |  |
| Senseonics Holdings, Inc. (3)(8)\* | Health Care Equipment & Supplies | 7/2019 | 469353 | 235 | 246 |
| Shoes for Crews Holdings, LLC | Diversified Consumer Services | 6/2024 | 1884 | 2759 | 2040 |
| SLR-AMI Topco Blocker, LLC (15)(24)\* | Internet & Catalog Retail | 6/2023 |  | 24085 | 12778 |
| SLR Business Credit (2)(3)(19) | Diversified Financial Services | 4/2022 | 100 | 111583 | 125370 |
| SLR Credit Solutions (2)(3)(20) | Diversified Financial Services | 12/2012 | 280303 | 280737 | 288250 |
| SLR Healthcare ABL (2)(3)(21) | Diversified Financial Services | 4/2022 | 32839 | 34335 | 37850 |
| SLR Senior Lending Program LLC (2)(3)(22) | Asset Management | 12/2022 |  | 47875 | 49091 |
| Venus Concept Ltd. Warrants\* (f/k/a<br> Restoration Robotics) | Health Care Equipment & Supplies | 5/2018 | 396 | 110 |  |
| Veronica Holdings, LLC (Vapotherm)(24)\* | Health Care Equipment & Supplies | 9/2027 | 293203 | 330 | 639 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Common Equity/Equity Interests/Warrants** |  |  |  | $**675818** | $**675818** |
| &nbsp;&nbsp;&nbsp;**Total Investments (6) — 202.0%** |  |  |  | $**2039566** | $**2005634** |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Acquisition<br>Date** | **Maturity<br>Date** | **Par Amount** | **Cost** | **Fair Value** |
| **Cash Equivalents —40.0%** |  |  |  |  |  |  |
| U.S. Treasury Bill (4.24% yield) | Government | 12/2024 | 2/2025 | $400000 | $397510 | $397510 |
| &nbsp;&nbsp;&nbsp;**Total Investments & Cash Equivalents — 242.0%** |  |  |  |  | $**2437076** | $**2403144** |
| &nbsp;&nbsp;&nbsp;Liabilities in Excess of Other Assets — (142.0%) |  |  |  |  |  | (1410218) |
| &nbsp;&nbsp;&nbsp;**Net Assets — 100.0%** |  |  |  |  |  | $**992926** |

---

(1)Floating rate debt investments typically bear interest at a rate determined by reference to the Secured Overnight Financing Rate ("SOFR" or "S") or the prime index rate ("PRIME" or "P"), and which typically reset monthly, quarterly or semi-annually. For each debt investment, we have provided the current rate of interest, or in the case of leases the current implied yield, in effect as of December 31, 2024.

(2)Denotes investments in which we are deemed to exercise a controlling influence over the management or policies of a company, as defined in the Investment Company Act of 1940, as amended (the "1940 Act"), due to beneficially owning, either directly or through one or more controlled companies, more than 25% of the outstanding voting securities of the investment. Transactions during the year ended December 31, 2024 in these controlled investments are as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name of Issuer** | **Fair Value at<br>December 31,<br>2023** | **Gross<br>Additions** | **Gross<br>Reductions** | **Realized<br>Loss** | **Change in<br>Unrealized<br>Gain<br>(Loss)** | **Fair Value at December 31, 2024** | **Interest/<br>Dividend/<br>Other<br>Income** |
| Equipment Operating Leases, LLC | $3296 | $— | $496 | $— | $12 | $2812 | $264 |
| Kingsbridge Holdings, LLC | 96000 | 4500 |  |  | 113 | 100500 | 11972 |
| KBH Topco, LLC (Kingsbridge) | 142000 | 4323 |  |  | 5748 | 152071 | 12159 |
| Loyer Capital LLC | 7361 |  |  |  |  | 7361 | 757 |
| RD Holdco, Inc. (Rug Doctor, common equity) |  |  |  |  |  |  |  |
| RD Holdco, Inc. (Rug Doctor, class B) |  |  |  |  |  |  |  |
| RD Holdco, Inc. (debt) | 7827 |  |  |  |  | 7827 |  |
| SLR Business Credit (revolver) |  | 19000 | 19000 |  |  |  | 33 |
| SLR Business Credit | 90370 | 30000 |  |  | 5000 | 125370 | 8350 |
| SLR Credit Solutions | 284000 |  |  |  | 4250 | 288250 | 20500 |
| SLR Equipment Finance (equity) | 120820 |  |  |  | (13220) | 107600 |  |
| SLR Equipment Finance (debt) | 3850 | 3000 | 3850 |  |  | 3000 | 28 |
| SLR Healthcare ABL | 35850 |  |  |  | 2000 | 37850 | 5123 |
| SLR Healthcare ABL (revolver) |  | 4000 |  |  |  | 4000 | 1 |
| SLR Senior Lending Program LLC | 43899 | 5000 |  |  | 192 | 49091 | 7262 |
| SOINT, LLC | 3801 | 63 |  |  | (1364) | 2500 | 62 |
|  | $839074 | $69886 | $23346 | $— | $2731 | $888232 | $66511 |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

(3)Indicates assets that the Company believes may not represent "qualifying assets" under Section 55(a) of the 1940 Act. If the Company fails to invest a sufficient portion of our assets in qualifying assets, it could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2024, on a fair value basis, non-qualifying assets in the Company's portfolio represented 26.3% of the total assets of the Company.

(4)The Company's investment in SOINT, LLC includes a one dollar investment in common shares.

(5)Kingsbridge Holdings, LLC is held through KBH Topco LLC, a Delaware corporation.

(6)Aggregate net unrealized appreciation for U.S. federal income tax purposes is $7,625; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $109,461 and $101,836, respectively, based on a tax cost of $1,998,009. Unless otherwise noted, all of the Company's investments are pledged as collateral against the borrowings outstanding on the Credit Facility (as defined below) (see note 7 to the consolidated financial statements). The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). These investments are generally subject to certain limitations on resale, and may be deemed to be "restricted securities" under the Securities Act. All investments are Level 3 unless otherwise indicated.

(7)Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor.

(8)Denotes a Level 1 investment.

(9)SLR Equipment Finance is held through NEFCORP LLC, a wholly-owned consolidated taxable subsidiary, and NEFPASS LLC, a wholly-owned consolidated subsidiary.

(10)Indicates an investment that is wholly held by the Company through NEFPASS LLC.

(11)Interest is paid in kind ("PIK").

(12)Denotes a subsidiary of SLR Equipment Finance.

(13)OmniGuide Holdings, Inc., Domain Surgical, Inc. and OmniGuide, Inc. are co-borrowers.

(14)Kaseya, Inc. may elect to defer up to 2.50% of the coupon as PIK.

(15)Through this entity and other intermediate entities, the Company owns approximately 5.7% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former Amerimark Interactive, LLC.

(16)Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SUNS SPV LLC. Such investments are pledged as collateral under the Senior Secured Revolving SPV Credit Facility (the "SPV Credit Facility") (see note 7 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.

(17)See note 12 to the consolidated financial statements.

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)**

**December 31, 2024** 

**(in thousands, except share/unit amounts)**

(18)See note 13 to the consolidated financial statements.

(19)See note 15 to the consolidated financial statements.

(20)See note 11 to the consolidated financial statements.

(21)See note 14 to the consolidated financial statements.

(22)See note 17 to the consolidated financial statements.

(23)Spread is S+200 cash / 4.75% PIK.

(24)Denotes investments in which we are an "Affiliated Person" but do not exercise a controlling influence, as defined in the 1940 Act, due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment. Transactions during the year ended December 31, 2024 (beginning with the date at which the Company became an Affiliated Person) in these affiliated investments are as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name of Issuer** | **Fair Value at<br>December 31,<br>2023** | **Gross<br>Additions** | **Gross<br>Reductions** | **Realized<br>Gain<br>(Loss)** | **Change in<br>Unrealized<br>Gain<br>(Loss)** | **Fair Value at<br>December 31,<br>2024** | **Interest/ Dividend<br>Income** |
| Bayside Opco, LLC | $19415 | $626 | $136 | $— | $— | $19905 | $2543 |
| Bayside Parent, LLC (loan) | 5153 | 855 |  |  |  | 6008 | 850 |
| Bayside Parent, LLC (equity) | 3815 |  |  |  | 3364 | 7179 |  |
| SLR-AMI Topco Blocker, LLC | 15867 |  |  |  | (3089) | 12778 |  |
| Vapotherm, Inc. |  | 14080 |  |  | 108 | 14254 | 488 |
| Veronica Holdings, LLC (preferred equity) |  | 27644 |  |  | 1413 | 29182 | 845 |
| Veronica Holdings, LLC (common equity) |  | 330 |  |  | 309 | 639 |  |
|  | $44250 | $43535 | $136 | $— | $2105 | $89945 | $4726 |

---

(25)Certain tranches have a spread of S+795, certain tranches have a spread of S+425 and certain tranches have a spread of S+400.

(26)Certain tranches have a spread of S+650 and certain tranches have a spread of S+700 (5.00% PIK/2.00% cash).

(27)Spread is S+600 cash / 1.00% PIK.

(28)Certain tranches have a spread of S+550 and certain tranches have a spread of S+650.

\* Non-income producing security.

\*\* Investment is on non-accrual status.

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**CONSOLIDATED SCHEDULE OF INVESTMENTS (continued)** 

**December 31, 2024** 

---

| | |
|:---|:---|
| **Industry Classification** | **Percentage of Total<br>Investments (at fair<br>value) as of<br>December 31, 2024** |
| Diversified Financial Services (includes SLR Credit Solutions, SLR Business Credit and SLR Healthcare ABL) | 27.7% |
| Multi-Sector Holdings (includes Kingsbridge Holdings, LLC, SLR Equipment Finance, Equipment Operating Leases, LLC and Loyer Capital LLC) | 18.6% |
| Health Care Providers & Services | 13.6% |
| Health Care Equipment & Supplies | 6.8% |
| Pharmaceuticals | 3.8% |
| Diversified Consumer Services | 3.3% |
| Capital Markets | 3.2% |
| Media | 3.0% |
| Software | 2.8% |
| Asset Management | 2.4% |
| Commercial Services & Supplies | 2.2% |
| Biotechnology | 1.9% |
| Insurance | 1.7% |
| Thrifts & Mortgage Finance | 1.5% |
| Personal Products | 1.2% |
| Life Sciences Tools & Services | 1.1% |
| Internet Software & Services | 1.0% |
| Communications Equipment | 0.7% |
| Internet & Catalog Retail | 0.6% |
| Transportation Infrastructure | 0.6% |
| Road & Rail | 0.5% |
| Trading Companies & Distributors | 0.3% |
| Health Care Technology | 0.3% |
| Food Products | 0.3% |
| Hotels, Restaurants, & Leisure | 0.2% |
| Aerospace & Defense | 0.2% |
| Machinery | 0.1% |
| Airlines | 0.1% |
| Auto Components | 0.1% |
| Construction & Engineering | 0.1% |
| Metals & Mining | 0.1% |
| Energy Equipment & Services | 0.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Investments | 100.0% |

---

See notes to consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)** 

**September 30, 2025** 

**(in thousands, except share and per share amounts)** 

**Note 1. Organization** 

SLR Investment Corp. (the "Company," "SLRC," "we," "us" or "our"), a Maryland corporation formed in November 2007, is an externally managed, non-diversified closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the "1940 Act"). Furthermore, as the Company is an investment company, it continues to apply the guidance in the Financial Accounting Standards Board Accounting Standards Codification ("ASC") Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code").

On February 9, 2010, the Company priced its initial public offering, selling 5.68 million shares of common stock, including the underwriters' over-allotment, at a price of $18.50 per share. Concurrent with this offering, the Company's senior management purchased an additional 600,000 shares through a private placement, also at $18.50 per share.

The Company's investment objective is to maximize both current income and capital appreciation through debt and equity investments. The Company directly and indirectly invests primarily in leveraged middle market companies in the form of senior secured loans, financing leases and, to a lesser extent, unsecured loans and equity securities. From time to time, we may also invest in public companies that are thinly traded.

On April 1, 2022, we acquired SLR Senior Investment Corp., a Maryland corporation ("SUNS"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 1, 2021, by and among us, SUNS, Solstice Merger Sub, Inc., a Maryland corporation and our wholly-owned subsidiary ("Merger Sub"), and, solely for the limited purposes set forth therein, SLR Capital Partners, LLC (the "Investment Adviser"). Pursuant to the Merger Agreement, Merger Sub merged with and into SUNS, with SUNS continuing as the surviving company and as SUNS's wholly-owned subsidiary (the "Merger") and, immediately thereafter, SUNS merged with and into us, with us continuing as the surviving company (together with the Merger, the "Mergers"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of SUNS's common stock was converted into the right to receive 0.7796 shares of our common stock (with SUNS's stockholders receiving cash in lieu of fractional shares of our common stock). As a result of the Mergers, we issued an aggregate of 12,511,825 shares of our common stock to former SUNS stockholders.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**Note 2. Significant Accounting Policies** 

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles ("GAAP"), and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to the current period presentation.

Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X, as appropriate. Accordingly, they may not include all of the information and notes required by GAAP for annual consolidated financial statements. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. The current period's results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending on December 31, 2025.

In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of consolidated financial statements, have been included.

The significant accounting policies consistently followed by the Company are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Investment transactions are accounted for on the trade date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Under procedures established by the board of directors (the "Board"), we value investments, including certain senior secured debt, subordinated debt and other debt securities with maturities greater than 60 days, for which market quotations are readily available and deemed to represent fair value under GAAP, at such market quotations (unless they are deemed not to represent fair value). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation. We attempt to obtain market quotations from at least two brokers or dealers (if available, otherwise from a principal market maker or a primary market dealer or other independent pricing service). We utilize mid-market pricing as a practical expedient for fair value unless a different point within the range is more representative. If and when market quotations are deemed not to represent fair value, we may utilize independent third-party valuation firms to assist us in determining the fair value of material assets. Accordingly, such investments go through our multi-step valuation process as described below. In each such case, independent valuation firms, that may from time to time be engaged by the Board, consider observable market inputs together with significant unobservable inputs in arriving at their valuation recommendations. Debt investments with maturities of 60 days or less shall each be valued at cost plus accreted discount, or minus amortized premium, which is expected to approximate fair value, unless such valuation, in the judgment of the Investment Adviser, does not represent fair value, in which case such investments shall be valued at fair value as determined in good faith by or under the direction of the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by or under the direction of the Board. Such determination of fair values involves subjective judgments and estimates.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value under GAAP, the Board has approved a multi-step valuation process each quarter, as described below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)our quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of the Investment Adviser responsible for the portfolio investment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)preliminary valuation conclusions are then documented and discussed with senior management of the Investment Adviser;

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)independent valuation firms engaged by the Board conduct independent appraisals and review the Investment Adviser's preliminary valuations and make their own independent assessment for all material assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)the audit committee of the Board reviews the preliminary valuation of the Investment Adviser and that of the independent valuation firm and responds to the valuation recommendation of the independent valuation firm, if any, to reflect any comments; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)the Board discusses valuations and determines the fair value of each investment in our portfolio in good faith based on the input of the Investment Adviser, the respective independent valuation firm, if any, and the audit committee.

The valuation principles set forth above may be modified from time to time, in whole or in part, as determined by the Board in its sole discretion. The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule 2a-5 under the 1940 Act; and (6) maintain recordkeeping requirements under Rule 2a-5.

Investments in all asset classes are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company's ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, our principal market (as the reporting entity) and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the nine months ended September 30, 2025, there has been no change to the Company's valuation approaches or techniques and the nature of the related inputs considered in the valuation process.

ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy:

<u>Level 1</u>: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date.

<u>Level 2</u>: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.

<u>Level 3</u>: Unobservable inputs for the asset or liability.

In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Gains or losses on investments are calculated by using the specific identification method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized, and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums received on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other non-recurring fee income, as well as a management fee and other fee income for services rendered, if any, are recorded as other income when earned.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)The Company intends to comply with the applicable provisions of the Code pertaining to regulated investment companies to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Book and tax basis differences relating to stockholder distributions and other permanent book and tax differences are typically reclassified among the Company's capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)Distributions to common stockholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)In accordance with Regulation S-X and ASC Topic 810—*Consolidation*, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against U.S. dollars on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company's investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)In accordance with ASC 835-30, the Company reports origination and other expenses related to certain debt issuances as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)The Company may enter into forward exchange contracts in order to hedge against foreign currency risk. These contracts are marked-to-market by recognizing the difference between the contract exchange rate and the current market rate as unrealized appreciation or depreciation. Realized gains or losses are recognized when contracts are settled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)The Company records expenses related to shelf registration statements and applicable equity offering costs as prepaid assets. These expenses are typically charged as a reduction of capital upon the sale of shares or expensed, in accordance with ASC 946-20-25.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when principal or interest cash payments are past due 30 days or more (90 days or more for equipment financing) and/or when it is no longer probable that principal or interest cash payments will be collected. Such non-accrual investments are restored to accrual status if past due principal and interest are paid in cash, and in management's judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management's judgment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.

*Recent Accounting Pronouncements*

The Company's management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**Note 3. Agreements** 

The Company has an investment advisory and management agreement (the "Advisory Agreement") with the Investment Adviser, under which the Investment Adviser manages the day-to-day operations of, and provides investment advisory services to, the Company. For providing these services, the Investment Adviser receives a fee from the Company, consisting of two components—a base management fee and a performance-based incentive fee. On April 1, 2022, in connection with the consummation of the Mergers, we entered into a letter agreement (the "Letter Agreement") pursuant to which the Investment Adviser voluntarily agreed to a permanent 25 basis point reduction of the annual base management fee rate payable by us to the Investment Adviser pursuant to the Advisory Agreement. Following the Letter Agreement, the base management fee is now determined by taking the average value of the Company's gross assets at the end of the two most recently completed calendar quarters calculated at an annual rate of 1.50% on gross assets up to 200% of the Company's total net assets as of the immediately preceding quarter end and 1.00% on gross assets that exceed 200% of the Company's total net assets as of the immediately preceding quarter end. For purposes of computing the base management fee, gross assets exclude temporary assets acquired at the end of each fiscal quarter for purposes of preserving investment flexibility in the next fiscal quarter. Temporary assets include, but are not limited to, U.S. Treasury bills, other short-term U.S. government or government agency securities, repurchase agreements or cash borrowings.

The performance-based incentive fee has two parts, as follows: one part is calculated and payable quarterly in arrears based on the Company's pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, pre-incentive fee net investment income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that we receive from portfolio companies) accrued during the calendar quarter, minus the Company's operating expenses for the quarter (including the base management fee, any expenses payable under the Administration Agreement (as defined below), and any interest expense and distributions paid on any issued and outstanding preferred stock, but excluding the performance-based incentive fee). Pre-incentive fee net investment income does not include any realized capital gains or losses, or unrealized capital appreciation or depreciation. Pre-incentive fee net investment income, expressed as a rate of return on the value of the Company's net assets at the end of the immediately preceding calendar quarter, is compared to the hurdle rate of 1.75% per quarter (7% annualized). The Company pays the Investment Adviser a performance-based incentive fee with respect to the Company's pre-incentive fee net investment income in each calendar quarter as follows: (1) no performance-based incentive fee in any calendar quarter in which the Company's pre-incentive fee net investment income does not exceed the hurdle rate; (2) 100% of the Company's pre-incentive fee net investment income with respect to that portion of such pre-incentive fee net investment income, if any, that exceeds the hurdle rate but is less than 2.1875% in any calendar quarter; and (3) 20% of the amount of the Company's pre-incentive fee net investment income, if any, that exceeds 2.1875% in any calendar quarter. These calculations are appropriately pro-rated for any period of less than three months.

The second part of the performance-based incentive fee is determined and payable in arrears as of the end of each calendar year (or upon termination of the Advisory Agreement, as of the termination date), and equals 20% of the Company's cumulative realized capital gains less cumulative realized capital losses, unrealized capital depreciation (unrealized depreciation on a gross investment-by-investment basis at the end of each calendar year) and all net capital gains upon which prior performance-based capital gains incentive fee payments were previously made to the Investment Adviser. For financial statement purposes, the second part of the performance-based incentive fee is accrued based upon 20% of cumulative net realized gains and net unrealized capital appreciation. No accrual was required for the three and nine months ended September 30, 2025 and 2024.

For the three and nine months ended September 30, 2025, the Company recognized $7,977 and $23,250, respectively, in base management fees and $5,403 and $16,326, respectively, in performance-based incentive fees. For the three and nine months ended September 30, 2025, $13 and $35, respectively, of such performance-based incentive fees were waived. For the three and nine months ended September 30, 2024, the Company recognized $7,893 and $23,650, respectively, in base management fees and $6,077 and $18,097, respectively, in performance-based incentive fees. For the three and nine months ended September 30, 2024, $41 and $131, respectively, of such performance-based incentive fees were waived. The Investment Adviser has agreed to waive incentive fees resulting from income earned due to the accretion of purchase discounts allocated to investments acquired as a result of the Mergers. Fees waived pursuant to the above are not subject to recoupment by the Investment Adviser.

The Company has also entered into an administration agreement (the "Administration Agreement") with SLR Capital Management, LLC (the "Administrator") under which the Administrator provides administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Administrator for the Company's allocable portion of overhead and other expenses incurred by the Administrator in performing its obligations under the Administration Agreement,

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

including rent. The Administrator will also provide, on the Company's behalf, managerial assistance to those portfolio companies to which the Company is required to provide such assistance. The Company typically reimburses the Administrator on a quarterly basis.

For the three and nine months ended September 30, 2025, the Company recognized expenses under the Administration Agreement of $1,456 and $4,320, respectively. No managerial assistance fees were accrued or collected for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, the Company recognized expenses under the Administration Agreement of $1,392 and $4,144, respectively. No managerial assistance fees were accrued or collected for the three and nine months ended September 30, 2024.

**Note 4. Net Asset Value Per Share** 

At September 30, 2025, the Company's total net assets and net asset value per share were $993,287 and $18.21, respectively. This compares to total net assets and net asset value per share at December 31, 2024 of $992,926 and $18.20, respectively.

**Note 5. Earnings Per Share** 

The following table sets forth the computation of basic and diluted net increase in net assets per share resulting from operations, pursuant to ASC 260-10, for the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| <u>Earnings per share (basic & diluted)</u> |  |  |  |  |
| Numerator - net increase in net assets resulting from<br> operations: | $23305 | $22049 | $67463 | $73148 |
| Denominator - weighted average shares: | 54554634 | 54554634 | 54554634 | 54554634 |
| Earnings per share: | $0.43 | $0.40 | $1.24 | $1.34 |

---

**Note 6. Fair Value** 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuations used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows:

**Level 1.** Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access.

**Level 2.** Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Quoted prices for similar assets or liabilities in active markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Quoted prices for identical or similar assets or liabilities in non-active markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Pricing models whose inputs are observable for substantially the full term of the asset or liability; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.

**Level 3.** Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's and, if applicable, an independent third-party valuation firm's own assumptions about the assumptions a market participant would use in pricing the asset or liability.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3).

Gains and losses for assets and liabilities categorized within the Level 3 tables below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).

A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1.

The following tables present the balances of assets measured at fair value on a recurring basis, as of September 30, 2025 and December 31, 2024:

**Fair Value Measurements** 

**<u>As of September 30, 2025</u>** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Measured at<br>Net Asset Value\*** | **Total** |
| **Assets:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Senior Secured Loans | $— | $— | $1251236 | $— | $1251236 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment Financing |  |  | 121823 |  | 121823 |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred Equity |  |  | 32156 |  | 32156 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common Equity/Equity Interests/Warrants | 216 |  | 651502 | 48360 | 700078 |
| Total Investments | $216 | $— | $2056717 | $48360 | $2105293 |

---

**Fair Value Measurements** 

**<u>As of December 31, 2024</u>** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Measured at<br>Net Asset Value\*** | **Total** |
| **Assets:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Senior Secured Loans | $— | $— | $1117118 | $— | $1117118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment Financing |  |  | 181016 |  | 181016 |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred Equity |  |  | 31682 |  | 31682 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common Equity/Equity Interests/Warrants | 257 |  | 626470 | 49091 | 675818 |
| Total Investments | $257 | $— | $1956286 | $49091 | $2005634 |

---

\* In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. The portfolio investment in this category is SSLP (as defined below). See Note 17 for more information on this investment, including its investment strategy and the Company's unfunded equity commitment to SSLP. This investment is not redeemable by the Company absent an election by the members of the entity to liquidate all investments and distribute the proceeds to the members.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

The following tables provide a summary of the changes in fair value of Level 3 assets for the three and nine months ended September 30, 2025, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at September 30, 2025:

**Fair Value Measurements Using Level 3 Inputs** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Senior<br>Secured<br>Loans** | **Equipment<br>Financing** | **Preferred Equity** | **Common<br>Equity/<br>Equity<br>Interests/<br>Warrants** | **Total** |
| **Fair value, June 30, 2025** | $1268904 | $138988 | $32510 | $645764 | $2086166 |
| Total gains or losses included in earnings: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gain (loss) | 1360 | (16) |  |  | 1344 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized gain (loss) | (2574) | (1844) | (519) | 5491 | 554 |
| Purchase of investment securities\* | 272045 | 7491 | 806 | 247 | 280589 |
| Proceeds from dispositions of investment securities | (288499) | (22796) | (641) |  | (311936) |
| Transfers in/out of Level 3 |  |  |  |  |  |
| **Fair value, September 30, 2025** | $1251236 | $121823 | $32156 | $651502 | $2056717 |
| Unrealized gains (losses) for the period relating to those<br> Level 3 assets that were still held by the Company at the<br> end of the period: |  |  |  |  |  |
| Net change in unrealized gain (loss) | $(2430) | $(1844) | $(519) | $5491 | $698 |
|  | **Senior<br>Secured<br>Loans** | **Equipment<br>Financing** | **Preferred Equity** | **Common<br>Equity/<br>Equity<br>Interests/<br>Warrants** | **Total** |
| **Fair value, December 31, 2024** | $1117118 | $181016 | $31682 | $626470 | $1956286 |
| Total gains or losses included in earnings: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gain (loss) | 1755 | (34) |  |  | 1721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized gain (loss) | (4098) | (12183) | (1247) | 19287 | 1759 |
| Purchase of investment securities\* | 791182 | 15041 | 2362 | 5745 | 814330 |
| Proceeds from dispositions of investment securities | (654721) | (62017) | (641) |  | (717379) |
| Transfers in/out of Level 3 |  |  |  |  |  |
| **Fair value, September 30, 2025** | $1251236 | $121823 | $32156 | $651502 | $2056717 |
| Unrealized gains (losses) for the period relating to those<br> Level 3 assets that were still held by the Company at the<br> end of the period: |  |  |  |  |  |
| Net change in unrealized gain (loss) | $(1133) | $(12183) | $(1247) | $19287 | $4724 |

---

\* Includes PIK capitalization and accretion of discount.

While the Company has not made an election to apply the fair value option of accounting to any of its current debt obligations, if the Company's debt obligations were carried at fair value at September 30, 2025, the fair value of the Credit Facility, SPV Credit Facility, 2026 Unsecured Notes, 2027 Unsecured Notes, 2027 Series F Unsecured Notes, 2027 Series G Unsecured Notes, 2028 Series H Unsecured Notes, 2028 Series I Unsecured Notes and 2028 Series J Unsecured Notes (each as defined below) would be $498,386, $165,050, $73,688, $47,875, $130,613, $49,368, $50,250, $50,000 and $75,000, respectively. All debt obligations would be considered Level 3 liabilities and would be valued with market yield as the unobservable input.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2024, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2024:

**Fair Value Measurements Using Level 3 Inputs** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Senior<br>Secured<br>Loans** | **Equipment<br>Financing** | **Preferred<br>Equity** | **Common<br>Equity/<br>Equity<br>Interests/<br>Warrants** | **Total** |
| **Fair value, December 31, 2023** | $1277539 | $256819 | $3801 | $572427 | $2110586 |
| Total gains or losses included in earnings: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized loss | (1400) |  |  | (668) | (2068) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized gain (loss) | (3598) | (12646) | 49 | 17726 | 1531 |
| Purchase of investment securities\* | 411598 | 2852 | 27832 | 37434 | 479716 |
| Proceeds from dispositions of investment securities | (567021) | (66009) |  | (449) | (633479) |
| Transfers in/out of Level 3 |  |  |  |  |  |
| **Fair value, December 31, 2024** | $1117118 | $181016 | $31682 | $626470 | $1956286 |
| Unrealized gains (losses) for the period relating to those<br> Level 3 assets that were still held by the Company at<br> the end of the period: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized gain (loss) | $1533 | $(12646) | $49 | $16751 | $5687 |

---

\* Includes PIK capitalization and accretion of discount

While the Company has not made an election to apply the fair value option of accounting to any of its current debt obligations,

if the Company's debt obligations were carried at fair value at December 31, 2024, the fair value of the Credit Facility, SPV Credit

Facility, 2025 Unsecured Notes, 2026 Unsecured Notes, 2027 Unsecured Notes, 2027 Series F Unsecured Notes and 2027 Series G

Unsecured Notes (each as defined below) would be $482,043, $165,050, $84,575, $72,750, $46,875, $128,250 and $49,368, respectively. All debt obligations would be considered Level 3 liabilities and would be valued with market yield as the unobservable input.

**<u>Quantitative Information about Level 3 Fair Value Measurements</u>** 

The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company.

Significant unobservable quantitative inputs typically used in the fair value measurement of the Company's Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization ("EBITDA") multiples of similar companies, and comparable market transactions for equity securities.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

Quantitative information about the Company's Level 3 asset and liability fair value measurements as of September 30, 2025 is summarized in the table below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Asset or<br>Liability** | **Fair Value at<br>September 30, 2025** | **Principal Valuation<br>Technique/Methodology** | **Unobservable<br>Input** | **Range (Weighted<br>Average)** |
| Senior Secured Loans | Asset | $1245434 | Income Approach | Market Yield | 8.4% – 19.8% (11.5%) |
|  | Asset | $5802 | Recovery Analysis | Recoverable Amount | N/A |
| Equipment Financing | Asset | $26823 | Income Approach | Market Yield | 8.0% – 8.5% (8.1%) |
|  |  | $95000 | Market Multiple<sup>(1)</sup> | Comparable Multiple | 1.1x – 1.3x (1.2x) |
| Preferred Equity | Asset | $31197 | Income Approach | Market Yield | 9.0% – 9.0% (9.0%) |
|  |  | $959 | Recovery Analysis | Recoverable Amount | N/A |
| Common Equity/Equity<br> Interests/Warrants | Asset | $481002 | Market Multiple<sup>(2)</sup> | Comparable Multiple | 1.3x – 12.3x (4.0x) |
|  |  | $170500 | Market Approach | Return on Equity | 0.0% – 24.4% (17.5%) |

---

(1)Includes $95,000 of investments valued using an implied multiple.

(2)Includes $134 of investments valued using a Black-Scholes model, $639 of investments valued using a transaction price, $2,040 of investments valued using a recovery analysis, $194,189 of investments valued using an EBITDA multiple and $284,000 of investments using an implied multiple.

Quantitative information about the Company's Level 3 asset and liability fair value measurements as of December 31, 2024 is summarized in the table below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Asset or<br>Liability** | **Fair Value at December 31, 2024** | **Principal Valuation<br>Technique/Methodology** | **Unobservable Input** | **Range (Weighted Average)** |
| Senior Secured Loans | Asset | $1095842 | Income Approach | Market Yield | 8.5% – 18.5% (11.8%) |
|  | Asset | $21276 | Recovery Analysis | Recoverable Amount | N/A |
| Equipment Financing | Asset | $73416 | Income Approach | Market Yield | 8.5% – 9.0% (9.0%) |
|  |  | $107600 | Market Multiple<sup>(1)</sup> | Comparable Multiple | 1.2x – 1.5x (1.5x) |
| Preferred Equity | Asset | $29182 | Income Approach | Market Yield | 9.0% – 9.0% (9.0%) |
|  |  | $2500 | Recovery Analysis | Recoverable Amount | N/A |
| Common Equity/Equity<br> Interests/Warrants | Asset | $175000 | Market Multiple<sup>(2)</sup> | Comparable Multiple | 5.5x – 12.3x (9.1x) |
|  |  | $451470 | Market Approach | Return on Equity | 7.8% – 21.7% (11.3%) |

---

(1)Includes $107,600 of investments valued using an implied multiple.

(2)Includes $293 of investments valued using a Black-Scholes model, $639 of investments valued using a transaction price, $2,040 of investments valued using a recovery analysis and $172,028 of investments valued using an EBITDA multiple.

Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving bid-ask spreads, if applicable, could result in significantly lower or higher fair value measurements for such assets and liabilities. Generally, an increase in market yields or decrease in EBITDA multiples may result in a decrease in the fair value of certain of the Company's investments. Weighted averages in the above tables are calculated based on fair value of the underlying assets.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**Note 7. Debt** 

Our debt obligations consisted of the following as of September 30, 2025 and December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** |
| **<u>Facility</u>** | **Face Amount** | **Carrying Value** | **Face Amount** | **Carrying Value** |
| Credit Facility | $498386 | $492182<br><sup>(1)</sup> | $482043 | $474715<br><sup>(1)</sup> |
| SPV Credit Facility | 165050 | 163814<br><sup>(2)</sup> | 165050 | 163335<br><sup>(2)</sup> |
| 2025 Unsecured Notes |  |  | 85000 | 84956<br><sup>(3)</sup> |
| 2026 Unsecured Notes | 75000 | 74837<br><sup>(4)</sup> | 75000 | 74741<br><sup>(4)</sup> |
| 2027 Unsecured Notes | 50000 | 49988<br><sup>(5)</sup> | 50000 | 49979<br><sup>(5)</sup> |
| 2027 Series F Unsecured Notes | 135000 | 134992<br><sup>(6)</sup> | 135000 | 134998<br><sup>(6)</sup> |
| 2027 Series G Unsecured Notes | 49000 | 48914<br><sup>(7)</sup> | 49000 | 48970<br><sup>(7)</sup> |
| 2028 Series H Unsecured Notes | 50000 | 49927<br><sup>(8)</sup> |  |  |
| 2028 Series I Unsecured Notes | 50000 | 49926<br><sup>(9)</sup> |  |  |
| 2028 Series J Unsecured Notes | 75000 | 74382<br><sup>(10)</sup> |  |  |
|  | $1147436 | $1138962 | $1041093 | $1031694 |

---

(1)Carrying Value equals the Face Amount net of unamortized debt issuance costs of $6,204 and $7,328 as of September 30, 2025 and December 31, 2024, respectively.

(2)Carrying Value equals the Face Amount net of unamortized debt issuance costs/market discount of $1,236 and $1,715 as of September 30, 2025 and December 31, 2024, respectively.

(3)Carrying Value equals the Face Amount net of unamortized market discount of $44 as of December 31, 2024.

(4)Carrying Value equals the Face Amount net of unamortized market discount of $163 and $259 as of September 30, 2025 and December 31, 2024, respectively.

(5)Carrying Value equals the Face Amount net of unamortized market discount of $12 and $21 as of September 30, 2025 and December 31, 2024, respectively.

(6)Carrying Value equals the Face Amount net of unamortized debt issuance costs of $8 and $2 as of September 30, 2025 and December 31, 2024, respectively.

(7)Carrying Value equals the Face Amount net of unamortized debt issuance costs of $86 and $30 as of September 30, 2025 and December 31, 2024, respectively.

(8) Carrying Value equals the Face Amount net of unamortized debt issuance costs of $73 as of September 30, 2025.

(9) Carrying Value equals the Face Amount net of unamortized debt issuance costs of $74 as of September 30, 2025.

(10) Carrying Value equals the Face Amount net of unamortized debt issuance costs of $618 as of September 30, 2025.

*Unsecured Notes* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August 21, 2025, the Company closed a private offering of $75,000 of unsecured notes due 2028 (the "2028 Series J Unsecured Notes") with a fixed interest rate of 5.95% and a maturity date of August 21, 2028. Interest on the 2028 Series J Unsecured Notes is due semi-annually on February 21 and August 21. The 2028 Series J Unsecured Notes were issued in a private placement only to qualified institutional buyers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July 30, 2025, the Company closed a private offering of $50,000 of unsecured notes due 2028 (the "2028 Series I Unsecured Notes") with a fixed interest rate of 5.96% and a maturity date of July 30, 2028. Interest on the 2028 Series I Unsecured Notes is due semi-annually on January 30 and July 30. The 2028 Series I Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On February 18, 2025, the Company closed a private offering of $50,000 of unsecured notes with a fixed interest rate of 6.14% and a maturity date of February 18, 2028 (the "2028 Series H Unsecured Notes"). Interest on the 2028 Series H Unsecured Notes is due semi-annually on February 18 and August 18. The 2028 Series H Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On December 16, 2024, the Company closed a private offering of $49,000 of unsecured notes with a fixed interest rate of 6.24% and a maturity date of December 16, 2027 (the "2027 Series G Unsecured Notes"). Interest on the 2027 Series G Unsecured Notes is

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

due semi-annually on June 16 and December 16. The 2027 Series G Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On April 1, 2022, the Company entered into an assumption agreement (the "Note Assumption Agreement"), effective as of the closing of the Mergers. The Note Assumption Agreement relates to the Company's assumption of $85,000 in aggregate principal amount of five-year, 3.90% senior unsecured notes, due March 31, 2025 (the "2025 Unsecured Notes"), and other obligations of SUNS under the Note Purchase Agreement, dated as of March 31, 2020 (the "Note Purchase Agreement"), among SUNS and certain institutional investors. Interest on the 2025 Unsecured Notes was due semi-annually on March 31 and September 30. Pursuant to the Note Assumption Agreement, the Company expressly assumed on behalf of SUNS the due and punctual payment of the principal of (and premium, if any) and interest on all the 2025 Unsecured Notes outstanding and the due and punctual performance and observance of every covenant and every condition of the Note Purchase Agreement to be performed or observed by SUNS. The 2025 Unsecured Notes were repaid in full at maturity on March 31, 2025.

On January 6, 2022, the Company closed a private offering of $135,000 of unsecured notes with a fixed interest rate of 3.33% and a maturity date of January 6, 2027 (the "2027 Series F Unsecured Notes"). Interest on the 2027 Series F Unsecured Notes is due semi-annually on January 6 and July 6. The 2027 Series F Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On September 14, 2021, the Company closed a private offering of $50,000 of unsecured notes with a fixed interest rate of 2.95% and a maturity date of March 14, 2027 (the "2027 Unsecured Notes"). Interest on the 2027 Unsecured Notes is due semi-annually on March 14 and September 14. The 2027 Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On December 18, 2019, the Company closed a private offering of $75,000 of unsecured notes with a fixed interest rate of 4.375% and a maturity date of December 15, 2026 (the "2026 Unsecured Notes"). Interest on the 2026 Unsecured Notes is due semi-annually on June 15 and December 15. The 2026 Unsecured Notes were issued in a private placement only to qualified institutional buyers.

*Revolving and Term Loan Facilities* 

On August 16, 2024, the Company closed on Amendment No. 3 to its August 28, 2019 senior secured credit agreement (as amended to date, the "Credit Facility"). Following the amendment and several commitment increases between the fourth quarter of 2024 and the quarter ended September 30, 2025, the Credit Facility is now composed of $720,000 of revolving credit and $140,000 of term loans. Borrowings generally bear interest at a rate per annum equal to the base rate plus a range of 1.75%-2.00% or the alternate base rate plus 0.75%-1.00%. The Credit Facility has a 0% floor, matures in August 2029 and includes ratable amortization in the final year. Subsequent to Amendment No. 4 on December 3, 2024, the Credit Facility may be increased up to $900,000 with additional new lenders or an increase in commitments from current lenders. The Credit Facility contains certain customary affirmative and negative covenants and events of default. In addition, the Credit Facility contains certain financial covenants that, among other things, require the Company to maintain a minimum stockholder's equity and a minimum asset coverage ratio. At September 30, 2025, outstanding USD equivalent borrowings under the Credit Facility totaled $498,386, composed of $358,386 of revolving credit and $140,000 of term loans.

On April 1, 2022, the Company entered into an assumption agreement (the "CF Assumption Agreement"), effective as of the closing of the Mergers. The CF Assumption Agreement relates to the Company's assumption of the Revolving Credit Facility, originally entered into on August 26, 2011 (as amended from time to time, the "SPV Credit Facility"), by and among SUNS SPV LLC (the "SUNS SPV"), a wholly-owned subsidiary of SUNS, acting as borrower, Citibank, N.A., acting as administrative agent and collateral agent, and the other parties thereto. Currently, subsequent to an August 30, 2024 amendment, the commitment under the SPV Credit Facility is $275,000. The stated interest rate on the SPV Credit Facility is SOFR plus 2.25%-2.75% with no SOFR floor requirement and the current final maturity date is August 30, 2028. The SPV Credit Facility is secured by all of the assets held by SUNS SPV. Under the terms of the SPV Credit Facility and related transaction documents, the Company as successor to SUNS, and SUNS SPV, as applicable, have made certain customary representations and warranties and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV Credit Facility also includes usual and customary events of default for credit facilities of this nature. At September 30, 2025, outstanding USD equivalent borrowings under the SPV Credit Facility totaled $165,050.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

Certain covenants on our issued debt may restrict our business activities, including limitations that could hinder our ability to finance additional loans and investments or to make the distributions required to maintain our status as a RIC under Subchapter M of the Code.

The average annualized interest cost for all borrowings for the nine months ended September 30, 2025 and the year ended December 31, 2024 was 5.72% and 5.91%, respectively. These costs are exclusive of other credit facility expenses such as unused fees, agency fees and other prepaid expenses related to establishing and/or amending the Credit Facility, the SPV Credit Facility, the 2025 Unsecured Notes, the 2026 Unsecured Notes, the 2027 Unsecured Notes, the 2027 Series F Unsecured Notes, the 2027 Series G Unsecured Notes, the 2028 Series H Unsecured Notes, the 2028 Series I Unsecured Notes and the 2028 Series J Unsecured Notes (collectively the "Debt Instruments"), if any. The maximum amounts borrowed on the Debt Instruments during the nine months ended September 30, 2025 and the year ended December 31, 2024 were $1,223,260 and $1,192,250, respectively.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**Note 8. Financial Highlights** 

The following is a schedule of financial highlights for the nine months ended September 30, 2025 and 2024:

---

| | | |
|:---|:---|:---|
|  | **Nine months ended<br>September 30, 2025** | **Nine months ended<br>September 30, 2024** |
| Per Share Data: (a) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net asset value, beginning of year | $18.20 | $18.09 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 1.20 | 1.33 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) | 0.04 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase in net assets resulting from operations | 1.24 | 1.34 |
| Distributions to stockholders: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From distributable earnings | (1.20) | (1.23) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From return of capital | (0.03) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net asset value, end of period | $18.21 | $18.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Per share market value, end of period | $15.29 | $15.05 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Return (b)(c) | 1.94% | 8.28% |
| &nbsp;&nbsp;&nbsp;&nbsp;Net assets, end of period | $993287 | $992685 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares outstanding, end of period | 54554634 | 54554634 |
| &nbsp;&nbsp;&nbsp;&nbsp;Ratios to average net assets (c): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 6.59% | 7.32% |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating expenses | 4.78%\* | 4.95%\* |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and other credit facility expenses | 5.17% | 5.58% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 9.95%\* | 10.53%\* |
| &nbsp;&nbsp;&nbsp;&nbsp;Average debt outstanding | $1084933 | $1138482 |
| &nbsp;&nbsp;&nbsp;&nbsp;Portfolio turnover ratio | 34.9% | 16.5% |

---

------

(a)Calculated using the average shares outstanding method.

(b)Total return is based on the change in market price per share during the period and takes into account distributions, if any, reinvested in accordance with the dividend reinvestment plan. The market price per share as of December 31, 2024 and December 31, 2023 was $16.16 and $15.03, respectively. Total return does not include a sales load.

(c)Not annualized for periods less than one year.

\* The ratio of operating expenses to average net assets and the ratio of total expenses to average net assets is shown net of the performance-based incentive fee waiver (see note 3). For the nine months ended September 30, 2025 and 2024, the ratios of operating expenses to average net assets would be 4.79% and 4.96%, respectively, without the performance-based incentive fee waiver. For the nine months ended September 30, 2025 and 2024, the ratios of total expenses to average net assets would be 9.96% and 10.54%, respectively, without the performance-based incentive fee waiver.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**Note 9. Commitments and Contingencies** 

*Off-Balance Sheet Arrangements* 

The Company has unfunded debt and equity commitments to various revolving and delayed-draw term loans as well as to SLR Credit and SLR Healthcare (each as defined below). The total amount of these unfunded commitments as of September 30, 2025 and December 31, 2024 was $408,424 and $234,554, respectively, comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,<br>2025** | **December 31,<br>2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cogent Biosciences, Inc. | $56150 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;SLR Credit Solutions\* | 44263 | 44263 |
| &nbsp;&nbsp;&nbsp;&nbsp;Ardelyx, Inc. | 29272 | 6648 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lyneer Staffing Solutions, LLC | 25943 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;OIS Management Services, LLC | 20882 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Infillion Inc. | 20712 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;SLR Business Credit\* | 20000 | 8000 |
| &nbsp;&nbsp;&nbsp;&nbsp;SLR Healthcare ABL\* | 15200 | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Wilbur-Ellis Holdings II, LLC | 14602 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Arcutis Biotherapeutics, Inc. | 12658 | 12658 |
| &nbsp;&nbsp;&nbsp;&nbsp;BDG Media, Inc. | 11661 | 11751 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stella & Chewy's, LLC | 10765 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;SLR Equipment Finance\* | 10500 | 3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;DeepIntent, Inc. | 10358 | 7254 |
| &nbsp;&nbsp;&nbsp;&nbsp;WALCO Funding, LLC | 8733 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Velocity One, LLC | 7250 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United Digestive MSO Parent, LLC | 6554 | 7496 |
| &nbsp;&nbsp;&nbsp;&nbsp;WMD Funding LLC | 6368 | 7243 |
| &nbsp;&nbsp;&nbsp;&nbsp;Quantcast Corporation | 6110 | 4071 |
| &nbsp;&nbsp;&nbsp;&nbsp;The Townsend Company, LLC | 5568 | 7923 |
| &nbsp;&nbsp;&nbsp;&nbsp;Plastic Management, LLC | 5397 | 10806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pinnacle Fertility, Inc. | 5280 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;33 Across Inc. | 4848 | 4226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Copper River Seafoods, Inc. | 4547 | 6912 |
| &nbsp;&nbsp;&nbsp;&nbsp;One Touch Direct, LLC | 4306 | 7970 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sightly Enterprises, Inc. | 3691 | 2687 |
| &nbsp;&nbsp;&nbsp;&nbsp;SPR Therapeutics, Inc. | 3650 | 6083 |
| &nbsp;&nbsp;&nbsp;&nbsp;Streamland Media Holdings LLC | 3285 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;iCIMS, Inc. | 3160 | 3530 |
| &nbsp;&nbsp;&nbsp;&nbsp;CVAUSA Management, LLC | 3151 | 10164 |
| &nbsp;&nbsp;&nbsp;&nbsp;Southern Lifting and Hoisting, LLC | 3064 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sherwood Management Co., Inc. | 2602 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Western Veterinary Partners LLC | 2145 | 18245 |
| &nbsp;&nbsp;&nbsp;&nbsp;SLR Senior Lending Program LLC\* | 2125 | 2125 |
| &nbsp;&nbsp;&nbsp;&nbsp;Bayside Opco, LLC | 2093 | 2093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Southern Transport LLC | 2092 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;SunMed Group Holdings, LLC | 1621 | 1621 |
| &nbsp;&nbsp;&nbsp;&nbsp;SPAR Marketing Force, Inc. | 1600 | 5449 |
| &nbsp;&nbsp;&nbsp;&nbsp;EyeSouth Eye Care Holdco LLC | 1279 | 1279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tilley Distribution, Inc. | 1007 | 1158 |
| &nbsp;&nbsp;&nbsp;&nbsp;Urology Management Holdings, Inc. | 863 | 863 |
| &nbsp;&nbsp;&nbsp;&nbsp;NS and Associates LLC | 727 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;High Street Buyer, Inc. | 629 | 631 |
| &nbsp;&nbsp;&nbsp;&nbsp;CC SAG Holdings Corp. (Spectrum Automotive) | 548 | 548 |
| &nbsp;&nbsp;&nbsp;&nbsp;Omniguide Holdings, Inc. | 350 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;TAUC Management, LLC | 294 | 294 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shoes for Crews Global, LLC | 284 | 284 |
| &nbsp;&nbsp;&nbsp;&nbsp;All States Ag Parts, LLC | 237 | 331 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pasadena Private Lending Inc. |  | 8369 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foundation Consumer Brands, LLC |  | 3009 |
| &nbsp;&nbsp;&nbsp;&nbsp;Erie Construction Mid-west, LLC |  | 2403 |
| &nbsp;&nbsp;&nbsp;&nbsp;Kaseya, Inc. |  | 1917 |
| &nbsp;&nbsp;&nbsp;&nbsp;RxSense Holdings LLC |  | 1250 |
| Total Commitments | $408424 | $234554 |

---

\* The Company controls the funding of these commitments and may cancel them at its discretion.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

The credit agreements governing the above loan commitments contain customary lending provisions and/or are subject to the portfolio company's achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of September 30, 2025 and December 31, 2024, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.

From time to time, the Company may become a party to certain legal proceedings incidental to the normal course of its business. As of September 30, 2025 and December 31, 2024, management is not aware of any material pending or threatened litigation that would require accounting recognition or financial statement disclosure.

**Note 10. Capital Share Transactions** 

As of September 30, 2025 and September 30, 2024, 200,000,000 shares of $0.01 par value capital stock were authorized.

On February 28, 2025, the Company entered into an equity distribution agreement (the "Equity Distribution Agreement") by and among the Company, the Investment Adviser and the Administrator, on the one hand, and Raymond James & Associates, Inc., Citizens JMP Securities, LLC and Jefferies LLC, as placement agents thereunder (collectively, the "Agents"), on the other hand. Under the Equity Distribution Agreement, the Company may, but has no obligation to, issue and sell up to $150,000 in aggregate amount of shares of its common stock from time to time through the Agents, or to them, as principal for their own account.

For the three and nine months ended September 30, 2025, the Company sold no shares of common stock under the Equity Distribution Agreement. As of September 30, 2025, shares representing $150,000 of the Company's common stock remain available for issuance and sale under the Equity Distribution Agreement.

Transactions in capital stock were as follows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Shares** | **Shares** | **Amount** | **Amount** |
|  | **Three months<br>ended September 30, 2025** | **Three months ended September 30, 2024** | **Three months<br>ended September 30, 2025** | **Three months ended September 30, 2024** |
| Share activity |  |  | $— | $— |
|  | **Shares** | **Shares** | **Amount** | **Amount** |
|  | **Nine months<br>ended September 30, 2025** | **Nine months ended September 30, 2024** | **Nine months<br>ended September 30, 2025** | **Nine months ended September 30, 2024** |
| Share activity |  |  | $— | $— |

---

**Note 11. SLR Credit Solutions**

On December 28, 2012, we acquired an equity interest in Crystal Capital Financial Holdings LLC ("Crystal Financial") for $275,000 in cash. Crystal Financial owned approximately 98% of the outstanding ownership interest in SLR Credit Solutions, f/k/a Crystal Financial LLC ("SLR Credit"). The remaining financial interest was held by various employees of SLR Credit, through their investment in Crystal Management LP. SLR Credit had a diversified portfolio of 23 loans having a total par value of approximately $400,000 at November 30, 2012 and a $275,000 committed revolving credit facility. On July 28, 2016, the Company purchased Crystal Management LP's approximately 2% equity interest in SLR Credit for approximately $5,737. Upon the closing of this transaction, the Company holds 100% of the equity interest in SLR Credit. On September 30, 2016, Crystal Capital Financial Holdings LLC was dissolved. As of September 30, 2025, total commitments to the revolving credit facility were $300,000.

As of September 30, 2025, SLR Credit had 34 funded commitments to 26 different issuers with total funded loans of approximately $389,967 on total assets of $419,123. As of December 31, 2024, SLR Credit had 27 funded commitments to 22

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

different issuers with total funded loans of approximately $317,565 on total assets of $364,258. As of September 30, 2025 and December 31, 2024, the largest loan outstanding totaled $27,689 and $27,879, respectively. For the same periods, the average exposure per issuer was $14,999 and $14,435, respectively. SLR Credit's credit facility, which is non-recourse to the Company, had approximately $217,695 and $149,997 of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Credit had net income (loss) of ($1,723) and $8,761, respectively, on gross income of $9,423 and $13,717, respectively. For the nine months ended September 30, 2025 and 2024, SLR Credit had net income of $6,979 and $21,340, respectively, on gross income of $31,955 and $42,313, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Credit's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Credit will be able to maintain consistent dividend payments to us.

**Note 12. SLR Equipment Finance** 

On July 31, 2017, we acquired a 100% equity interest in NEF Holdings, LLC, which conducts its business through its wholly-owned subsidiary Nations Equipment Finance, LLC. Effective February 25, 2021, Nations Equipment Finance, LLC and its related companies are doing business as SLR Equipment Finance ("SLR Equipment"). SLR Equipment is an independent equipment finance company that provides senior secured loans and leases primarily to U.S.-based companies. We invested $209,866 in cash to effect the transaction, of which $145,000 was invested in the equity of SLR Equipment through our wholly-owned consolidated taxable subsidiary NEFCORP LLC and our wholly-owned consolidated subsidiary NEFPASS LLC and $64,866 was used to purchase certain leases and loans held by SLR Equipment through NEFPASS LLC. On January 31, 2024, SLR Equipment entered into a $225,000 senior secured credit facility with a maturity date of January 31, 2027. On March 1, 2024, the credit facility was expanded to $350,000 of commitments.

As of September 30, 2025, SLR Equipment had 507 funded equipment-backed leases and loans to 244 different customers with a total net investment in leases and loans of approximately $300,636 on total assets of $337,547. As of December 31, 2024, SLR Equipment had 398 funded equipment-backed leases and loans to 217 different customers with a total net investment in leases and loans of approximately $324,939 on total assets of $366,258. As of September 30, 2025 and December 31, 2024, the largest position outstanding totaled $16,402 and $17,883, respectively. For the same periods, the average exposure per customer was $1,232 and $1,497, respectively. SLR Equipment's credit facility, which is non-recourse to the Company, had approximately $237,631 and $260,974 of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Equipment had net income (loss) of $1,335 and ($2,328), respectively, on gross income of $5,959 and $5,596, respectively. For the nine months ended September 30, 2025 and 2024, SLR Equipment had net income (loss) of $1,981 and ($6,061), respectively, on gross income of $21,394 and $15,734, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Equipment's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Equipment will be able to maintain consistent dividend payments to us.

**Note 13. Kingsbridge Holdings, LLC** 

On November 3, 2020, the Company acquired 87.5% of the equity securities of Kingsbridge Holdings, LLC ("KBH") through KBH Topco LLC ("KBHT"), a Delaware corporation. KBH is a residual-focused independent mid-ticket lessor of equipment primarily to U.S. investment grade companies. The Company invested $216,596 to effect the transaction, of which $136,596 was invested to acquire 87.5% of KBHT's equity and $80,000 of KBH's debt. The existing management team of KBH committed to continuing to lead KBH after the transaction. Following the transaction, the Company owned 87.5% of KBHT's equity and the KBH management team owned the remaining 12.5% of KBHT's equity. On March 13, 2024, as per the terms of the original purchase agreement, the Company acquired 3.125% of KBHT's equity from the KBH management team. On March 11, 2025, as per the terms of the original purchase agreement, the Company acquired an additional 3.125% of KBHT's equity from the KBH management team. Effective with these purchases, the Company owns 93.75% of KBHT's equity and the KBH management team owns the remaining 6.25%.

As of September 30, 2025 and December 31, 2024, KBHT had total assets of $897,557 and $920,072, respectively. For the same periods, debt recourse to KBHT totaled $257,456 and $271,584, respectively, and non-recourse debt totaled $416,031 and $421,587, respectively. None of the debt is recourse to the Company. For the three months ended September 30, 2025 and 2024,

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

KBHT had net income of $3,510 and $2,890, respectively, on gross income of $87,439 and $83,092, respectively. For the nine months ended September 30, 2025 and 2024, KBHT had net income of $9,750 and $7,493, respectively, on gross income of $275,388 and $241,586, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in KBHT's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that KBHT will be able to maintain consistent dividend payments to us.

**Note 14. SLR Healthcare ABL** 

SUNS acquired an equity interest in SLR Healthcare ABL, f/k/a Gemino Healthcare Finance, LLC ("SLR Healthcare"), on September 30, 2013. SLR Healthcare is a commercial finance company that originates, underwrites, and manages primarily secured, asset-based loans for small and mid-sized companies operating in the healthcare industry. SUNS's initial investment in SLR Healthcare ABL was $32,839. The management team of SLR Healthcare co-invested in the transaction and continues to lead SLR Healthcare. As of September 30, 2025, SLR Healthcare's management team and the Company owned approximately 8% and 92% of the equity in SLR Healthcare, respectively. SLRC acquired SLR Healthcare in connection with the Mergers on April 1, 2022. Effective upon an amendment dated September 19, 2024, SLR Healthcare has a $160,000 non-recourse credit facility, which is expandable to $200,000 under its accordion facility. The maturity date of this facility is March 31, 2026.

SLR Healthcare currently manages a highly diverse portfolio of directly-originated and underwritten senior-secured commitments. As of September 30, 2025, the portfolio totaled approximately $298,750 of commitments with a total net investment in loans of $151,790 on total assets of $160,231. As of December 31, 2024, the portfolio totaled approximately $288,250 of commitments with a total net investment in loans of $130,207 on total assets of $138,494. At September 30, 2025, the portfolio consisted of 48 issuers with an average balance of approximately $3,162 versus 47 issuers with an average balance of approximately $2,770 at December 31, 2024. All of the commitments in SLR Healthcare's portfolio are floating-rate, senior-secured, cash-pay loans. SLR Healthcare's credit facility, which is non-recourse to us, had approximately $122,800 and $99,600 of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Healthcare had net income of $1,501 and $1,289, respectively, on gross income of $6,020 and $4,997, respectively. For the nine months ended September 30, 2025 and 2024, SLR Healthcare had net income of $4,387 and $3,898, respectively, on gross income of $17,116 and $14,874, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Healthcare's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Healthcare will be able to maintain consistent dividend payments to us.

**Note 15. SLR Business Credit** 

SUNS acquired 100% of the equity interests of North Mill Capital LLC ("NMC") on October 20, 2017. NMC is a leading asset-backed lending commercial finance company that provides senior secured asset-backed financings to U.S. based small-to-medium-sized businesses primarily in the manufacturing, services and distribution industries. SUNS invested approximately $51,000 to effect the transaction. Subsequently, SUNS contributed 1% of its equity interest in NMC to ESP SSC Corporation. Immediately thereafter, SUNS and ESP SSC Corporation contributed their equity interests to NorthMill LLC ("North Mill"). On May 1, 2018, North Mill merged with and into NMC, with NMC being the surviving company. SUNS and ESP SSC Corporation then owned 99% and 1% of the equity interests of NMC, respectively. The management team of NMC continues to lead NMC. On June 28, 2019, North Mill Holdco LLC ("NM Holdco"), a newly formed entity and ESP SSC Corporation acquired 100% of Summit Financial Resources, a Salt Lake City-based provider of asset-backed financing to small and medium-sized businesses. As part of this transaction, SUNS's 99% interest in the equity of NMC was contributed to NM Holdco. This approximately $15,500 transaction was financed with borrowings on NMC's credit facility. Effective February 25, 2021, NMC and its related companies are doing business as SLR Business Credit. On June 3, 2021, NMC acquired 100% of Fast Pay Partners LLC, a Los Angeles-based provider of asset-backed financing to digital media companies. The transaction purchase price of $66,671 was financed with equity from SUNS of $19,000 and borrowings on NMC's credit facility of $47,671. SLRC acquired SLR Business Credit in connection with the Mergers on April 1, 2022. On September 27, 2024, NMC acquired an asset-based factoring portfolio and operations from Webster Bank, N.A.'s Commercial Services Division. The transaction purchase price of approximately $127,000 was funded with $30,000 of equity from the Company and the remaining $97,000 from borrowings on NMC's credit facility.

SLR Business Credit currently manages a highly diverse portfolio of directly-originated and underwritten senior-secured commitments. As of September 30, 2025, the portfolio totaled approximately $994,776 of commitments, of which, on a net basis,

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

approximately $552,668 were funded, on total assets of $597,455. As of December 31, 2024, the portfolio totaled approximately $857,953 of commitments, of which $488,402 were funded, on total assets of $527,077. At September 30, 2025, the portfolio consisted of 191 issuers with an average balance of approximately $2,894 versus 188 issuers with an average balance of approximately $2,598 at December 31, 2024. NMC has a senior credit facility with a bank lending group for $367,000 which expires on November 13, 2028. Borrowings are secured by substantially all of NMC's assets. NMC's credit facility, which is non-recourse to us, had approximately $290,335 and $231,034 of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Business Credit had net income of $2,545 and $824 respectively, on gross income of $15,417 and $9,567, respectively. For the nine months ended September 30, 2025 and 2024, SLR Business Credit had net income of $8,026 and $6,329 respectively, on gross income of $41,568 and $31,172, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Business Credit's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Business Credit will be able to maintain consistent dividend payments to us.

**Note 16. Stock Repurchase Program** 

On May 7, 2025, our Board authorized an extension of a program for the purpose of repurchasing up to $50,000 of our outstanding shares of common stock. Under the repurchase program, we may, but are not obligated to, repurchase shares of our outstanding common stock in the open market from time to time provided that we comply with our code of ethics and the guidelines specified in Rule 10b-18 of the Securities Exchange Act of 1934, as amended, including certain price, market volume and timing constraints. In addition, any repurchases will be conducted in accordance with the 1940 Act. Unless further amended or extended by our Board, we expect the repurchase program to be in place until the earlier of May 7, 2026 or until $50,000 of our outstanding shares of common stock have been repurchased. The timing and number of additional shares to be repurchased will depend on a number of factors, including market conditions. There are no assurances that we will engage in any repurchases beyond what is reported herein. There were no share repurchases during the three and nine months ended September 30, 2025 or for the fiscal year ended December 31, 2024.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**Note 17. SLR Senior Lending Program LLC** 

On October 12, 2022, the Company entered into an amended and restated limited liability company agreement with Sunstone Senior Credit L.P. (the "Investor") to create a joint venture vehicle, SLR Senior Lending Program LLC ("SSLP"). SSLP is expected to invest primarily in senior secured cash flow loans. The Company and the Investor each have made initial equity commitments of $50,000, resulting in a total equity commitment of $100,000. Investment decisions and all material decisions in respect of SSLP must be approved by representatives of the Company and the Investor.

On December 1, 2022, SSLP commenced operations. On December 12, 2022, SSLP, as servicer, and SLR Senior Lending Program SPV LLC ("SSLP SPV"), a newly formed wholly owned subsidiary of SSLP, as borrower, entered into a $100,000 senior secured revolving credit facility (the "SSLP Facility") with Goldman Sachs Bank USA acting as administrative agent. On October 20, 2023, the SSLP Facility was expanded to $150,000. Effective with an amendment on March 25, 2024, the SSLP Facility is scheduled to mature on December 12, 2028 and generally bears interest at a rate of SOFR plus 2.90%. SSLP and SSLP SPV, as applicable, have made certain customary representations and warranties and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SSLP Facility also includes usual and customary events of default for credit facilities of this nature. At September 30, 2025 and December 31, 2024, borrowings outstanding on the SSLP Facility totaled $112,500 and $96,600, respectively.

As of September 30, 2025 and December 31, 2024, the Company and the Investor had contributed combined equity capital in the amount of $95,750 and $95,750, respectively. As of September 30, 2025 and December 31, 2024, the Company and the Investor's combined remaining commitments to SSLP totaled $4,250 and $4,250, respectively. The Company and the Investor control the funding of SSLP, and SSLP may not call the unfunded commitments of the Company or the Investor without the approval of both the Company and the Investor.

As of September 30, 2025 and December 31, 2024, SSLP had total assets of $211,521 and $197,461, respectively. For the same periods, SSLP's portfolio consisted of floating rate senior secured loans to 28 and 32 different borrowers, respectively. For the three and nine months ended September 30, 2025, SSLP invested $18,513 and $57,354, respectively, in 4 and 11 portfolio companies, respectively. Investments sold or prepaid totaled $15,258 and $49,030, respectively, for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, SSLP invested $4,331 and $45,532, respectively, in 7 and 16 portfolio companies, respectively. Investments prepaid totaled $21,307 and $29,780, respectively for the three and nine months ended September 30, 2024.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**<u>SSLP Portfolio as of September 30, 2025</u>** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(1)</sup> | **Floor** | **Interest<br>Rate**<sup>(2)</sup> | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value**<sup>(3)</sup> |
| Alkeme Intermediary Holdings, LLC (4) | Insurance | S+500 | 1.00% | 9.00% | 5/2027 | $6554 | $6454 | $6554 |
| All States Ag Parts, LLC (4) | Trading Companies & Distributors | S+650 | 1.00% | 10.76% | 9/2026 | 2078 | 2078 | 2078 |
| BayMark Health Services, Inc. (4) | Health Care Providers & Services | S+500 | 1.00% | 9.26% | 6/2027 | 3971 | 3971 | 3773 |
| CC SAG Holdings Corp. (4) | Diversified Consumer Services | S+525 | 0.75% | 9.41% | 6/2028 | 9948 | 9948 | 9948 |
| Crewline Buyer, Inc. | IT Services | S+675 | 1.00% | 10.91% | 11/2030 | 5084 | 4977 | 5084 |
| CVAUSA Management, LLC (4) | Health Care Providers & Services | S+525 | 1.00% | 9.39% | 5/2029 | 9949 | 9740 | 9949 |
| Exactcare Parent, Inc. | Health Care Providers & Services | S+550 | 1.00% | 9.75% | 11/2029 | 3179 | 3111 | 3179 |
| Eyesouth Eye Care Holdco LLC (4) | Health Care Providers & Services | S+550 | 1.00% | 9.76% | 10/2029 | 9949 | 9906 | 9949 |
| Fertility (ITC) Investment Holdco, LLC (4) | Health Care Providers & Services | S+650 | 1.00% | 10.62% | 1/2029 | 5850 | 5734 | 5850 |
| Foundation Consumer Brands, LLC | Personal Care Products | S+500 | 1.00% | 9.47% | 2/2029 | 7811 | 7811 | 7811 |
| High Street Buyer, Inc. | Insurance | S+525 | 0.75% | 9.25% | 4/2028 | 7468 | 7468 | 7468 |
| iCIMS, Inc.(4) | Software | S+575 | 0.75% | 10.07% | 8/2028 | 10000 | 9968 | 10000 |
| Legacy Service Partners, LLC | Diversified Consumer Services | S+525 | 1.00% | 9.40% | 1/2029 | 2775 | 2724 | 2775 |
| Maxor Acquisition, Inc.(4) | Health Care Providers & Services | S+600 | 1.00% | 10.26% | 3/2029 | 7972 | 7834 | 7972 |
| Medrina, LLC | Health Care Providers & Services | S+600 | 1.00% | 10.13% | 10/2029 | 2765 | 2710 | 2765 |
| ONS MSO, LLC(4) | Health Care Providers & Services | S+625 | 1.00% | 10.56% | 7/2028 | 5804 | 5695 | 5804 |
| Pinnacle Fertility, Inc.(4) | Health Care Providers & Services | S+500 | 0.75% | 9.27% | 3/2028 | 13466 | 13466 | 13466 |
| Plastic Management, LLC(4) | Health Care Providers & Services | S+500 | 1.00% | 9.00% | 8/2027 | 5536 | 5442 | 5536 |
| RQM+ Corp.(4) | Life Sciences Tools & Services | S+675 | 1.00% | 11.01% | 8/2029 | 6079 | 6079 | 5471 |
| RxSense Holdings LLC | Diversified Consumer Services | S+500 | 1.00% | 9.31% | 3/2026 | 8805 | 8805 | 8805 |
| SunMed Group Holdings, LLC(4) | Health Care Equipment & Supplies | S+550 | 0.75% | 9.91% | 6/2028 | 8788 | 8788 | 8788 |
| The Townsend Company, LLC(4) | Commercial Services & Supplies | S+500 | 1.00% | 9.00% | 8/2030 | 12224 | 11911 | 12224 |
| Tilley Distribution, Inc.(4) | Trading Companies & Distributors | S+600 | 1.00% | 10.15% | 12/2026 | 5563 | 5563 | 5452 |
| United Digestive MSO Parent, LLC(4) | Health Care Providers & Services | S+575 | 1.00% | 9.75% | 3/2029 | 3419 | 3344 | 3419 |
| Urology Management Holdings, Inc.(4) | Health Care Providers & Services | S+550 | 1.00% | 9.66% | 6/2027 | 4081 | 4026 | 4081 |
| UVP Management, LLC | Health Care Providers & Services | S+550 | 1.00% | 9.65% | 9/2027 | 3288 | 3240 | 3288 |
| WCI-BXC Purchaser, LLC | Distributors | S+625 | 1.00% | 10.50% | 11/2030 | 2853 | 2795 | 2853 |
| Western Veterinary Partners LLC(4) | Diversified Consumer Services | S+525 | 1.00% | 9.25% | 10/2027 | 12868 | 12815 | 12868 |
|  |  |  |  |  |  |  | $186403 | $187210 |

---

(1)Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR. These instruments are typically subject to a SOFR floor.

(2)Floating rate debt investments typically bear interest at a rate determined by reference to the SOFR ("S"), and which typically reset monthly, quarterly or semi-annually. For each debt investment, we have provided the current interest rate in effect as of September 30, 2025.

(3)Represents the fair value in accordance with ASC Topic 820. The determination of such fair value is not included in the Board's valuation process described elsewhere herein.

(4)The Company also holds this security on its Consolidated Statements of Assets and Liabilities.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

**<u>SSLP Portfolio as of December 31, 2024</u>** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(1)</sup> | **Floor** | **Interest<br>Rate**<sup>(2)</sup> | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value**<sup>(3)</sup> |
| Accession Risk Management Group, Inc. | Insurance | S+475 | 0.75% | 9.08% | 11/2029 | $6888 | $6865 | $6888 |
| Aegis Toxicology Sciences Corporation (4) | Health Care Providers & Services | S+550 | 1.00% | 10.28% | 5/2025 | 2895 | 2895 | 2895 |
| Alkeme Intermediary Holdings, LLC (4) | Insurance | S+575 | 1.00% | 10.08% | 10/2026 | 5984 | 5861 | 5984 |
| All States Ag Parts, LLC (4) | Trading Companies & Distributors | S+600 | 1.00% | 10.59% | 9/2026 | 2111 | 2111 | 2111 |
| BayMark Health Services, Inc. (4) | Health Care Providers & Services | S+500 | 1.00% | 9.59% | 6/2027 | 3992 | 3992 | 3992 |
| CC SAG Holdings Corp. (4) | Diversified Consumer Services | S+525 | 0.75% | 9.58% | 6/2028 | 8877 | 8877 | 8877 |
| Crewline Buyer, Inc. | IT Services | S+675 | 1.00% | 11.11% | 11/2030 | 5084 | 4966 | 5084 |
| CVAUSA Management, LLC (4) | Health Care Providers & Services | S+650 | 1.00% | 10.84% | 5/2029 | 5357 | 5220 | 5357 |
| Erie Construction Mid-west, LLC | Building Products | S+475 | 1.00% | 10.09% | 7/2027 | 8000 | 8000 | 8000 |
| Exactcare Parent, Inc. | Health Care Providers & Services | S+550 | 1.00% | 10.03% | 11/2029 | 3203 | 3125 | 3203 |
| Eyesouth Eye Care Holdco LLC (4) | Health Care Providers & Services | S+550 | 1.00% | 10.15% | 10/2029 | 2646 | 2596 | 2646 |
| Fertility (ITC) Investment Holdco, LLC (4) | Health Care Providers & Services | S+650 | 1.00% | 11.74% | 1/2029 | 5895 | 5757 | 5895 |
| Foundation Consumer Brands, LLC (4) | Personal Products | S+625 | 1.00% | 10.89% | 2/2027 | 8102 | 8102 | 8102 |
| High Street Buyer, Inc. | Insurance | S+525 | 0.75% | 9.58% | 4/2028 | 7527 | 7527 | 7527 |
| iCIMS, Inc.(4) | Software | S+575 | 0.75% | 10.38% | 8/2028 | 3195 | 3158 | 3195 |
| Kaseya, Inc.(4) | Software | S+550 | 0.75% | 10.75% | 6/2029 | 9127 | 9127 | 9127 |
| Kid Distro Holdings, LLC | Software | S+475 | 1.00% | 9.49% | 10/2029 | 8848 | 8848 | 8848 |
| Legacy Service Partners, LLC | Diversified Consumer Services | S+525 | 1.00% | 9.73% | 1/2029 | 2796 | 2733 | 2796 |
| Maxor Acquisition, Inc.(4) | Health Care Providers & Services | S+600 | 1.00% | 10.46% | 3/2029 | 6058 | 5906 | 6058 |
| Medrina, LLC | Health Care Providers & Services | S+600 | 1.00% | 10.44% | 10/2029 | 2386 | 2333 | 2386 |
| ONS MSO, LLC(4) | Health Care Providers & Services | S+625 | 1.00% | 10.84% | 7/2026 | 5833 | 5738 | 5833 |
| Plastic Management, LLC(4) | Health Care Providers & Services | S+500 | 1.00% | 9.43% | 8/2027 | 5579 | 5453 | 5579 |
| Retina Midco, Inc.(4) | Health Care Providers & Services | S+575 | 1.00% | 10.35% | 1/2026 | 9918 | 9793 | 10116 |
| RQM+ Corp.(4) | Life Sciences Tools & Services | S+675 | 1.00% | 11.34% | 8/2029 | 5895 | 5895 | 5659 |
| RxSense Holdings LLC(4) | Diversified Consumer Services | S+500 | 1.00% | 9.69% | 3/2026 | 8875 | 8875 | 8875 |
| SunMed Group Holdings, LLC(4) | Health Care Equipment & Supplies | S+550 | 0.75% | 10.19% | 6/2028 | 8856 | 8856 | 8856 |
| The Townsend Company, LLC(4) | Commercial Services & Supplies | S+500 | 1.00% | 9.36% | 8/2030 | 4117 | 4026 | 4078 |
| Tilley Distribution, Inc.(4) | Trading Companies & Distributors | S+600 | 1.00% | 10.48% | 12/2026 | 5607 | 5607 | 5495 |
| United Digestive MSO Parent, LLC(4) | Health Care Providers & Services | S+575 | 1.00% | 10.08% | 3/2029 | 3433 | 3346 | 3433 |
| Urology Management Holdings, Inc.(4) | Health Care Providers & Services | S+550 | 1.00% | 9.83% | 6/2027 | 4112 | 4035 | 4112 |
| UVP Management, LLC(4) | Health Care Providers & Services | S+625 | 1.00% | 10.73% | 9/2025 | 4858 | 4803 | 4858 |
| WCI-BXC Purchaser, LLC | Distributors | S+625 | 1.00% | 10.78% | 11/2030 | 2875 | 2810 | 2875 |
|  |  |  |  |  |  |  | $177236 | $178740 |

---

(1)Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR. These instruments are typically subject to a SOFR floor.

(2)Floating rate debt investments typically bear interest at a rate determined by reference to the SOFR ("S"), and which typically reset monthly, quarterly or semi-annually. For each debt investment, we have provided the current interest rate in effect as of December 31, 2024.

(3)Represents the fair value in accordance with ASC Topic 820. The determination of such fair value is not included in the Board's valuation process described elsewhere herein.

(4)The Company also holds this security on its Consolidated Statements of Assets and Liabilities.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

Below is certain summarized financial information for SSLP as of September 30, 2025 and December 31, 2024 and for the three and nine months ended September 30, 2025 and September 30, 2024:

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31,<br>2024** |
| **Selected Balance Sheet Information for SSLP:** |  |  |
| Investments at fair value (cost $186,403 and $177,236,<br> respectively) | $187210 | $178740 |
| Cash and other assets | 24311 | 18721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $211521 | $197461 |
| Debt outstanding ($112,500 and $96,600 face amounts,<br> respectively, reported net of unamortized debt issuance<br> costs of $1,194 and $1,572, respectively) | $111306 | $95028 |
| Distributions payable | 2684 | 3381 |
| Interest payable and other credit facility related expenses | 429 | 472 |
| Accrued expenses and other payables | 383 | 398 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $114802 | $99279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Members' equity | $96719 | $98182 |
| Total liabilities and members' equity | $211521 | $197461 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| **Selected Income Statement Information for SSLP:** |  |  |  |  |
| Interest income | $5092 | $6375 | $14119 | $18960 |
| Service fees\* | 116 | 132 | 330 | 392 |
| Interest and other credit facility expenses | 2263 | 2800 | 6753 | 8438 |
| Other general and administrative expenses | 57 | 46 | 189 | 136 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 2436 | 2978 | 7272 | 8966 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net investment income | $2656 | $3397 | $6847 | $9994 |
| Realized gain on investments | 21 |  | 358 |  |
| Net change in unrealized gain (loss) on investments | (353) | 29 | (697) | 420 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | $(332) | $29 | $(339) | $420 |
| Net income | $2324 | $3426 | $6508 | $10414 |

---

\* Service fees are included within the Company's Consolidated Statements of Operations as other income.

**Note 18. Segment Reporting**

The Company operates as a single reporting segment and derives its revenue from providing comprehensive financing solutions primarily to middle market borrowers in the United States through direct cash flow lending or specialty finance instruments. The Company has identified its co-CEOs as the Chief Operating Decision Maker ("CODM"). The CODM reviews all significant segment expenses on the Consolidated Statements of Operations and uses net investment income to evaluate the performance of the Company

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR INVESTMENT CORP.** 

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (continued)**

**September 30, 2025**

**(in thousands, except share and per share amounts)**

and to determine distributions. Additionally, the CODM uses net asset value per share (see Note 4) to determine capital adequacy of the Company. All metrics are used to ultimately allocate resources to the Company as needed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accounting policies used to measure the revenue and expenses of the segment are the same as those described in Note 2.

**Note 19. Subsequent Events** 

The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 4, 2025, the Board declared a quarterly distribution of $0.41 per share payable on December 26, 2025 to holders of record as of December 12, 2025.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Report of Independent Registered Public Accounting Firm** 

To the Stockholders and Board of Directors

SLR Investment Corp.:

*Results of Review of Interim Financial Information* 

We have reviewed the consolidated statement of assets and liabilities of SLR Investment Corp. (and subsidiaries) (the Company), including the consolidated schedule of investments, as of September 30, 2025, the related consolidated statements of operations and changes in net assets for the three-month and nine-month periods ended September 30, 2025 and 2024, the related consolidated statements of cash flows for the nine-month periods ended September 30, 2025 and 2024, and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statement of assets and liabilities, including the consolidated schedule of investments, of the Company as of December 31, 2024, and the related consolidated statements of operations, changes in net assets, and cash flows for the year then ended (not presented herein); and in our report dated February 25, 2025, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated statement of assets and liabilities, including the consolidated schedule of investments, as of December 31, 2024, is fairly stated, in all material respects, in relation to the consolidated statement of assets and liabilities, including the consolidated schedule of investments, from which it has been derived.

*Basis for Review Results* 

This consolidated interim financial information is the responsibility of the Company's management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ KPMG LLP

New York, New York

November 4, 2025

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

*The information contained in this section should be read in conjunction with our consolidated financial statements and notes thereto appearing elsewhere in this report.* 

Some of the statements in this report constitute forward-looking statements, which relate to future events or our future performance or financial condition. The forward-looking statements contained herein involve risks and uncertainties, including statements as to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our future operating results, including our ability to achieve objectives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our business prospects and the prospects of our portfolio companies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of investments that we expect to make;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our contractual arrangements and relationships with third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the dependence of our future success on the general economy and its impact on the industries in which we invest;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of any protracted decline in the liquidity of credit markets on our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the uncertainty associated with the imposition of tariffs and trade barriers and changes in trade policy and its impact on our portfolio companies and the global economy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in import/export regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the ability of our portfolio companies to achieve their objectives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the valuation of our investments in portfolio companies, particularly those having no liquid trading market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•market conditions and our ability to access alternative debt markets and additional debt and equity capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expected financings and investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the adequacy of our cash resources and working capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the timing of cash flows, if any, from the operations of our portfolio companies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the ability of SLR Capital Partners, LLC (the "Investment Adviser") to locate suitable investments for us and to monitor and administer our investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the ability of the Investment Adviser to attract and retain highly talented professionals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the ability of the Investment Adviser to adequately allocate investment opportunities among the Company and the Investment Adviser's other advisory clients;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•any conflicts of interest posed by the structure of the management fee and incentive fee to be paid to the Investment Adviser;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in political, economic or industry conditions, relations between the United States, Russia, Ukraine and other nations, the interest rate environment or conditions affecting the financial and capital markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the escalating conflict in the Middle East;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of geopolitical conditions on our portfolio companies and on the industries in which we invest;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in the general economy, slowing economy, inflation, risk of recession, risks in respect of a failure to increase the U.S. debt ceiling or government shutdown and uncertainty surrounding the financial and political stability of the United States and other countries; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to anticipate and identify evolving market expectations with respect to environmental, social and governance matters, including the environmental impacts of our portfolio companies' supply chains and operations.

------

[**<u>**Table of Contents**</u>**](#toc_page)

These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•an economic downturn could impair our portfolio companies' ability to continue to operate, which could lead to the loss of some or all of our investments in such portfolio companies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•a contraction of available credit and/or an inability to access the equity markets could impair our lending and investment activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•interest rate volatility could adversely affect our results, particularly because we use leverage as part of our investment strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•currency fluctuations could adversely affect the results of our investments in foreign companies, particularly to the extent that we receive payments denominated in foreign currency rather than U.S. dollars; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the risks, uncertainties and other factors we identify in Item 1A. — Risk Factors contained in our Annual Report on Form 10-K for the year ended December 31, 2024, elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (the "SEC").

We generally use words such as "anticipates," "believes," "expects," "intends" and similar expressions to identify forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements for any reason, including any factors set forth in "Risk Factors" and elsewhere in this report.

We have based the forward-looking statements included in this report on information available to us on the date of this report, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the SEC, including any annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.

**Overview** 

SLR Investment Corp. (the "Company," "SLRC," "we" or "our"), a Maryland corporation formed in November 2007, is an externally managed, non-diversified closed-end management investment company that has elected to be regulated as a business development company ("BDC") under the Investment Company Act of 1940, as amended (the "1940 Act"). Furthermore, as the Company is an investment company, it continues to apply the guidance in the Financial Accounting Standards Board Accounting Standards Codification ("ASC") Topic 946. In addition, for U.S federal income tax purposes, the Company has elected to be treated as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code").

On February 9, 2010, we priced our initial public offering, selling 5.68 million shares of our common stock. Concurrent with our initial public offering, Michael S. Gross, our Chairman, Co-Chief Executive Officer and President, and Bruce Spohler, our Co-Chief Executive Officer, Chief Operating Officer and board member, collectively purchased an additional 0.6 million shares of our common stock through a private placement transaction exempt from registration under the Securities Act of 1933, as amended.

We invest primarily in privately held U.S. middle-market companies, where we believe the supply of primary capital is limited and the investment opportunities are most attractive. Our investment objective is to generate both current income and capital appreciation through debt and equity investments. We invest primarily in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities. From time to time, we may also invest in public companies that are thinly traded. Our business is focused primarily on the direct origination of investments through portfolio companies or their financial sponsors. Our investments generally range between $5 million and $100 million each, although we expect that this investment size will vary proportionately with the size of our capital base and/or with strategic initiatives. Our investment activities are managed by the Investment Adviser and supervised by our board of directors (the "Board"), a majority of whom are non-interested, as such term is defined in the 1940 Act. SLR Capital Management, LLC (the "Administrator") provides the administrative services necessary for us to operate.

In addition, we may invest a portion of our portfolio in other types of investments, which we refer to as opportunistic investments, which are not our primary focus but are intended to enhance our overall returns. These investments may include, but are not limited to, direct investments in public companies that are not thinly traded and securities of leveraged companies located in select countries outside of the United States.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Recent Developments** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 4, 2025, the Board declared a quarterly distribution of $0.41 per share payable on December 26, 2025 to holders of record as of December 12, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.

**Investments** 

Our level of investment activity can and does vary substantially from period to period depending on many factors, including the amount of debt and equity capital available to middle market companies, the level of merger and acquisition activity for such companies, the general economic environment and the competitive environment for the types of investments we make. As a BDC, we must not acquire any assets other than "qualifying assets" specified in the 1940 Act unless, at the time the acquisition is made, at least 70% of our total assets are qualifying assets (with certain limited exceptions). Qualifying assets include investments in "eligible portfolio companies." The definition of "eligible portfolio company" includes certain public companies that do not have any securities listed on a national securities exchange and companies whose securities are listed on a national securities exchange but whose market capitalization is less than $250 million.

**Revenue** 

We generate revenue primarily in the form of interest and dividend income from the securities we hold and capital gains, if any, on investment securities that we may sell. Our debt investments generally have a stated term of three to seven years and typically bear interest at a floating rate usually determined on the basis of a benchmark Secured Overnight Financing Rate ("SOFR"), commercial paper rate, or the prime rate. Interest on our debt investments is generally payable monthly or quarterly but may be bi-monthly or semi-annually. In addition, our investments may provide payment-in-kind ("PIK") income. Such amounts of accrued PIK income are added to the cost of the investment on the respective capitalization dates and generally become due at maturity of the investment or upon the investment being called by the issuer. We may also generate revenue in the form of commitment, origination, structuring fees, fees for providing managerial assistance and, if applicable, consulting fees, etc.

**Expenses** 

All investment professionals of the Investment Adviser and their respective staffs, when and to the extent engaged in providing investment advisory and management services, and the compensation and routine overhead expenses of such personnel allocable to such services, are provided and paid for by the Investment Adviser. We bear all other costs and expenses of our operations and transactions, including (without limitation):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the cost of our organization and public offerings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the cost of calculating our net asset value, including the cost of any third-party valuation services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the cost of effecting sales and repurchases of our shares and other securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•interest payable on debt, if any, to finance our investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•fees payable to third parties relating to, or associated with, making investments, including fees and expenses associated with performing due diligence reviews of prospective investments and advisory fees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•transfer agent and custodial fees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•fees and expenses associated with marketing efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•federal and state registration fees, any stock exchange listing fees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•federal, state and local taxes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•independent directors' fees and expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•brokerage commissions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•fidelity bond, directors and officers errors and omissions liability insurance and other insurance premiums;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•direct costs and expenses of administration, including printing, mailing, long distance telephone and staff;

------

[**<u>**Table of Contents**</u>**](#toc_page)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•fees and expenses associated with independent audits and outside legal costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•costs associated with our reporting and compliance obligations under the 1940 Act and applicable federal and state securities laws; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•all other expenses incurred by either the Administrator or us in connection with administering our business, including payments under the Administration Agreement (as defined below) that will be based upon our allocable portion of overhead and other expenses incurred by the Administrator in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions, and our allocable portion of the costs of compensation and related expenses of our chief compliance officer and our chief financial officer and their respective staffs.

We expect our general and administrative operating expenses related to our ongoing operations to increase moderately in dollar terms. During periods of asset growth, we generally expect our general and administrative operating expenses to decline as a percentage of our total assets and increase during periods of asset declines. Incentive fees, interest expense and costs relating to future offerings of securities, among others, may also increase or reduce overall operating expenses based on portfolio performance, interest rate benchmarks and offerings of our securities relative to comparative periods, among other factors.

**Portfolio and Investment Activity** 

During the three months ended September 30, 2025, we invested approximately $276.9 million across 33 portfolio companies. This compares to investing approximately $157.1 million in 25 portfolio companies during the three months ended September 30, 2024. Investments sold, prepaid or repaid during the three months ended September 30, 2025 totaled approximately $311.9 million versus approximately $223.5 million for the three months ended September 30, 2024.

At September 30, 2025, our portfolio consisted of 109 portfolio companies and was invested 22.9% in cash flow senior secured loans, 46.2% in asset-based senior secured loans / SLR Credit Solutions ("SLR Credit") / SLR Healthcare ABL / SLR Business Credit, 18.7% in equipment senior secured financings / SLR Equipment Finance ("SLR Equipment") / Kingsbridge Holdings, LLC ("KBH") and 12.2% in life science investments, in each case, measured at fair value, versus 131 portfolio companies invested 33.0% in cash flow senior secured loans, 32.6% in asset-based senior secured loans / SLR Credit / SLR Healthcare ABL / SLR Business Credit, 21.5% in equipment senior secured financings / SLR Equipment / KBH, and 12.9% in life science investments, in each case, measured at fair value, at September 30, 2024.

At September 30, 2025, 83.4%, or $1.74 billion, of our income producing investment portfolio<sup>\*</sup> was floating rate and 16.6%, or $344.7 million, was fixed rate, measured at fair value. At September 30, 2024, 80.8%, or $1.66 billion, of our income producing investment portfolio\* was floating rate and 19.2%, or $393.8 million, was fixed rate, measured at fair value. As of September 30, 2025 and 2024, we had one and one issuers, respectively, on non-accrual status.

<sup>\*</sup> We have included SLR Credit Solutions, SLR Equipment Finance, SLR Healthcare ABL, SLR Business Credit and Kingsbridge Holdings, LLC within our income producing investment portfolio.

**SLR Credit Solutions** 

On December 28, 2012, we acquired an equity interest in Crystal Capital Financial Holdings LLC ("Crystal Financial") for $275 million in cash. Crystal Financial owned approximately 98% of the outstanding ownership interest in SLR Credit Solutions, f/k/a Crystal Financial LLC. The remaining financial interest was held by various employees of SLR Credit, through their investment in Crystal Management LP. SLR Credit had a diversified portfolio of 23 loans having a total par value of approximately $400 million at November 30, 2012 and a $275 million committed revolving credit facility. On July 28, 2016, the Company purchased Crystal Management LP's approximately 2% equity interest in SLR Credit for approximately $5.7 million. Upon the closing of this transaction, the Company holds 100% of the equity interest in SLR Credit. On September 30, 2016, Crystal Capital Financial Holdings LLC was dissolved. As of September 30, 2025, total commitments to the revolving credit facility were $300 million.

As of September 30, 2025, SLR Credit had 34 funded commitments to 26 different issuers with total funded loans of approximately $390.0 million on total assets of $419.1 million. As of December 31, 2024, SLR Credit had 27 funded commitments to 22 different issuers with total funded loans of approximately $317.6 million on total assets of $364.3 million. As of September 30, 2025 and December 31, 2024, the largest loan outstanding totaled $27.7 million and $27.9 million, respectively. For the same periods, the average exposure per issuer was $15.0 million and $14.4 million, respectively. SLR Credit's credit facility, which is non-recourse to the Company, had approximately $217.7 million and $150.0 million of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Credit had net income (loss) of

------

[**<u>**Table of Contents**</u>**](#toc_page)

($1.7) million and $8.8 million, respectively, on gross income of $9.4 million and $13.7 million, respectively. For the nine months ended September 30, 2025 and 2024, SLR Credit had net income of $7.0 million and $21.3 million, respectively, on gross income of $32.0 million and $42.3 million, respectively. Due to timing and non-cash items, there may be material differences between U.S. generally accepted accounting principles ("GAAP") net income and cash available for distributions. As such, and subject to fluctuations in SLR Credit's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Credit will be able to maintain consistent dividend payments to us.

**SLR Equipment Finance** 

On July 31, 2017, we acquired a 100% equity interest in NEF Holdings, LLC, which conducts its business through its wholly-owned subsidiary Nations Equipment Finance, LLC. Effective February 25, 2021, Nations Equipment Finance, LLC and its related companies are doing business as SLR Equipment Finance. SLR Equipment is an independent equipment finance company that provides senior secured loans and leases primarily to U.S. based companies. We invested $209.9 million in cash to effect the transaction, of which $145.0 million was invested in the equity of SLR Equipment through our wholly-owned consolidated taxable subsidiary NEFCORP LLC and our wholly-owned consolidated subsidiary NEFPASS LLC and $64.9 million was used to purchase certain leases and loans held by SLR Equipment through NEFPASS LLC. On January 31, 2024, SLR Equipment entered into a $225 million senior secured credit facility with a maturity date of January 31, 2027. On March 1, 2024, the credit facility was expanded to $350 million of commitments.

As of September 30, 2025, SLR Equipment had 507 funded equipment-backed leases and loans to 244 different customers with a total net investment in leases and loans of approximately $300.6 million on total assets of $337.5 million. As of December 31, 2024, SLR Equipment had 398 funded equipment-backed leases and loans to 217 different customers with a total net investment in leases and loans of approximately $324.9 million on total assets of $366.3 million. As of September 30, 2025 and December 31, 2024, the largest position outstanding totaled $16.4 million and $17.9 million, respectively. For the same periods, the average exposure per customer was $1.2 million and $1.5 million, respectively. SLR Equipment's credit facility, which is non-recourse to the Company, had approximately $237.6 million and $261.0 million of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Equipment had net income (loss) of $1.3 million and ($2.3) million, respectively, on gross income of $6.0 million and $5.6 million, respectively. For the nine months ended September 30, 2025 and 2024, SLR Equipment had net income (loss) of $2.0 million and ($6.1) million, respectively, on gross income of $21.4 million and $15.7 million, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Equipment's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Equipment will be able to maintain consistent dividend payments to us.

**Kingsbridge Holdings, LLC** 

On November 3, 2020, the Company acquired 87.5% of the equity securities of Kingsbridge Holdings, LLC through KBH Topco LLC ("KBHT"), a Delaware corporation. KBH is a residual focused independent mid-ticket lessor of equipment primarily to U.S. investment grade companies. The Company invested $216.6 million to effect the transaction, of which $136.6 million was invested to acquire 87.5% of KBHT's equity and $80.0 million of KBH's debt. The existing management team of KBH committed to continuing to lead KBH after the transaction. Following the transaction, the Company owns 87.5% of KBHT's equity and the KBH management team owns the remaining 12.5% of KBHT's equity. On March 13, 2024, as per the terms of the original purchase agreement, the Company acquired 3.125% of KBHT's equity from the KBH management team. On March 11, 2025, as per the terms of the original purchase agreement, the Company acquired an additional 3.125% of KBHT's equity from the KBH management team. Effective with these purchases, the Company owns 93.75% of KBHT's equity and the KBH management team owns the remaining 6.25%.

As of September 30, 2025 and December 31, 2024, KBHT had total assets of $897.6 million and $920.1 million, respectively. For the same periods, debt recourse to KBHT totaled $257.5 million and $271.6 million, respectively, and non-recourse debt totaled $416.0 million and $421.6 million, respectively. None of the debt is recourse to the Company. For the three months ended September 30, 2025 and 2024, KBHT had net income of $3.5 million and $2.9 million, respectively, on gross income of $87.4 million and $83.1 million, respectively. For the nine months ended September 30, 2025 and 2024, KBHT had net income of $9.8 million and $7.5 million, respectively, on gross income of $275.4 million and $241.6 million, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in KBHT's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that KBHT will be able to maintain consistent dividend payments to us.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SLR Healthcare ABL** 

SLR Senior Investment Corp. ("SUNS") acquired an equity interest in SLR Healthcare ABL, f/k/a Gemino Healthcare Finance, LLC ("SLR Healthcare") on September 30, 2013. SLR Healthcare is a commercial finance company that originates, underwrites, and manages primarily secured, asset-based loans for small and mid-sized companies operating in the healthcare industry. SUNS's initial investment in SLR Healthcare ABL was approximately $32.8 million. The management team of SLR Healthcare co-invested in the transaction and continues to lead SLR Healthcare. As of September 30, 2025, SLR Healthcare's management team and the Company owned approximately 8% and 92% of the equity in SLR Healthcare, respectively. SLRC acquired SLR Healthcare in connection with the Mergers (as defined in Note 1 to the Company's Consolidated Financial Statements) on April 1, 2022. Effective with an amendment dated September 19, 2024, SLR Healthcare has a $160 million non-recourse credit facility, which is expandable to $200 million under its accordion facility. The maturity date of this facility is March 31, 2026.

SLR Healthcare currently manages a highly diverse portfolio of directly-originated and underwritten senior-secured commitments. As of September 30, 2025, the portfolio totaled approximately $298.8 million of commitments with a total net investment in loans of $151.8 million on total assets of $160.2 million. As of December 31, 2024, the portfolio totaled approximately $288.3 million of commitments with a total net investment in loans of $130.2 million on total assets of $138.5 million. At September 30, 2025, the portfolio consisted of 48 issuers with an average balance of approximately $3.2 million versus 47 issuers with an average balance of approximately $2.8 million at December 31, 2024. All of the commitments in SLR Healthcare's portfolio are floating-rate, senior-secured, cash-pay loans. SLR Healthcare's credit facility, which is non-recourse to us, had approximately $122.8 million and $99.6 million of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Healthcare had net income of $1.5 million and $1.3 million, respectively, on gross income of $6.0 million and $5.0 million, respectively. For the nine months ended September 30, 2025 and 2024, SLR Healthcare had net income of $4.4 million and $3.9 million, respectively, on gross income of $17.1 million and $14.9 million, respectively. Due to timing and non-cash items, there may be material differences between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Healthcare's funded commitments, the timing of originations, and the repayment of financings, the Company cannot guarantee that SLR Healthcare will be able to maintain consistent dividend payments to us.

**SLR Business Credit** 

SUNS acquired 100% of the equity interests of North Mill Capital LLC ("NMC") on October 20, 2017. NMC is a leading asset-backed lending commercial finance company that provides senior secured asset-backed financings to U.S. based small-to-medium-sized businesses primarily in the manufacturing, services and distribution industries. SUNS invested approximately $51.0 million to effect the transaction. Subsequently, SUNS contributed 1% of its equity interest in NMC to ESP SSC Corporation. Immediately thereafter, SUNS and ESP SSC Corporation contributed their equity interests to NorthMill LLC ("North Mill"). On May 1, 2018, North Mill merged with and into NMC, with NMC being the surviving company. SUNS and ESP SSC Corporation then owned 99% and 1% of the equity interests of NMC, respectively. The management team of NMC continues to lead NMC. On June 28, 2019, North Mill Holdco LLC ("NM Holdco"), a newly formed entity and ESP SSC Corporation acquired 100% of Summit Financial Resources, a Salt Lake City-based provider of asset-backed financing to small and medium-sized businesses. As part of this transaction, SUNS's 99% interest in the equity of NMC was contributed to NM Holdco. This approximately $15.5 million transaction was financed with borrowings on NMC's credit facility. Effective February 25, 2021, NMC and its related companies are doing business as SLR Business Credit. On June 3, 2021, NMC acquired 100% of Fast Pay Partners LLC, a Los Angeles-based provider of asset-backed financing to digital media companies. The transaction purchase price of $66.7 million was financed with equity from SUNS of $19.0 million and borrowings on NMC's credit facility of $47.7 million. SLRC acquired SLR Business Credit in connection with the Mergers on April 1, 2022. On September 27, 2024, NMC acquired an asset-based factoring portfolio and operations from Webster Bank, N.A.'s Commercial Services Division. The transaction purchase price of approximately $127 million was funded with $30 million of equity from the Company and the remaining $97 million from borrowings on NMC's credit facility.

SLR Business Credit currently manages a highly diverse portfolio of directly-originated and underwritten senior-secured commitments. As of September 30, 2025, the portfolio totaled approximately $994.8 million of commitments, of which, on a net basis, approximately $552.7 million were funded, on total assets of $597.5 million. As of December 31, 2024, the portfolio totaled approximately $858.0 million of commitments, of which $488.4 million were funded, on total assets of $527.1 million. At September 30, 2025, the portfolio consisted of 191 issuers with an average balance of approximately $2.9 million versus 188 issuers with an average balance of approximately $2.6 million at December 31, 2024. NMC has a senior credit facility with a bank lending group for $367.0 million, which expires on November 13, 2028. Borrowings are secured by substantially all of NMC's assets. NMC's credit facility, which is non-recourse to us, had approximately $290.3 million and $231.0 million of borrowings outstanding at September 30, 2025 and December 31, 2024, respectively. For the three months ended September 30, 2025 and 2024, SLR Business Credit had net income of $2.5 million and $0.8 million, respectively, on gross income of $15.4 million and $9.6 million, respectively. For the nine months ended September 30, 2025 and 2024, SLR Business Credit had net income of $8.0 million and $6.3 million, respectively, on gross income of $41.6 million and $31.2 million, respectively. Due to timing and non-cash items, there may be material differences

------

[**<u>**Table of Contents**</u>**](#toc_page)

between GAAP net income and cash available for distributions. As such, and subject to fluctuations in SLR Business Credit's funded commitments, the timing of originations, and the repayments of financings, the Company cannot guarantee that SLR Business Credit will be able to maintain consistent dividend payments to us.

**SLR Senior Lending Program LLC** 

On October 12, 2022, the Company entered into an amended and restated limited liability company agreement with Sunstone Senior Credit L.P. (the "Investor") to create a joint venture vehicle, SLR Senior Lending Program LLC ("SSLP"). SSLP is expected to invest primarily in senior secured cash flow loans. The Company and the Investor each have made initial equity commitments of $50 million, resulting in a total equity commitment of $100 million. Investment decisions and all material decisions in respect of SSLP must be approved by representatives of the Company and the Investor.

On December 1, 2022, SSLP commenced operations. On December 12, 2022, SSLP, as servicer, and SLR Senior Lending Program SPV LLC ("SSLP SPV"), a newly formed wholly owned subsidiary of SSLP, as borrower, entered into a $100 million senior secured revolving credit facility (the "SSLP Facility") with Goldman Sachs Bank USA acting as administrative agent. On October 20, 2023, the SSLP Facility was expanded to $150 million. Effective with an amendment on March 25, 2024, the SSLP Facility is scheduled to mature on December 12, 2028 and generally bears interest at a rate of SOFR plus 2.90%. SSLP and SSLP SPV, as applicable, have made certain customary representations and warranties and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SSLP Facility also includes usual and customary events of default for credit facilities of this nature. At September 30, 2025 and December 31, 2024, borrowings outstanding on the SSLP Facility totaled $112.5 million and $96.6 million, respectively.

As of September 30, 2025 and December 31, 2024, the Company and the Investor had contributed combined equity capital in the amount of $95.75 million and $95.75 million, respectively. As of September 30, 2025 and December 31, 2024, the Company and the Investor's combined remaining commitments to SSLP totaled $4.25 million and $4.25 million, respectively. The Company, along with the Investor, controls the funding of SSLP, and SSLP may not call the unfunded commitments of the Company or the Investor without the approval of both the Company and the Investor.

As of September 30, 2025 and December 31, 2024, SSLP had total assets of $211.5 million and $197.5 million, respectively. For the same periods, SSLP's portfolio consisted of floating rate senior secured loans to 28 and 32 different borrowers, respectively. For the three and nine months ended September 30, 2025, SSLP invested $18.5 million and $57.4 million, respectively, in 4 and 11 portfolio companies, respectively. Investments sold or prepaid totaled $15.3 million and $49.0 million, respectively for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, SSLP invested $4.3 million and $45.5 million, respectively, in 7 and 16 portfolio companies, respectively. Investments prepaid totaled $21.3 million and $29.8 million, respectively, for the three and nine months ended September 30, 2024.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**<u>SSLP Portfolio as of September 30, 2025 (dollar amounts in thousands)</u>** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(1)</sup> | **Floor** | **Interest<br>Rate**<sup>(2)</sup> | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value**<sup>(3)</sup> |
| Alkeme Intermediary Holdings, LLC (4) | Insurance | S+500 | 1.00% | 9.00% | 5/2027 | $6554 | $6454 | $6554 |
| All States Ag Parts, LLC (4) | Trading Companies & Distributors | S+650 | 1.00% | 10.76% | 9/2026 | 2078 | 2078 | 2078 |
| BayMark Health Services, Inc. (4) | Health Care Providers & Services | S+500 | 1.00% | 9.26% | 6/2027 | 3971 | 3971 | 3773 |
| CC SAG Holdings Corp. (4) | Diversified Consumer Services | S+525 | 0.75% | 9.41% | 6/2028 | 9948 | 9948 | 9948 |
| Crewline Buyer, Inc. | IT Services | S+675 | 1.00% | 10.91% | 11/2030 | 5084 | 4977 | 5084 |
| CVAUSA Management, LLC (4) | Health Care Providers & Services | S+525 | 1.00% | 9.39% | 5/2029 | 9949 | 9740 | 9949 |
| Exactcare Parent, Inc. | Health Care Providers & Services | S+550 | 1.00% | 9.75% | 11/2029 | 3179 | 3111 | 3179 |
| Eyesouth Eye Care Holdco LLC (4) | Health Care Providers & Services | S+550 | 1.00% | 9.76% | 10/2029 | 9949 | 9906 | 9949 |
| Fertility (ITC) Investment Holdco, LLC (4) | Health Care Providers & Services | S+650 | 1.00% | 10.62% | 1/2029 | 5850 | 5734 | 5850 |
| Foundation Consumer Brands, LLC | Personal Care Products | S+500 | 1.00% | 9.47% | 2/2029 | 7811 | 7811 | 7811 |
| High Street Buyer, Inc. | Insurance | S+525 | 0.75% | 9.25% | 4/2028 | 7468 | 7468 | 7468 |
| iCIMS, Inc.(4) | Software | S+575 | 0.75% | 10.07% | 8/2028 | 10000 | 9968 | 10000 |
| Legacy Service Partners, LLC | Diversified Consumer Services | S+525 | 1.00% | 9.40% | 1/2029 | 2775 | 2724 | 2775 |
| Maxor Acquisition, Inc.(4) | Health Care Providers & Services | S+600 | 1.00% | 10.26% | 3/2029 | 7972 | 7834 | 7972 |
| Medrina, LLC | Health Care Providers & Services | S+600 | 1.00% | 10.13% | 10/2029 | 2765 | 2710 | 2765 |
| ONS MSO, LLC(4) | Health Care Providers & Services | S+625 | 1.00% | 10.56% | 7/2028 | 5804 | 5695 | 5804 |
| Pinnacle Fertility, Inc.(4) | Health Care Providers & Services | S+500 | 0.75% | 9.27% | 3/2028 | 13466 | 13466 | 13466 |
| Plastic Management, LLC(4) | Health Care Providers & Services | S+500 | 1.00% | 9.00% | 8/2027 | 5536 | 5442 | 5536 |
| RQM+ Corp.(4) | Life Sciences Tools & Services | S+675 | 1.00% | 11.01% | 8/2029 | 6079 | 6079 | 5471 |
| RxSense Holdings LLC | Diversified Consumer Services | S+500 | 1.00% | 9.31% | 3/2026 | 8805 | 8805 | 8805 |
| SunMed Group Holdings, LLC(4) | Health Care Equipment & Supplies | S+550 | 0.75% | 9.91% | 6/2028 | 8788 | 8788 | 8788 |
| The Townsend Company, LLC(4) | Commercial Services & Supplies | S+500 | 1.00% | 9.00% | 8/2030 | 12224 | 11911 | 12224 |
| Tilley Distribution, Inc.(4) | Trading Companies & Distributors | S+600 | 1.00% | 10.15% | 12/2026 | 5563 | 5563 | 5452 |
| United Digestive MSO Parent, LLC(4) | Health Care Providers & Services | S+575 | 1.00% | 9.75% | 3/2029 | 3419 | 3344 | 3419 |
| Urology Management Holdings, Inc.(4) | Health Care Providers & Services | S+550 | 1.00% | 9.66% | 6/2027 | 4081 | 4026 | 4081 |
| UVP Management, LLC | Health Care Providers & Services | S+550 | 1.00% | 9.65% | 9/2027 | 3288 | 3240 | 3288 |
| WCI-BXC Purchaser, LLC | Distributors | S+625 | 1.00% | 10.50% | 11/2030 | 2853 | 2795 | 2853 |
| Western Veterinary Partners LLC(4) | Diversified Consumer Services | S+525 | 1.00% | 9.25% | 10/2027 | 12868 | 12815 | 12868 |
|  |  |  |  |  |  |  | $186403 | $187210 |

---

(1)Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR. These instruments are typically subject to a SOFR floor.

(2)Floating rate debt investments typically bear interest at a rate determined by reference to the SOFR ("S"), and which typically reset monthly, quarterly or semi-annually. For each debt investment, we have provided the current interest rate in effect as of September 30, 2025.

(3)Represents the fair value in accordance with ASC Topic 820. The determination of such fair value is not included in the Board's valuation process described elsewhere herein.

(4)The Company also holds this security on its Consolidated Statements of Assets and Liabilities.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**<u>SSLP Portfolio as of December 31, 2024 (dollar amounts in thousands)</u>** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Description** | **Industry** | **Spread<br>Above<br>Index**<sup>(1)</sup> | **Floor** | **Interest<br>Rate**<sup>(2)</sup> | **Maturity<br>Date** | **Par<br>Amount** | **Cost** | **Fair<br>Value**<sup>(3)</sup> |
| Accession Risk Management Group, Inc. | Insurance | S+475 | 0.75% | 9.08% | 11/2029 | $6888 | $6865 | $6888 |
| Aegis Toxicology Sciences Corporation (4) | Health Care Providers & Services | S+550 | 1.00% | 10.28% | 5/2025 | 2895 | 2895 | 2895 |
| Alkeme Intermediary Holdings, LLC (4) | Insurance | S+575 | 1.00% | 10.08% | 10/2026 | 5984 | 5861 | 5984 |
| All States Ag Parts, LLC (4) | Trading Companies & Distributors | S+600 | 1.00% | 10.59% | 9/2026 | 2111 | 2111 | 2111 |
| BayMark Health Services, Inc. (4) | Health Care Providers & Services | S+500 | 1.00% | 9.59% | 6/2027 | 3992 | 3992 | 3992 |
| CC SAG Holdings Corp. (4) | Diversified Consumer Services | S+525 | 0.75% | 9.58% | 6/2028 | 8877 | 8877 | 8877 |
| Crewline Buyer, Inc. | IT Services | S+675 | 1.00% | 11.11% | 11/2030 | 5084 | 4966 | 5084 |
| CVAUSA Management, LLC (4) | Health Care Providers & Services | S+650 | 1.00% | 10.84% | 5/2029 | 5357 | 5220 | 5357 |
| Erie Construction Mid-west, LLC | Building Products | S+475 | 1.00% | 10.09% | 7/2027 | 8000 | 8000 | 8000 |
| Exactcare Parent, Inc. | Health Care Providers & Services | S+550 | 1.00% | 10.03% | 11/2029 | 3203 | 3125 | 3203 |
| Eyesouth Eye Care Holdco LLC (4) | Health Care Providers & Services | S+550 | 1.00% | 10.15% | 10/2029 | 2646 | 2596 | 2646 |
| Fertility (ITC) Investment Holdco, LLC (4) | Health Care Providers & Services | S+650 | 1.00% | 11.74% | 1/2029 | 5895 | 5757 | 5895 |
| Foundation Consumer Brands, LLC (4) | Personal Products | S+625 | 1.00% | 10.89% | 2/2027 | 8102 | 8102 | 8102 |
| High Street Buyer, Inc. | Insurance | S+525 | 0.75% | 9.58% | 4/2028 | 7527 | 7527 | 7527 |
| iCIMS, Inc.(4) | Software | S+575 | 0.75% | 10.38% | 8/2028 | 3195 | 3158 | 3195 |
| Kaseya, Inc.(4) | Software | S+550 | 0.75% | 10.75% | 6/2029 | 9127 | 9127 | 9127 |
| Kid Distro Holdings, LLC | Software | S+475 | 1.00% | 9.49% | 10/2029 | 8848 | 8848 | 8848 |
| Legacy Service Partners, LLC | Diversified Consumer Services | S+525 | 1.00% | 9.73% | 1/2029 | 2796 | 2733 | 2796 |
| Maxor Acquisition, Inc.(4) | Health Care Providers & Services | S+600 | 1.00% | 10.46% | 3/2029 | 6058 | 5906 | 6058 |
| Medrina, LLC | Health Care Providers & Services | S+600 | 1.00% | 10.44% | 10/2029 | 2386 | 2333 | 2386 |
| ONS MSO, LLC(4) | Health Care Providers & Services | S+625 | 1.00% | 10.84% | 7/2026 | 5833 | 5738 | 5833 |
| Plastic Management, LLC(4) | Health Care Providers & Services | S+500 | 1.00% | 9.43% | 8/2027 | 5579 | 5453 | 5579 |
| Retina Midco, Inc.(4) | Health Care Providers & Services | S+575 | 1.00% | 10.35% | 1/2026 | 9918 | 9793 | 10116 |
| RQM+ Corp.(4) | Life Sciences Tools & Services | S+675 | 1.00% | 11.34% | 8/2029 | 5895 | 5895 | 5659 |
| RxSense Holdings LLC(4) | Diversified Consumer Services | S+500 | 1.00% | 9.69% | 3/2026 | 8875 | 8875 | 8875 |
| SunMed Group Holdings, LLC(4) | Health Care Equipment & Supplies | S+550 | 0.75% | 10.19% | 6/2028 | 8856 | 8856 | 8856 |
| The Townsend Company, LLC(4) | Commercial Services & Supplies | S+500 | 1.00% | 9.36% | 8/2030 | 4117 | 4026 | 4078 |
| Tilley Distribution, Inc.(4) | Trading Companies & Distributors | S+600 | 1.00% | 10.48% | 12/2026 | 5607 | 5607 | 5495 |
| United Digestive MSO Parent, LLC(4) | Health Care Providers & Services | S+575 | 1.00% | 10.08% | 3/2029 | 3433 | 3346 | 3433 |
| Urology Management Holdings, Inc.(4) | Health Care Providers & Services | S+550 | 1.00% | 9.83% | 6/2027 | 4112 | 4035 | 4112 |
| UVP Management, LLC(4) | Health Care Providers & Services | S+625 | 1.00% | 10.73% | 9/2025 | 4858 | 4803 | 4858 |
| WCI-BXC Purchaser, LLC | Distributors | S+625 | 1.00% | 10.78% | 11/2030 | 2875 | 2810 | 2875 |
|  |  |  |  |  |  |  | $177236 | $178740 |

---

(1)Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR. These instruments are typically subject to a SOFR floor.

(2)Floating rate debt investments typically bear interest at a rate determined by reference to the SOFR ("S"), and which typically reset monthly, quarterly or semi-annually. For each debt investment, we have provided the current interest rate in effect as of December 31, 2024.

(3)Represents the fair value in accordance with ASC Topic 820. The determination of such fair value is not included in the Board's valuation process described elsewhere herein.

(4)The Company also holds this security on its Consolidated Statements of Assets and Liabilities.

Below is certain summarized financial information for SSLP as of September 30, 2025 and December 31, 2024 and for the three and nine months ended September 30, 2025 and 2024:

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31,<br>2024** |
| **Selected Balance Sheet Information for SSLP:** |  |  |
| Investments at fair value (cost $186,403 and $177,236,<br> respectively) | $187210 | $178740 |
| Cash and other assets | 24311 | 18721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $211521 | $197461 |
| Debt outstanding ($112,500 and $96,600 face amounts,<br> respectively, reported net of unamortized debt issuance<br> costs of $1,194 and $1,572, respectively) | $111306 | $95028 |
| Distributions payable | 2684 | 3381 |
| Interest payable and other credit facility related expenses | 429 | 472 |
| Accrued expenses and other payables | 383 | 398 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $114802 | $99279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Members' equity | $96719 | $98182 |
| Total liabilities and members' equity | $211521 | $197461 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| **Selected Income Statement Information for SSLP (in thousands):** |  |  |  |  |
| Interest income | $5092 | $6375 | $14119 | $18960 |
| Service fees\* | 116 | 132 | 330 | 392 |
| Interest and other credit facility expenses | 2263 | 2800 | 6753 | 8438 |
| Other general and administrative expenses | 57 | 46 | 189 | 136 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 2436 | 2978 | 7272 | 8966 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net investment income | $2656 | $3397 | $6847 | $9994 |
| Realized gain on investments | 21 |  | 358 |  |
| Net change in unrealized gain (loss) on investments | (353) | 29 | (697) | 420 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | $(332) | $29 | $(339) | $420 |
| Net income | $2324 | $3426 | $6508 | $10414 |

---

\* Service fees are included within the Company's Consolidated Statements of Operations as other income.

**Critical Accounting Policies** 

The preparation of consolidated financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following items as critical accounting policies. Within the context of these critical accounting policies and disclosed subsequent events herein, we are not currently aware of any other reasonably likely events or circumstances that would result in materially different amounts being reported.

***Valuation of Portfolio Investments*** 

In December 2020, the SEC adopted Rule 2a-5 under the 1940 Act addressing fair valuation of fund investments. The rule sets forth requirements for good faith determinations of fair value, as well as for the performance of fair value determinations, including related oversight and reporting obligations. The rule also defines "readily available market quotations" for purposes of the definition of "value" under the 1940 Act, and the SEC noted that this definition will apply in all contexts under the 1940 Act. The Company complies with the Rule 2a-5 valuation requirements.

We conduct the valuation of our assets, pursuant to which our net asset value is determined, at all times consistent with GAAP and the 1940 Act. The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule 2a-5 under the 1940 Act; and (6) maintain recordkeeping requirements under Rule 2a-5.

It is anticipated that in respect of many of the Company's assets, readily available market quotations will not be obtainable and that such assets will be valued at fair value. A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation.

Our valuation procedures are set forth in more detail in Note 2(b) to the Company's consolidated financial statements. Determination of fair value involves subjective judgments and estimates. Accordingly, the notes to our consolidated financial statements express the uncertainty with respect to the possible effect of such valuations, and any change in such valuations, on our consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Revenue Recognition*** 

The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Investments that are expected to pay regularly scheduled interest and/or dividends in cash are generally placed on non-accrual status when principal or interest/dividend cash payments are past due 30 days or more (90 days or more for equipment financing) and/or when it is no longer probable that principal or interest/dividend cash payments will be collected. Such non-accrual investments are restored to accrual status if past due principal and interest or dividends are paid in cash, and in management's judgment, are likely to continue timely payment of their remaining interest or dividend obligations. Interest or dividend cash payments received on investments may be recognized as income or applied to principal depending upon management's judgment. Some of our investments may have contractual PIK income. PIK income computed at the contractual rate, as applicable, is accrued and reflected as a receivable up to the capitalization date. PIK investments offer issuers the option at each payment date of making payments in cash or in additional securities. When additional securities are received, they typically have the same terms, including maturity dates and interest rates, as the original securities issued. On these payment dates, the Company capitalizes the accrued interest or dividends receivable (reflecting such amounts as the basis in the additional securities received). PIK generally becomes due at the maturity of the investment or upon the investment being called by the issuer. At the point the Company believes PIK is not expected to be realized, the PIK investment will be placed on non-accrual status. When a PIK investment is placed on non-accrual status, the accrued, uncapitalized interest or dividends is reversed from the related receivable through interest or dividend income, respectively. The Company does not reverse previously capitalized PIK income. Upon capitalization, PIK is subject to the fair value estimates associated with their related investments. PIK investments on non-accrual status are restored to accrual status if the Company again believes that PIK is expected to be realized. Loan origination fees, original issue discount, and market discounts are capitalized and amortized into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record prepayment premiums on loans and other investments as interest income when we receive such amounts. Capital structuring fees are recorded as other income when earned.

The typically higher yields and interest rates on PIK securities, to the extent we invested, reflect the payment deferral and increased credit risks associated with such instruments and that such investments may represent a significantly higher credit risk than coupon loans. PIK securities may have unreliable valuations because their continuing accruals require continuing judgments about the collectability of the deferred payments and the value of any associated collateral. PIK income has the effect of generating investment income and increasing the incentive fees payable at a compounding rate. In addition, the deferral of PIK income also increases the loan-to-value ratio at a compounding rate. PIK securities create the risk that incentive fees will be paid to the Investment Adviser based on non-cash accruals that ultimately may not be realized, but the Investment Adviser will be under no obligation to reimburse the Company for these fees. For the three and nine months ended September 30, 2025, capitalized PIK income totaled $1.9 million and $5.4 million, respectively. For the three and nine months ended September 30, 2024, capitalized PIK income totaled $1.4 million and $6.1 million, respectively.

***Net Realized Gain or Loss and Net Change in Unrealized Gain or Loss*** 

We generally measure realized gain or loss by the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment, without regard to unrealized appreciation or depreciation previously recognized, but considering unamortized origination or commitment fees and prepayment penalties. The net change in unrealized gain or loss reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized gain or loss, when gains or losses are realized. Gains or losses on investments are calculated by using the specific identification method.

***Income Taxes*** 

SLRC, a U.S. corporation, has elected to be treated, and intends to qualify annually, as a RIC under Subchapter M of the Code. In order to qualify for U.S. federal income taxation as a RIC, the Company is required, among other things, to timely distribute to its stockholders at least 90% of investment company taxable income, as defined by the Code, for each year. Depending on the level of taxable income earned in a given tax year, we may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a nondeductible 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues an estimated excise tax, if any, on estimated excess taxable income.

**Recent Accounting Pronouncements** 

The Company considers the applicability and impact of all accounting standard updates ("ASU") issued by the Financial Accounting Standards Board. ASUs not listed were assessed and either determined to be not applicable or expected to have minimal impact on its consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**RESULTS OF OPERATIONS** 

Results comparisons for the three and nine months ended September 30, 2025 and September 30, 2024 are presented below:

**Investment Income** 

For the three and nine months ended September 30, 2025, gross investment income totaled $57.0 million and $164.1 million, respectively. For the three and nine months ended September 30, 2024, gross investment income totaled $59.8 million and $176.8 million, respectively. The decrease in gross investment income for the year over year three and nine month periods was primarily due to a decrease in the average size of the income-producing investment portfolio as well as a decrease in index rates.

**Expenses** 

Net expenses totaled $35.4 million and $98.7 million, respectively, for the three and nine months ended September 30, 2025, of which $13.4 million and $39.6 million, respectively, consisted of base management fees and performance-based incentive fees and $18.7 million and $51.3 million, respectively, consisted of interest and other credit facility expenses. Other general and administrative expenses totaled $3.3 million and $7.9 million, respectively, for the three and nine months ended September 30, 2025. Over the same periods, $13 thousand and $35 thousand of performance-based incentive fees were waived. Net expenses totaled $35.4 million and $104.3 million, respectively, for the three and nine months ended September 30, 2024, of which $14.0 million and $41.7 million, respectively, were base management fees and performance-based incentive fees and $18.9 million and $55.3 million, respectively, were interest and other credit facility expenses. Other general and administrative expenses totaled $2.6 million and $7.4 million, respectively, for the three and nine months ended September 30, 2024. Over the same periods, $41 thousand and $0.1 million of performance-based incentive fees were waived. Expenses generally consist of management and performance-based incentive fees, interest and other credit facility expenses, administrative services fees, insurance expenses, legal fees, directors' fees, transfer agency fees, printing and proxy expenses, audit and tax services expenses and other general and administrative expenses. Interest and other credit facility expenses generally consist of interest, unused fees, agency fees and loan origination fees, if any, among others. The decrease in expenses for the year over year nine month periods was primarily due to lower interest expense from a decrease in average borrowings as well as a decrease in the index rates on borrowings.

**Net Investment Income** 

The Company's net investment income totaled $21.6 million and $65.3 million, or $0.40 and $1.20, per average share, respectively, for the three and nine months ended September 30, 2025. The Company's net investment income totaled $24.3 million and $72.5 million, or $0.45 and $1.33, per average share, respectively, for the three and nine months ended September 30, 2024.

**Net Realized Gain (Loss)**

The Company had investment sales and prepayments totaling approximately $312 million and $718 million, respectively, for the three and nine months ended September 30, 2025. Net realized gains over the same periods were $1.3 million and $1.1 million, respectively. The Company had investment sales and prepayments totaling approximately $224 million and $447 million, respectively, for the three and nine months ended September 30, 2024. Net realized losses over the same periods were $2.7 million and $2.5 million, respectively. Net realized gain (loss) for the three and nine months ended September 30, 2025 and 2024 were primarily due to the disposition of selected assets.

**Net Change in Unrealized Gain (Loss)** 

For the three and nine months ended September 30, 2025, net change in unrealized gain on the Company's assets totaled $0.4 million and $1.0 million, respectively. Net unrealized gain for the three months ended September 30, 2025 was primarily due to appreciation in the value of our investments in SLR Business Credit, KBH Topco, LLC, SLR-AMI Topco Blocker LLC, Arcutis Biotherapeutics, Inc., Bayside Parent, LLC and Cerapedics, Inc., among others, partially offset by depreciation in the value of our investments in SLR Credit Solutions, SLR Equipment Finance and RQM+ Corp., among others, as well as the reversal of previously recognized unrealized appreciation upon the refinance of our investment in DeepIntent, Inc. Net unrealized gain for the nine months ended September 30, 2025 was primarily due to appreciation in the value of our investments in KBH Topco, LLC, SLR Business Credit, Bayside Parent, LLC, Arcutis Biotherapeutics, Inc., Cerapedics, Inc. and Centinel Spine LLC, among others, partially offset by depreciation in the value of our investments in SLR Equipment Finance, SLR Credit Solutions, SLR-AMI Topco Blocker, LLC, RQM+ Corp., OmniGuide Holdings, Inc., SOINT, LLC and SLR Senior Lending Program LLC, among others, as well as the reversal of previously recognized unrealized appreciation upon the exit of our investments in Outset Medical, Inc. and Retina Midco, Inc. For the three and nine months ended September 30, 2024, net change in unrealized gain (loss) on the Company's assets totaled $0.4 million and $3.1 million, respectively. Net unrealized gain for the three months ended September 30, 2024 was primarily due to

------

[**<u>**Table of Contents**</u>**](#toc_page)

appreciation in the value of our investments in KBH Topco, LLC, Outset Medical, Inc. and Bayside Parent, LLC, among others, partially offset by the reversal of previously recognized unrealized appreciation on our investments in Neuronetics, Inc. and Alimera Sciences, Inc. as well as depreciation in the value of our investment in SLR Equipment Finance and Logix Holding Company, among others. Net unrealized gain for the nine months ended September 30, 2024 was primarily due to appreciation in the value of our investments in KBH Topco, LLC, SLR Credit Solutions, Outset Medical, Inc. and Bayside Parent, LLC, among others, partially offset the reversal of previously recognized unrealized appreciation on our investment in Alimera Sciences, Inc. as well as by depreciation in the value of our investments in SLR Equipment Finance, SOINT, LLC and RQM+ Corp., among others.

**Net Increase in Net Assets from Operations** 

For the three and nine months ended September 30, 2025, the Company had a net increase in net assets resulting from operations of $23.3 million and $67.5 million, respectively. For the same periods, earnings per average share were $0.43 and $1.24, respectively. For the three and nine months ended September 30, 2024, the Company had a net increase in net assets resulting from operations of $22.0 million and $73.1 million, respectively. For the same periods, earnings per average share were $0.40 and $1.34, respectively.

**LIQUIDITY AND CAPITAL RESOURCES** 

The Company's liquidity and capital resources are generated and generally available through its Credit Facility and SPV Credit Facility, the 2026 Unsecured Notes, the 2027 Unsecured Notes, the 2027 Series F Unsecured Notes, the 2027 Series G Unsecured Notes, the 2028 Series H Unsecured Notes, the 2028 Series I Unsecured Notes and the 2028 Series J Unsecured Notes (each as defined below and, collectively, the "Debt Instruments"), through cash flows from operations, investment sales, prepayments of senior and subordinated loans, income earned on investments and cash equivalents, and periodic follow-on equity and/or debt offerings. As of September 30, 2025, we had a total of $471.6 million of collective unused borrowing capacity under the Credit Facility and SPV Credit Facility, subject to borrowing base limits.

On February 28, 2025, the Company entered into an equity distribution agreement (the "Equity Distribution Agreement") by and among the Company, the Investment Adviser and the Administrator, on the one hand, and Raymond James & Associates, Inc., Citizens JMP Securities, LLC and Jefferies LLC, as placement agents thereunder (collectively, the "Agents"), on the other hand. Under the Equity Distribution Agreement, the Company may, but has no obligation to, issue and sell up to $150.0 million in aggregate amount of shares of its common stock from time to time through the Agents, or to them, as principal for their own account.

For the three and nine months ended September 30, 2025, the Company sold no shares of common stock under the Equity Distribution Agreement. As of September 30, 2025, shares representing $150.0 million of our common stock remain available for issuance and sale under the Equity Distribution Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may from time to time issue other equity and/or debt securities in either public or private offerings. The issuance of such securities will depend on future market conditions, funding needs and other factors and there can be no assurance that any such issuance will occur or be successful. The primary uses of existing funds and any funds raised in the future are expected to be for investments in portfolio companies, repayment of indebtedness, cash distributions to our stockholders, or for other general corporate purposes.

**Debt** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August 21, 2025, the Company closed a private offering of $75 million of unsecured notes due 2028 (the "2028 Series J Unsecured Notes") with a fixed interest rate of 5.95% and a maturity date of August 21, 2028. Interest on the 2028 Series J Unsecured Notes is due semi-annually on February 21 and August 21. The 2028 Series J Unsecured Notes were issued in a private placement only to qualified institutional buyers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July 30, 2025, the Company closed a private offering of $50 million of unsecured notes due 2028 (the "2028 Series I Unsecured Notes") with a fixed interest rate of 5.96% and a maturity date of July 30, 2028. Interest on the 2028 Series I Unsecured Notes is due semi-annually on January 30 and July 30. The 2028 Series I Unsecured Notes were issued in a private placement only to qualified institutional buyers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February 18, 2025, the Company closed a private offering of $50 million of unsecured notes with a fixed interest rate of 6.14% and a maturity date of February 18, 2028 (the "2028 Series H Unsecured Notes"). Interest on the 2028 Series H Unsecured Notes is due semi-annually on February 18 and August 18. The 2028 Series H Unsecured Notes were issued in a private placement only to qualified institutional buyers.

------

[**<u>**Table of Contents**</u>**](#toc_page)

On December 16, 2024, the Company closed a private offering of $49 million of unsecured notes with a fixed interest rate of 6.24% and a maturity date of December 16, 2027 (the "2027 Series G Unsecured Notes"). Interest on the 2027 Series G Unsecured Notes is due semi-annually on June 16 and December 16. The 2027 Series G Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On August 16, 2024, the Company closed on Amendment No. 3 to its August 28, 2019 senior secured credit agreement (as amended to date, the "Credit Facility"). Following this amendment and several commitment increases between the fourth quarter of 2024 and the quarter ended September 30, 2025, the Credit Facility is now composed of $720 million of revolving credit and $140 million of term loans. Borrowings generally bear interest at a rate per annum equal to the base rate plus a range of 1.75%-2.00% or the alternate base rate plus 0.75%-1.00%. The Credit Facility has a 0% floor, matures in August 2029 and includes ratable amortization in the final year. Subsequent to Amendment No. 4 on December 3, 2024, the Credit Facility may be increased up to $900 million with additional new lenders or an increase in commitments from current lenders. The Credit Facility contains certain customary affirmative and negative covenants and events of default. In addition, the Credit Facility contains certain financial covenants that, among other things, require the Company to maintain a minimum stockholder's equity and a minimum asset coverage ratio. At September 30, 2025, outstanding USD equivalent borrowings under the Credit Facility totaled $498.4 million, composed of $358.4 million of revolving credit and $140.0 million of term loans.

On April 1, 2022, the Company entered into an assumption agreement (the "Note Assumption Agreement"), effective as of the closing of the Mergers. The Note Assumption Agreement relates to the Company's assumption of $85 million in aggregate principal amount of five-year, 3.90% senior unsecured notes, due March 31, 2025 (the "2025 Unsecured Notes"), and other obligations of SUNS under the Note Purchase Agreement, dated as of March 31, 2020 (the "Note Purchase Agreement"), among SUNS and certain institutional investors. Interest on the 2025 Unsecured Notes was due semi-annually on March 31 and September 30. Pursuant to the Note Assumption Agreement, the Company expressly assumed on behalf of SUNS the due and punctual payment of the principal of (and premium, if any) and interest on all the 2025 Unsecured Notes outstanding and the due and punctual performance and observance of every covenant and every condition of the Note Purchase Agreement to be performed or observed by SUNS. The 2025 Unsecured Notes were repaid in full at maturity on March 31, 2025.

On April 1, 2022, we entered into an assumption agreement (the "CF Assumption Agreement"), effective as of the closing of the Mergers. The CF Assumption Agreement relates to our assumption of the revolving credit facility, originally entered into on August 26, 2011 (as amended from time to time, the "SPV Credit Facility"), by and among SUNS SPV LLC (the "SUNS SPV"), a wholly-owned subsidiary of SUNS, acting as borrower, Citibank, N.A., acting as administrative agent and collateral agent, and the other parties thereto. Currently, subsequent to an August 30, 2024 amendment, the commitment under the SPV Credit Facility is $275 million. The stated interest rate on the SPV Credit Facility is SOFR plus 2.25%-2.75% with no SOFR floor requirement, and the current final maturity date is August 30, 2028. The SPV Credit Facility is secured by all of the assets held by SUNS SPV. Under the terms of the SPV Credit Facility and related transaction documents, we, as successor to SUNS, and SUNS SPV, as applicable, have made certain customary representations and warranties and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV Credit Facility also includes usual and customary events of default for credit facilities of this nature. At September 30, 2025, outstanding USD equivalent borrowings under the SPV Credit Facility totaled $165.1 million.

On January 6, 2022, the Company closed a private offering of $135 million of unsecured notes with a fixed interest rate of 3.33% and a maturity date of January 6, 2027 (the "2027 Series F Unsecured Notes"). Interest on the 2027 Series F Unsecured Notes is due semi-annually on January 6 and July 6. The 2027 Series F Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On September 14, 2021, the Company closed a private offering of $50 million of unsecured notes with a fixed interest rate of 2.95% and a maturity date of March 14, 2027 (the "2027 Unsecured Notes"). Interest on the 2027 Unsecured Notes is due semi-annually on March 14 and September 14. The 2027 Unsecured Notes were issued in a private placement only to qualified institutional buyers.

On December 18, 2019, the Company closed a private offering of $75 million of unsecured notes with a fixed interest rate of 4.375% and a maturity date of December 15, 2026 (the "2026 Unsecured Notes"). Interest on the 2026 Unsecured Notes is due semi-annually on June 15 and December 15. The 2026 Unsecured Notes were issued in a private placement only to qualified institutional buyers.

Certain covenants on our issued debt may restrict our business activities, including limitations that could hinder our ability to finance additional loans and investments or to make the distributions required to maintain our status as a RIC under Subchapter M of the Code. At September 30, 2025, the Company was in compliance with all financial and operational covenants required by the Debt Instruments.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Cash Equivalents** 

We deem certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities as cash equivalents. The Company makes purchases that are consistent with its purpose of making investments in securities described in paragraphs 1 through 3 of Section 55(a) of the 1940 Act. From time to time, including at or near the end of each fiscal quarter, we consider using various temporary investment strategies for our business. One strategy includes taking proactive steps by utilizing cash equivalents as temporary assets with the objective of enhancing our investment flexibility pursuant to Section 55 of the 1940 Act. More specifically, from time to time we may purchase U.S. Treasury bills or other high-quality, short-term debt securities at or near the end of the quarter and typically close out the position on a net cash basis subsequent to quarter end. We may also utilize repurchase agreements or other balance sheet transactions, including drawing down on the Credit Facility, as deemed appropriate. The amount of these transactions or such drawn cash for this purpose are excluded from total assets for purposes of computing the asset base upon which the management fee is determined. As of September 30, 2025 and December 31, 2024, we held face amounts of $375 million and $400 million, respectively, in cash equivalents.

***Contractual Obligations*** 

A summary of our significant contractual payment obligations is as follows as of September 30, 2025:

**Payments Due by Period (in millions)** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Total** | **Less than<br>1 Year** | **1-3 Years** | **3-5 Years** | **More Than<br>5 Years** |
| Revolving credit facilities (1) | $523.4 | $— | $165.1 | $358.3 | $— |
| Unsecured senior notes | 484.0 |  | 484.0 |  |  |
| Term loans | 140.0 |  |  | 140.0 |  |

---

------

(1)As of September 30, 2025, we had a total of $471.6 million of unused borrowing capacity under our revolving credit facilities, subject to borrowing base limits.

Under the provisions of the 1940 Act, we are permitted, as a BDC, to issue senior securities in amounts such that our asset coverage ratio, as defined in the 1940 Act, equals at least 150% of gross assets less all liabilities and indebtedness not represented by senior securities, after each issuance of senior securities. If the value of our assets declines, we may be unable to satisfy the asset coverage test. If that happens, we may be required to sell a portion of our investments and, depending on the nature of our leverage, repay a portion of our indebtedness at a time when such sales may be disadvantageous. Also, any amounts that we use to service our indebtedness would not be available for distributions to our common stockholders. Furthermore, as a result of issuing senior securities, we would also be exposed to typical risks associated with leverage, including an increased risk of loss.

We have also entered into two contracts under which we have future commitments: an investment advisory and management agreement (the "Advisory Agreement"), pursuant to which the Investment Adviser has agreed to serve as our investment adviser, and an administration agreement (the "Administration Agreement"), pursuant to which the Administrator has agreed to furnish us with the facilities and administrative services necessary to conduct our day-to-day operations and provide on our behalf managerial assistance to those portfolio companies to which we are required to provide such assistance. Payments under the Advisory Agreement are equal to (1) a percentage of the value of our average gross assets and (2) a two-part incentive fee. Payments under the Administration Agreement are equal to an amount based upon our allocable portion of the Administrator's overhead in performing its obligations under the Administration Agreement, including rent, technology systems, insurance and our allocable portion of the costs of our chief financial officer and chief compliance officer and their respective staffs. Either party may terminate each of the Advisory Agreement and Administration Agreement without penalty upon 60 days written notice to the other. See Note 3 to our Consolidated Financial Statements.

On July 31, 2017, the Company, NEFPASS LLC and NEFCORP LLC entered into a servicing agreement. NEFCORP LLC was engaged to provide NEFPASS LLC with administrative services related to the loans and capital leases held by NEFPASS LLC. NEFPASS LLC may terminate this agreement upon 30 days written notice to NEFCORP LLC.

On October 7, 2022, the Company committed $50 million to SSLP and entered into a servicing agreement. SSLP engaged and retained the Company to provide certain administrative services relating to the facilities, supplies and necessary ongoing overhead support services for the operation of SSLP's ongoing business affairs in exchange for a fee.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Senior Securities*** 

Information about our senior securities is shown in the following table (in thousands) as of the quarter ended September 30, 2025 and each year ended December 31 for the past ten years, unless otherwise noted. The "—" indicates information which the SEC expressly does not require to be disclosed for certain types of senior securities.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Class and Year** | **Total Amount<br>Outstanding(1)** | **Asset<br>Coverage<br>Per Unit(2)** | **Involuntary<br>Liquidating<br>Preference<br>Per Unit(3)** | **Average<br>Market Value<br>Per Unit(4)** |
| **Credit Facility** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | $358386 | $583 |  | N/A |
| Fiscal 2024 | 342043 | 642 |  | N/A |
| Fiscal 2023 | 407000 | 631 |  | N/A |
| Fiscal 2022 | 293000 | 513 |  | N/A |
| Fiscal 2021 | 222500 | 552 |  | N/A |
| Fiscal 2020 | 126000 | 421 |  | N/A |
| Fiscal 2019 | 42900 | 182 |  | N/A |
| Fiscal 2018 | 96400 | 593 |  | N/A |
| Fiscal 2017 | 245600 | 1225 |  | N/A |
| Fiscal 2016 | 115200 | 990 |  | N/A |
| Fiscal 2015 | 207900 | 1459 |  | N/A |
| **SPV Credit Facility** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 165050 | 268 |  | N/A |
| Fiscal 2024 | 165050 | 310 |  | N/A |
| Fiscal 2023 | 206250 | 320 |  | N/A |
| Fiscal 2022 | 155200 | 272 |  | N/A |
| **2022 Unsecured Notes** |  |  |  |  |
| Fiscal 2022 |  |  |  | N/A |
| Fiscal 2021 | 150000 | 372 |  | N/A |
| Fiscal 2020 | 150000 | 501 |  | N/A |
| Fiscal 2019 | 150000 | 638 |  | N/A |
| Fiscal 2018 | 150000 | 923 |  | N/A |
| Fiscal 2017 | 150000 | 748 |  | N/A |
| Fiscal 2016 | 50000 | 430 |  | N/A |
| **2022 Tranche C Notes** |  |  |  |  |
| Fiscal 2022 |  |  |  | N/A |
| Fiscal 2021 | 21000 | 52 |  | N/A |
| Fiscal 2020 | 21000 | 70 |  | N/A |
| Fiscal 2019 | 21000 | 89 |  | N/A |
| Fiscal 2018 | 21000 | 129 |  | N/A |
| Fiscal 2017 | 21000 | 105 |  | N/A |
| **2023 Unsecured Notes** |  |  |  |  |
| Fiscal 2023 |  |  |  | N/A |
| Fiscal 2022 | 75000 | 131 |  | N/A |
| Fiscal 2021 | 75000 | 186 |  | N/A |
| Fiscal 2020 | 75000 | 250 |  | N/A |
| Fiscal 2019 | 75000 | 319 |  | N/A |
| Fiscal 2018 | 75000 | 461 |  | N/A |
| Fiscal 2017 | 75000 | 374 |  | N/A |
| **2024 Unsecured Notes** |  |  |  |  |
| Fiscal 2024 |  |  |  | N/A |
| Fiscal 2023 | 125000 | 194 |  | N/A |
| Fiscal 2022 | 125000 | 219 |  | N/A |
| Fiscal 2021 | 125000 | 309 |  | N/A |
| Fiscal 2020 | 125000 | 417 |  | N/A |
| Fiscal 2019 | 125000 | 531 |  | N/A |
| **2025 Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) |  |  |  | N/A |
| Fiscal 2024 | 85000 | 159 |  | N/A |
| Fiscal 2023 | 85000 | 132 |  | N/A |
| Fiscal 2022 | 85000 | 149 |  | N/A |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Class and Year** | **Total Amount<br>Outstanding(1)** | **Asset<br>Coverage<br>Per Unit(2)** | **Involuntary<br>Liquidating<br>Preference<br>Per Unit(3)** | **Average<br>Market Value<br>Per Unit(4)** |
| **2026 Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | $75000 | $122 |  | N/A |
| Fiscal 2024 | 75000 | 141 |  | N/A |
| Fiscal 2023 | 75000 | 116 |  | N/A |
| Fiscal 2022 | 75000 | 131 |  | N/A |
| Fiscal 2021 | 75000 | 186 |  | N/A |
| Fiscal 2020 | 75000 | 250 |  | N/A |
| Fiscal 2019 | 75000 | 319 |  | N/A |
| **2027 Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 50000 | 81 |  | N/A |
| Fiscal 2024 | 50000 | 94 |  | N/A |
| Fiscal 2023 | 50000 | 77 |  | N/A |
| Fiscal 2022 | 50000 | 88 |  | N/A |
| Fiscal 2021 | 50000 | 124 |  | N/A |
| **2027 Series F Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 135000 | 220 |  | N/A |
| Fiscal 2024 | 135000 | 253 |  | N/A |
| Fiscal 2023 | 135000 | 209 |  | N/A |
| Fiscal 2022 | 135000 | 237 |  | N/A |
| **2027 Series G Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 49000 | 80 |  | N/A |
| Fiscal 2024 | 49000 | 92 |  | N/A |
| **2028 Series H Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 50000 | 81 |  | N/A |
| **2028 Series I Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 50000 | 81 |  | N/A |
| **2028 Series J Unsecured Notes** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 75000 | 122 |  | N/A |
| **2042 Unsecured Notes** |  |  |  |  |
| Fiscal 2017 |  |  |  | N/A |
| Fiscal 2016 | 100000 | 859 |  | $1002 |
| Fiscal 2015 | 100000 | 702 |  | 982 |
| **Senior Secured Notes** |  |  |  |  |
| Fiscal 2017 |  |  |  | N/A |
| Fiscal 2016 | 75000 | 645 |  | N/A |
| Fiscal 2015 | 75000 | 527 |  | N/A |
| **Term Loans** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | 140000 | 228 |  | N/A |
| Fiscal 2024 | 140000 | 263 |  | N/A |
| Fiscal 2023 | 100000 | 155 |  | N/A |
| Fiscal 2022 | 100000 | 175 |  | N/A |
| Fiscal 2021 | 100000 | 248 |  | N/A |
| Fiscal 2020 | 75000 | 250 |  | N/A |
| Fiscal 2019 | 75000 | 319 |  | N/A |
| Fiscal 2018 | 50000 | 308 |  | N/A |
| Fiscal 2017 | 50000 | 250 |  | N/A |
| Fiscal 2016 | 50000 | 430 |  | N/A |
| Fiscal 2015 | 50000 | 351 |  | N/A |
| **NEFPASS Facility** |  |  |  |  |
| Fiscal 2021 |  |  |  | N/A |
| Fiscal 2020 | 30000 | 100 |  | N/A |
| Fiscal 2019 | 30000 | 128 |  | N/A |
| Fiscal 2018 | 30000 | 185 |  | N/A |
| **SSLP Facility** |  |  |  |  |
| Fiscal 2019 |  |  |  | N/A |
| Fiscal 2018 | 53785 | 331 |  | N/A |
| **Total Senior Securities** |  |  |  |  |
| Fiscal 2025 (through September 30, 2025) | $1147436 | $1866 |  | N/A |
| Fiscal 2024 | 1041093 | 1954 |  | N/A |
| Fiscal 2023 | 1183250 | 1834 |  | N/A |
| Fiscal 2022 | 1093200 | 1915 |  | N/A |
| Fiscal 2021 | 818500 | 2029 |  | N/A |
| Fiscal 2020 | 677000 | 2259 |  | N/A |
| Fiscal 2019 | 593900 | 2525 |  | N/A |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | |
|:---|:---|:---|:---|
| Fiscal 2018 | 476,185 | 2,930 | N/A |
| Fiscal 2017 | 541,600 | 2,702 | N/A |
| Fiscal 2016 | 390,200 | 3,354 | N/A |
| Fiscal 2015 | 432,900 | 3,039 | N/A |

---

------

(1)Total amount of each class of senior securities outstanding (in thousands) at the end of the period presented.

(2)The asset coverage ratio for a class of senior securities representing indebtedness is calculated as our consolidated total assets, less all liabilities and indebtedness not represented by senior securities, divided by all senior securities representing indebtedness. This asset coverage ratio is multiplied by one thousand to determine the Asset Coverage Per Unit. In order to determine the specific Asset Coverage Per Unit for each class of debt, the total Asset Coverage Per Unit is allocated based on the amount outstanding in each class of debt at the end of the period. As of September 30, 2025, asset coverage was 186.6%.

(3)The amount to which such class of senior security would be entitled upon the involuntary liquidation of the issuer in preference to any security junior to it.

(4)Not applicable except for the 2042 Unsecured Notes which were publicly traded. The Average Market Value Per Unit is calculated by taking the daily average closing price during the period and dividing it by twenty-five dollars per share and multiplying the result by one thousand to determine a unit price per thousand consistent with Asset Coverage Per Unit. The average market value for the fiscal 2016 and 2015 periods was $100,175 and $98,196, respectively.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Off-Balance Sheet Arrangements*** 

From time to time and in the normal course of business, the Company may make unfunded capital commitments to current or prospective portfolio companies. Typically, the Company may agree to provide delayed-draw term loans or, to a lesser extent, revolving loans or equity commitments. These unfunded capital commitments always take into account the Company's liquidity and cash available for investment, portfolio and issuer diversification, and other considerations. Accordingly, the Company had the following unfunded capital commitments at September 30, 2025 and December 31, 2024, respectively:

---

| | | |
|:---|:---|:---|
| ***(in millions)*** | **September 30,<br>2025** | **December 31,<br>2024** |
| Cogent Biosciences, Inc. | $56.1 | $— |
| SLR Credit Solutions\* | 44.3 | 44.3 |
| Ardelyx, Inc. | 29.3 | 6.6 |
| Lyneer Staffing Solutions, LLC | 25.9 |  |
| OIS Management Services, LLC | 20.9 |  |
| Infillion Inc. | 20.7 |  |
| SLR Business Credit\* | 20.0 | 8.0 |
| SLR Healthcare ABL\* | 15.2 | 10.0 |
| Wilbur-Ellis Holdings II, LLC | 14.6 |  |
| Arcutis Biotherapeutics, Inc. | 12.7 | 12.7 |
| BDG Media, Inc. | 11.7 | 11.8 |
| Stella & Chewy's, LLC | 10.8 |  |
| SLR Equipment Finance\* | 10.5 | 3.0 |
| DeepIntent, Inc. | 10.4 | 7.3 |
| WALCO Funding, LLC | 8.7 |  |
| Velocity One, LLC | 7.2 |  |
| United Digestive MSO Parent, LLC | 6.6 | 7.5 |
| WMD Funding LLC | 6.4 | 7.2 |
| Quantcast Corporation | 6.1 | 4.1 |
| The Townsend Company, LLC | 5.6 | 7.9 |
| Plastic Management, LLC | 5.4 | 10.8 |
| Pinnacle Fertility, Inc. | 5.3 |  |
| 33 Across Inc. | 4.8 | 4.2 |
| Copper River Seafoods, Inc. | 4.5 | 6.9 |
| One Touch Direct, LLC | 4.3 | 8.0 |
| Sightly Enterprises, Inc. | 3.7 | 2.7 |
| SPR Therapeutics, Inc. | 3.7 | 6.1 |
| Streamland Media Holdings LLC | 3.3 |  |
| iCIMS, Inc. | 3.2 | 3.5 |
| CVAUSA Management, LLC | 3.1 | 10.2 |
| Southern Lifting and Hoisting, LLC | 3.1 |  |
| Sherwood Management Co., Inc. | 2.6 |  |
| Western Veterinary Partners LLC | 2.1 | 18.2 |
| SLR Senior Lending Program LLC\* | 2.1 | 2.1 |
| Bayside Opco, LLC | 2.1 | 2.1 |
| Southern Transport LLC | 2.1 |  |
| SunMed Group Holdings, LLC | 1.6 | 1.6 |
| SPAR Marketing Force, Inc. | 1.6 | 5.4 |
| EyeSouth Eye Care Holdco LLC | 1.3 | 1.3 |
| Tilley Distribution, Inc. | 1.0 | 1.2 |
| Urology Management Holdings, Inc. | 0.9 | 0.9 |
| NS and Associates LLC | 0.7 |  |
| High Street Buyer, Inc. | 0.6 | 0.6 |
| CC SAG Holdings Corp. (Spectrum Automotive) | 0.5 | 0.5 |
| Omniguide Holdings, Inc. | 0.3 |  |
| TAUC Management, LLC | 0.3 | 0.3 |
| Shoes for Crews Global, LLC | 0.3 | 0.3 |
| All States Ag Parts, LLC | 0.2 | 0.3 |
| Pasadena Private Lending Inc. |  | 8.4 |
| Foundation Consumer Brands, LLC |  | 3.0 |
| Erie Construction Mid-west, LLC |  | 2.4 |
| Kaseya, Inc. |  | 1.9 |
| RxSense Holdings LLC |  | 1.3 |
| Total Commitments | $408.4 | $234.6 |

---

\* The Company controls the funding of these commitments and may cancel them at its discretion.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The credit agreements governing the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company's achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of September 30, 2025 and December 31, 2024, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.

In the normal course of business, we invest or trade in various financial instruments and may enter into various investment activities with off-balance sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of off-balance sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities.

***Distributions*** 

The following table reflects the cash distributions per share on our common stock for the two most recent fiscal years and the current fiscal year to date:

---

| | | | |
|:---|:---|:---|:---|
| **Date Declared** | **Record Date** | **Payment Date** | **Amount** |
| Fiscal 2025 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;November 4, 2025 | December 12, 2025 | December 26, 2025 | $0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;August 5, 2025 | September 12, 2025 | September 26, 2025 | 0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;May 7, 2025 | June 13, 2025 | June 27, 2025 | 0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;February 25, 2025 | March 14, 2025 | March 28, 2025 | 0.41 |
| *Total 2025* |  |  | $1.64 |
| Fiscal 2024 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;November 6, 2024 | December 13, 2024 | December 27, 2024 | $0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;August 7, 2024 | September 13, 2024 | September 27, 2024 | 0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;May 8, 2024 | June 13, 2024 | June 27, 2024 | 0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;February 27, 2024 | March 14, 2024 | March 28, 2024 | 0.41 |
| *Total 2024* |  |  | $1.64 |
| Fiscal 2023 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;November 7, 2023 | December 14, 2023 | December 28, 2023 | $0.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;September 5, 2023 | September 20, 2023 | September 28, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;August 8, 2023 | August 18, 2023 | August 30, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;July 5, 2023 | July 20, 2023 | August 1, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;June 1, 2023 | June 20, 2023 | June 29, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;May 10, 2023 | May 24, 2023 | June 1, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;April 4, 2023 | April 20, 2023 | May 2, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;February 28, 2023 | March 23, 2023 | April 4, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;February 2, 2023 | February 16, 2023 | March 1, 2023 | 0.136667 |
| &nbsp;&nbsp;&nbsp;&nbsp;January 10, 2023 | January 26, 2023 | February 2, 2023 | 0.136667 |
| *Total 2023* |  |  | $1.64 |

---

Tax characteristics of all distributions will be reported to stockholders on Form 1099 after the end of the calendar year. Future quarterly distributions, if any, will be determined by the Board. We expect that our distributions to stockholders will generally be from accumulated net investment income, net realized capital gains or non-taxable return of capital, if any, as applicable.

We have elected to be taxed as a RIC under Subchapter M of the Code. To maintain our RIC tax treatment, we must distribute at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any, out of the assets legally available for distribution. In addition, although we currently intend to distribute realized net capital gains (*i.e.*, net long-term capital gains in excess of short-term capital losses), if any, at least annually, out of the assets legally available for such distributions, we may in the future decide to retain such capital gains for investment.

------

[**<u>**Table of Contents**</u>**](#toc_page)

We maintain an "opt out" dividend reinvestment plan for our common stockholders. As a result, if we declare a distribution, then stockholders' cash distributions will be automatically reinvested in additional shares of our common stock, unless they specifically "opt out" of the dividend reinvestment plan so as to receive cash distributions.

We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, due to the asset coverage test applicable to us as a business development company, we may in the future be limited in our ability to make distributions. Also, the Credit Facility may limit our ability to declare distributions if we default under certain provisions. If we do not distribute a certain percentage of our income annually, we will suffer adverse tax consequences, including possible loss of the tax benefits available to us as a RIC. In addition, in accordance with GAAP and tax regulations, we include in income certain amounts that we have not yet received in cash, such as contractual payment-in-kind income, which represents contractual income added to the loan balance that becomes due at the end of the loan term, or the accrual of original issue or market discount. Since we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the requirement to distribute at least 90% of our investment company taxable income to obtain tax benefits as a RIC.

With respect to the distributions to stockholders, income from origination, structuring, closing and certain other upfront fees associated with investments in portfolio companies are treated as taxable income and, accordingly, distributed to stockholders.

**Related Parties** 

We have entered into a number of business relationships with affiliated or related parties, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We have entered into the Advisory Agreement with the Investment Adviser. Mr. Michael S. Gross, our Chairman, Co-Chief Executive Officer and President, and Mr. Bruce J. Spohler, our Co-Chief Executive Officer, Chief Operating Officer and board member, are managing members and senior investment professionals of, and have financial and controlling interests in, the Investment Adviser. In addition, Mr. Shiraz Y. Kajee, our Chief Financial Officer and Treasurer, serves as the Chief Financial Officer for the Investment Adviser, and Mr. Guy F. Talarico, our Chief Compliance Officer and Secretary, serves as Partner, General Counsel and Chief Compliance Officer for the Investment Adviser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The Administrator provides us with the office facilities and administrative services necessary to conduct day-to-day operations pursuant to our Administration Agreement. We reimburse the Administrator for the allocable portion of overhead and other expenses incurred by it in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions, and the compensation of our chief compliance officer, our chief financial officer and their respective staffs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We have entered into a license agreement with the Investment Adviser, pursuant to which the Investment Adviser has granted us a non-exclusive, royalty-free license to use the licensed marks "SOLAR" and "SLR".

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Investment Adviser may also manage other funds in the future that may have investment mandates that are similar, in whole or in part, with ours. For example, the Investment Adviser presently serves as investment adviser to SCP Private Credit Income BDC LLC, an unlisted BDC that focuses on investing primarily in senior secured loans, including non-traditional asset-based loans and first lien loans, SLR HC BDC LLC, an unlisted BDC whose principal focus is to invest directly and indirectly in senior secured loans and other debt instruments typically to middle market companies within the healthcare industry, and SLR Private Credit BDC II LLC, an unlisted BDC focused on first lien senior secured floating rate loans. In addition, Mr. Gross, our Chairman, Co-Chief Executive Officer and President, Mr. Spohler, our Co-Chief Executive Officer, Chief Operating Officer and board member, Mr. Kajee, our Chief Financial Officer and Treasurer, and Mr. Talarico, our Chief Compliance Officer and Secretary, serve in similar capacities for SCP Private Credit Income BDC LLC, SLR HC BDC LLC and SLR Private Credit BDC II LLC. The Investment Adviser and certain investment advisory affiliates may determine that an investment is appropriate for us and for one or more of those other funds. In such event, depending on the availability of such investment and other appropriate factors, the Investment Adviser or its affiliates may determine that we should invest side-by-side with one or more other funds. Any such investments will be made only to the extent permitted by applicable law and interpretive positions of the SEC and its staff, and consistent with the Investment Adviser's allocation procedures. On June 13, 2017, the Investment Adviser received an exemptive order that permits the Company to participate in negotiated co-investment transactions with certain affiliates, in a manner consistent with the Company's investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors, and pursuant to various conditions (the "Exemptive Order"). If the Company is unable to rely on the Exemptive Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity's investment strategy, on an alternating basis. Although the Investment Adviser's investment professionals will endeavor to allocate investment opportunities in a fair and equitable manner, the Company and its stockholders could be adversely affected to the extent investment opportunities are allocated among us and other investment vehicles managed or sponsored by, or affiliated with, our executive officers, directors and members of the Investment Adviser.

Related party transactions may occur among us, SLR Senior Lending Program LLC, SLR Senior Lending Program SPV LLC, SLR Credit, Equipment Operating Leases LLC, KBH, Loyer Capital LLC, SLR Business Credit, SLR Healthcare ABL and SLR Equipment. These transactions may occur in the normal course of business. No administrative or other fees are paid to the Investment Adviser by SLR Senior Lending Program LLC, SLR Senior Lending Program SPV LLC, SLR Credit, Equipment Operating Leases LLC, KBH, Loyer Capital LLC, SLR Business Credit, SLR Healthcare ABL or SLR Equipment.

In addition, we have adopted a formal code of ethics that governs the conduct of our officers and directors. Our officers and directors also remain subject to the duties imposed by both the 1940 Act and the Maryland General Corporation Law.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk** 

We are subject to financial market risks, including changes in interest rates. Uncertainty with respect to interest rates, inflationary pressures, risks in respect of a failure to increase the U.S. debt ceiling, a downgrade in the U.S. credit rating or a prolonged government shutdown, the war between Ukraine and Russia, the ongoing war in the Middle East and other geopolitical risk and the U.S. government's recent enactments and proposals to enact substantial tariffs introduced significant volatility in the financial markets, and the effects of this volatility have materially impacted and could continue to materially impact our market risks. Because we fund a portion of our investments with borrowings, our net investment income is affected by the difference between the rate at which we invest and the rate at which we borrow. As a result, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In a low interest rate environment, including a reduction of SOFR to zero, the difference between the total interest income earned on interest earning assets and the total interest expense incurred on interest bearing liabilities may be compressed, reducing our net interest income and potentially adversely affecting our operating results. Conversely, in a rising interest rate environment, such difference could potentially increase thereby increasing our net investment income. During the nine months ended September 30, 2025, certain investments in our comprehensive investment portfolio had floating interest rates. These floating rate investments were primarily based on floating SOFR and typically have durations of one to three months after which they reset to current market interest rates. Additionally, some of these investments have floors. The Company also has revolving credit facilities that are generally based on floating SOFR. Assuming no changes to our balance sheet as of September 30, 2025 and no new defaults by portfolio companies, a hypothetical one percent decrease in SOFR on our comprehensive floating rate assets and liabilities would decrease our net investment income by seven cents per average share over the next twelve months. Assuming no changes to our balance sheet as of September 30, 2025 and no new defaults by portfolio companies, a hypothetical one percent increase in SOFR on our comprehensive floating rate assets and liabilities would increase our net investment income by approximately six cents per average share over the next twelve months. However, we may hedge against interest rate fluctuations from time to time by using standard hedging instruments such as futures, options, swaps and forward contracts subject to the requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest

------

[**<u>**Table of Contents**</u>**](#toc_page)

rates, they may also limit our ability to participate in any benefits of certain changes in interest rates with respect to our portfolio of investments. At September 30, 2025, we had no interest rate hedging instruments outstanding on our balance sheet.

---

| | | | |
|:---|:---|:---|:---|
| Increase (Decrease) in SOFR | (1.00%) | 1.00 | % |
| Increase (Decrease) in Net Investment Income Per Share<br> Per Year | $(0.07) | $0.06 |  |

---

We may also have exposure to foreign currencies through various investments. These investments are converted into U.S. dollars at the balance sheet date, exposing us to movements in foreign exchange rates. In order to reduce our exposure to fluctuations in foreign exchange rates, we may borrow from time to time in such currencies under our multi-currency revolving credit facility or enter into forward currency or similar contracts.

**Item 4. Controls and Procedures** 

***(a) Evaluation of Disclosure Controls and Procedures*** 

As of September 30, 2025 (the end of the period covered by this report), we, including our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the 1934 Act). Based on that evaluation, our management, including our Co-Chief Executive Officers and Chief Financial Officer, concluded that, as of September 30, 2025, our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.

***(b) Changes in Internal Control Over Financial Reporting*** 

Management has not identified any change in the Company's internal control over financial reporting that occurred during the third quarter of 2025 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART II. OTHER INFORMATION** 

**Item 1. Legal Proceedings** 

We and our consolidated subsidiaries are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us or our consolidated subsidiaries. From time to time, we and our consolidated subsidiaries may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

**Item 1A. Risk Factors** 

In addition to the other information set forth in this report, you should carefully consider the factors discussed in "Risk Factors" in the February 25, 2025 filing of our Annual Report on Form 10-K (the "Annual Report") , which could materially affect our business, financial condition and/or operating results. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. There have been no material changes during the period ended September 30, 2025 to the risk factors discussed in "Risk Factors" in the February 25, 2025 filing of our Annual Report on Form 10-K.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds** 

None.

**Item 3. Defaults Upon Senior Securities** 

None.

**Item 4. Mine Safety Disclosures** 

Not applicable.

**Item 5. Other Information** 

***Rule 10b5-1 Trading Plans*** 

During the fiscal quarter ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the 1934 Act) adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the 1934 Act or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Unsecured Note Issuance***

On August 21, 2025, the Company closed a private offering of $75 million of the 2028 Series J Unsecured Notes with a fixed interest rate of 5.95% and a maturity date of August 21, 2028. Interest on the 2028 Series J Unsecured Notes is due semi-annually on February 21 and August 21. The 2028 Series J Unsecured Notes were issued in a private placement only to qualified institutional buyers.

The description above is only a summary of the material provisions of the 2028 Series J Unsecured Notes and is qualified in its entirety by reference to the full text of the Form of Ninth Supplement to Note Purchase Agreement, which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Item 6. Exhibits** 

The following exhibits are filed as part of this report or hereby incorporated by reference to exhibits previously filed with the SEC:

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 3.1 | [<u>Articles of Amendment and Restatement</u>](https://www.sec.gov/Archives/edgar/data/1418076/000119312510002244/dex99a.htm)(1) |
| 3.2 | [<u>Second Amended and Restated Bylaws</u>](https://www.sec.gov/Archives/edgar/data/1418076/000119312521345547/d133100dex31.htm)(4) |
| 4.1 | [<u>Form of Common Stock Certificate</u>](https://www.sec.gov/Archives/edgar/data/1418076/000119312510025192/dex99d1.htm)(2) |
| 4.2 | [<u>Indenture, dated as of November 16, 2012, between the Registrant and U.S. Bank National Association as trustee</u>](https://www.sec.gov/Archives/edgar/data/1418076/000119312512473528/d431925dex99d5.htm)(3) |
| 10.1 | [<u>Form of Ninth Supplement to Note Purchase Agreement\*</u>](ck0001418076-ex10_1.htm) |
| 23.1 | [<u>Awareness Letter of Independent Registered Public Accounting Firm\*</u>](ck0001418076-ex23_1.htm) |
| 31.1 | [<u>Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.\*</u>](ck0001418076-ex31_1.htm) |
| 31.2 | [<u>Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.\*</u>](ck0001418076-ex31_2.htm) |
| 31.3 | [<u>Certification of Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.\*</u>](ck0001418076-ex31_3.htm) |
| 32.1 | [<u>Certification of Co-Chief Executive Officer pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.\*\*</u>](ck0001418076-ex32_1.htm) |
| 32.2 | [<u>Certification of Co-Chief Executive Officer pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.\*\*</u>](ck0001418076-ex32_2.htm) |
| 32.3 | [<u>Certification of Chief Financial Officer pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.\*\*</u>](ck0001418076-ex32_3.htm) |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document\* |
| 104 | Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |

---

------

(1)Previously filed in connection with SLR Investment Corp.'s registration statement on Form N-2 Pre-Effective Amendment No. 7 (File No. 333-148734) filed on January 7, 2010.

(2)Previously filed in connection with SLR Investment Corp.'s registration statement on Form N-2 (File No. 333-148734) filed on February 9, 2010.

(3)Previously filed in connection with SLR Investment Corp.'s registration statement on Form N-2 Post-Effective Amendment No. 6 (File No. 333-172968) filed on November 16, 2012.

(4)Previously filed in connection with SLR Investment Corp.'s current report on Form 8-K filed on December 1, 2021.

\* Filed herewith.

\*\* Furnished herewith.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SIGNATURES** 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on November 4, 2025.

---

| | |
|:---|:---|
| SLR INVESTMENT CORP. | SLR INVESTMENT CORP. |
| By: | /s/ MICHAEL S. GROSS |
|  | **Michael S. Gross**<br>**Co-Chief Executive Officer**<br>**(Principal Executive Officer)** |
| By: | /s/ BRUCE J. SPOHLER  |
|  | **Bruce J. Spohler**<br>**Co-Chief Executive Officer**<br>**(Principal Executive Officer)** |
| By: | /s/ SHIRAZ Y. KAJEE  |
|  | **Shiraz Y. Kajee**<br>**Chief Financial Officer**<br>**(Principal Financial and Accounting Officer)** |

---

------

## Exhibit 10.1

**Exhibit 10.1**

Execution Version

**SLR Investment Corp.** 

500 Park Avenue, 3rd Floor

New York, New York 10022

Dated as of August 21, 2025

To the Series 2016J Additional

Purchasers named in

Schedule A hereto

Ladies and Gentlemen:

This Ninth Supplement to Note Purchase Agreement (the *"Supplement"* or *"Ninth Supplement"*) is among SLR Investment Corp., a Maryland corporation (the *"Company"*), and the institutional investors named on Schedule A attached hereto (the *"Series 2016J Additional Purchasers"*).

Reference is hereby made to that certain Note Purchase Agreement dated as of November 8, 2016 (the *"Note Purchase Agreement"*) among the Company (f/k/a Solar Capital Ltd.) and the Purchasers listed on **Schedule A** thereto. All capitalized terms not otherwise defined herein shall have the same meanings as specified in the Note Purchase Agreement. Reference is further made to **Section 4.18** of the Note Purchase Agreement which requires that, prior to the delivery of any Additional Notes, the Company and each Additional Purchaser shall execute and deliver a Supplement.

The Company hereby agrees with the Series 2016J Additional Purchasers as follows:

1. The Company has authorized the issue and sale of $75,000,000 aggregate principal amount of its 5.95% Series 2016J, Senior Notes, due August 21, 2028 (the *"Series 2016J Notes"*). The Series 2016J Notes, together with the Series 2016A Notes issued pursuant to the Note Purchase Agreement, the Series 2016B Notes issued pursuant to the First Supplement to Note Purchase Agreement dated as of February 15, 2017, the Series 2016C Notes issued pursuant to the Second Supplement to Note Purchase Agreement dated as of December 28, 2017, the Series 2016D Notes issued pursuant to the Third Supplement to Note Purchase Agreement dated as of December 18, 2019, the Series 2016E Notes issued pursuant to the Fourth Supplement to Note Purchase Agreement dated as of September 14, 2021, the Series 2016F Notes issued pursuant to the Fifth Supplement to Note Purchase Agreement dated as of January 6, 2022, the Series 2016G Notes issued pursuant to the Sixth Supplement to Note Purchase Agreement dated as of December 16, 2024, the Series 2016H Notes issued pursuant to the Seventh Supplement to Note Purchase

FILENAME 2016I Eighth Supplement and Note 4921-7523-8993 v6.docx

4481016

------

SLR Investment Corp. Eighth Supplement

Agreement dated as of February 18, 2025, the Series 2016I Notes issued pursuant to the Ninth Supplement to Note Purchase Agreement dated as of July 30, 2025 and each series of Additional Notes which may from time to time hereafter be issued pursuant to the provisions of **Section 2.4** of the Note Purchase Agreement, are collectively referred to as the *"Notes"* (such term shall also include any such notes issued in substitution therefor pursuant to **Section 13** of the Note Purchase Agreement). The Series 2016J Notes shall be substantially in the form set out in Exhibit 1 hereto with such changes therefrom, if any, as may be approved by the Series 2016J Additional Purchasers and the Company.

2. Subject to the terms and conditions hereof and as set forth in the Note Purchase Agreement and on the basis of the representations and warranties hereinafter set forth, the Company agrees to issue and sell to each Series 2016J Additional Purchaser, and each Series 2016J Additional Purchaser agrees to purchase from the Company, Series 2016J Notes in the principal amount set forth opposite such Series 2016J Additional Purchaser's name on Schedule A hereto at a price of 100% of the principal amount thereof on the closing date hereinafter mentioned.

3. The sale and purchase of the Series 2016J Notes to be purchased by each Series 2016J Additional Purchaser shall occur at the offices of Chapman and Cutler LLP in Chicago, Illinois, at 8:00 a.m. Chicago time, at a closing (the *"Series 2016J Closing"*) on August 21, 2025. At the Series 2016J Closing, the Company will deliver to each Series 2016J Additional Purchaser the Series 2016J Notes of the tranche to be purchased by such Purchaser in the form of a single Series 2016J Note (or such greater number of Series 2016J Notes in denominations of at least $100,000 as such Series 2016J Additional Purchaser may request) dated the date of the Series 2016J Closing and registered in such Series 2016J Additional Purchaser's name (or in the name of such Series 2016J Additional Purchaser's nominee), against delivery by such Series 2016J Additional Purchaser to the Company or its order of immediately available funds in the amount of the purchase price therefor by wire transfer of immediately available funds for the account of the Company to account number [], Account Name: []. If, at the Series 2016J Closing, the Company shall fail to tender such Series 2016J Notes to any Series 2016J Additional Purchaser as provided above in this Section 3, or any of the conditions specified in Section 4 shall not have been fulfilled to any Series 2016J Additional Purchaser's satisfaction, such Series 2016J Additional Purchaser shall, at such Series 2016J Additional Purchaser's election, be relieved of all further obligations under this Agreement, without thereby waiving any rights such Series 2016J Additional Purchaser may have by reason of such failure or such nonfulfillment.

4. The obligation of each Series 2016J Additional Purchaser to purchase and pay for the Series 2016J Notes to be sold to such Series 2016J Additional Purchaser at the Series 2016J Closing is subject to the fulfillment to such Series 2016J Additional Purchaser's satisfaction, prior to the Series 2016J Closing, of the conditions set forth in **Section 4** of the Note Purchase Agreement with respect to the Series 2016J Notes to be purchased at the Series 2016J Closing as if each reference to "2016A Notes" or "Notes," "Closing" and "Purchaser" set forth therein was modified to refer the "Series 2016J Notes," the "Series 2016J Closing" and the "Series 2016J Additional Purchaser" (each as defined in this Ninth Supplement) and to the following additional conditions:

------

SLR Investment Corp. Eighth Supplement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Each of the representations and warranties of the Company set forth in Exhibit A hereto shall be correct as of the date of the Series 2016J Closing (except for representations and warranties which apply to a specific earlier date (other than an earlier closing date in connection with the Note Purchase Agreement or a prior supplement) which shall be true as of such earlier date) and the Company shall have delivered to each Series 2016J Additional Purchaser an Officer's Certificate, dated the date of the Series 2016J Closing certifying that such condition has been fulfilled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) Contemporaneously with the Series 2016J Closing, the Company shall sell to each Series 2016J Additional Purchaser, and each Series 2016J Additional Purchaser shall purchase, the Series 2016J Notes to be purchased by such Series 2016J Additional Purchaser at the Series 2016J Closing as specified in Schedule A hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) Contemporaneously with the Series 2016J Closing, the Company shall provide to each Series 2016J Additional Purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) a copy of each of the Subsidiary Guarantees delivered by NEFCORP, LLC and NEFPASS, LLC, respectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) a certificate signed by an authorized responsible officer of such Subsidiary Guarantors dated the date of the Series 2016J Closing certifying that the representations and warranties of each Subsidiary Guarantor made at the time of the execution and delivery of its Subsidiary Guarantee are true and correct as of the date of the Series 2016J Closing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iii) a certificate of its Secretary or Assistant Secretary dated the date of the Series 2016J Closing certifying as to the due organization, continuing existence and good standing of such Subsidiary and the due authorization by all requisite action on the part of such Subsidiary of the execution and delivery of such Subsidiary Guaranty and the performance by such Subsidiary of its obligations thereunder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iv) a reliance letter of counsel dated the date of the Series 2016J Closing permitting reliance by the Series 2016J Additional Purchasers on the opinions of Latham & Watkins LLP delivered in accordance with Section 9.7(b)(iv) of the Note Purchase Agreement at the time of the execution and delivery of each Subsidiary Guarantee.

5. The Company covenants and agrees with the holders of the Series 2016J Notes that Section 13.2 of the Note Purchase Agreement shall be amended by deleting the last sentence of such Section 13.2 and replacing it with the following: "Any transferee, by its acceptance of the Note registered in its name (or the name of its nominee), shall be deemed to have made the representations and agreements set forth in Section 6.1(b) and (f) and Section 6.2 of the Note Purchase Agreement and in Section 6(b) of the Ninth Supplement."

------

SLR Investment Corp. Eighth Supplement

6. (a) Each Series 2016J Additional Purchaser severally represents and warrants that the representations and warranties set forth in **Section 6.1(a), (b), (c), (e)** and **(f)** and in **Section 6.2** of the Note Purchase Agreement are true and correct on the date hereof with respect to the purchase of the Series 2016J Notes by such Series 2016J Additional Purchaser as if each reference to "2016A Notes" or "Notes," "Closing" and "Purchaser" set forth therein was modified to refer the "Series 2016J Notes," the "Series 2016J Closing" and the "Series 2016J Additional Purchaser" and each reference to "this Agreement" therein was modified to refer to the Note Purchase Agreement as supplemented by this Ninth Supplement.

(b) Each Series 2016J Additional Purchaser for itself represents that it is either (i) an Institutional Accredited Investor acting for its own account or as a fiduciary or agent for others (which others are also Institutional Accredited Investors) or (ii) a "qualified institutional buyer" as defined under Rule 144A acting for its own account or as a fiduciary or agent for others (which others are also "qualified institutional buyers").

7. The Company and each Series 2016J Additional Purchaser agree to be bound by and comply with the terms and provisions of the Note Purchase Agreement as fully and completely as if such Series 2016J Additional Purchaser were an original signatory to the Note Purchase Agreement.

8. This Ninth Supplement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the law of the State of New York*,* excluding choice-of-law principles of the law of such State that would permit the application of the laws of a jurisdiction other than such State.

9. The Company covenants and agrees with the holders of the Series 2016J Notes that the definitions of *"Canada Blocked Person"* and *"Canadian Economic Sanctions Laws"* shall be amended and restated in their entirety to read as follows:

*"Canada Blocked Person"* means (i) a "terrorist group" as defined for the purposes of Part II.1 of the Criminal Code (Canada), as amended or (ii) a Person identified in or pursuant to (w) Part II.1 of the Criminal Code (Canada), as amended or (x) the Proceeds of Crime (Money Laundering) and Terrorist Financing Act, as amended or (y) the Justice for Victims of Corrupt Foreign Officials Act (Sergei Magnitsky Law), as amended or (z) regulations or orders promulgated pursuant to the Special Economic Measures Act (Canada), as amended, the United Nations Act (Canada), as amended, or the Freezing Assets of Corrupt Foreign Officials Act (Canada), as amended, in any case pursuant to this clause (ii) as a Person in respect of whose property or benefit a holder of Notes would be prohibited from entering into or facilitating a related financial transaction.

*"Canadian Economic Sanctions Laws"* means those laws, including enabling legislation, orders-in-council or other regulations administered and enforced by Canada or a political subdivision of Canada pursuant to which economic sanctions have been imposed on any Person, entity, organization, country or regime, including Part II.1 of the Criminal Code (Canada), as amended, the Special Economic Measures Act (Canada), as amended, the Proceeds of Crime (Money Laundering) and Terrorist Financing Act, as amended, the

------

SLR Investment Corp. Eighth Supplement

Justice for Victims of Corrupt Foreign Officials Act (Sergei Magnitsky Law), as amended, the United Nations Act (Canada), as amended, the Export and Import Permits Act (Canada), as amended, and the Freezing Assets of Corrupt Foreign Officials Act (Canada), as amended, and including all regulations promulgated under any of the foregoing, or any other similar sanctions program or action.

10. The Company covenants and agrees with the holders of the Series 2016J Notes that, notwithstanding **Section 9.12** of the Note Purchase Agreement, the Company shall be required to deliver to the 2016J Additional Purchasers in the manner provided in **Section 18** of the Note Purchase Agreement a Rating in form and substance satisfactory to the 2016J Additional Purchasers evidencing that the Series 2016J Notes have been rated Investment Grade or better by either Fitch, S&P or another NRSRO, within 60 days after the 2016J Closing or such later date as may be agreed to by the 2016J Additional Purchasers.

The Company further covenants and agrees with the holders of the Series 2016J Notes that For purposes of this paragraph 10 the definitions of *"Rating"* and *"Private Rating Rationale Report"* shall read as follows:

*"Rating"* means a rating of the Series 2016J Notes issued by either Fitch, S&P or another NRSRO, which rating shall (a) specifically describe the Series 2016J Notes, including their interest rate, maturity and Private Placement Number and (b) in the event that such Rating is a "private letter rating," also (i) state that the Rating addresses the likelihood of payment of both the principal and interest of such Series 2016J Notes (which requirement shall be deemed satisfied if the evidence of such Rating is silent as to the likelihood of payment of both principal and interest and does not otherwise include any indication to the contrary), (ii) not include any prohibition against sharing such evidence with the SVO or any other regulatory authority having jurisdiction over the holders of the Series 2016J Notes, (iii) include such other information relating to the Rating for the Notes as may be required from time to time by the SVO or any other regulatory authority having jurisdiction over the holders of the Notes and (iv) include or be accompanied by the related Private Rating Rationale Report.

*"Private Rating Rationale Report"* means, with respect to any private Rating, a report issued by either Fitch, S&P or another NRSRO in connection with such private Rating setting forth an analytical review of the Series 2016J Notes explaining the transaction structure, methodology relied upon, and, as appropriate, analysis of the credit, legal, and operational risks and mitigants supporting the assigned private Rating for the Series 2016J Notes, in each case, on the letterhead of the Rating Agency or its controlled website and generally consistent with the work product that a Rating Agency would produce for a similar publicly rated security and otherwise in form and substance generally required by the SVO or any other regulatory authority having jurisdiction over any holder of any Series 2016J Notes from time to time.

------

SLR Investment Corp. Eighth Supplement

11. The Company covenants and agrees with the holders of the Series 2016J Notes that Section 18 of the Note Purchase Agreement shall be amended and restated in its entirety to read as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) All notices and communications provided for hereunder shall be in writing and sent (i) by tele-facsimile if the recipient has provided a fax number in its notice details and if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid), (ii) by registered or certified mail with return receipt requested (postage prepaid), (iii) by priority or express mail with online tracking services, (iv) by a recognized overnight delivery service with online tracking services (with charges prepaid) or (v) by e-mail if the recipient has provided an e-mail address in its notice details. Any such notice must be sent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (A) if to any Purchaser or its nominee, to such Purchaser or nominee at the address specified for such communications in Schedule A, or at such other address as such Purchaser or nominee shall have specified to the Company in writing,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (B) if to any other holder of any Note, to such holder at such address as such other holder shall have specified to the Company in writing, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (C) if to the Company, to the Company at its address or e-mail address set forth at the beginning hereof or in Section 12 of this Supplement, to the attention of the Chief Financial Officer, or at such other address as the Company shall have specified to the holder of each Note in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (D) if to an Additional Purchaser or such Additional Purchaser's nominee, to such Additional Purchaser or such Additional Purchaser's nominee at the address specified for such communications in Schedule A to any Supplement, or at such other address as such Additional Purchaser or such Additional Purchaser's nominee shall have specified to the Company in writing.

Notices under this Section 18 will be deemed given only when actually received. Notices delivered through electronic communications to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) Notices and other communications to the Company, Purchasers, Additional Purchasers or other holders of any Note hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites); provided that the foregoing shall not apply to notices to a Purchaser, Additional Purchaser or other holder of any Note if such Purchaser, Additional Purchaser or holder has notified the Company that it is incapable of receiving notices under this Agreement by electronic communication. Notices and other communications (i) sent to an e-mail address shall be deemed received upon the sender's receipt of an acknowledgment from the intended recipient (such as by the "return receipt requested" function, as available, return e-mail or other written acknowledgment), provided that if such notice or other communication is not sent during normal business hours of the recipient, such notice or communication shall be

------

SLR Investment Corp. Eighth Supplement

deemed to have been sent at the opening of business on the next Business Day for the recipient, and (ii) posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of the notification that such notice or communication is available and identifying the website address therefor. Unless a Purchaser, Additional Purchaser or other holder of any Note has notified the Company that it is incapable of receiving notices by electronic communication, each Purchaser, Additional Purchaser or other holder of any Note agrees to notify the Company in writing (including by electronic communication) from time to time of any change in such Purchaser's, Additional Purchaser's or holder's e-mail address to which the foregoing notice may be sent by electronic transmission and that the foregoing notice may be sent to such e-mail address.

12. Pursuant to Section 18(a)(C) of the Note Purchase Agreement and Section 14(a) of each Subsidiary Guarantee, notices and communications to (i) the Company provided for under the Note Purchase Agreement and (ii) each Guarantor under the Subsidiary Guarantees, should be sent to the address or e-mail below:

SLR Investment Corp.

500 Park Avenue, 3rd Floor

New York, New York 10022

Attention: Chief Financial Officer

Email: slr_capital_finance@slrcp.com

The execution hereof shall constitute a contract between the Company and the Series 2016J Additional Purchasers for the uses and purposes hereinabove set forth, and this agreement may be executed in any number of counterparts, each executed counterpart constituting an original but all together only one agreement. Each counterpart may consist of a number of copies hereof, each signed by less than all, but together signed by all, of the parties hereto. The parties agree to electronic contracting and signatures with respect to this agreement and the other Note Documents (other than the Notes). Delivery of an electronic signature to, or a signed copy of, this agreement and such other Note Documents (other than the Notes) by email or other electronic transmission shall be fully binding on the parties to the same extent as the delivery of the signed originals and shall be admissible into evidence for all purposes.

------

SLR Investment Corp. Eighth Supplement

SLR Investment Corp.

By:

Name:

Title:

------

SLR Investment Corp. Ninth Supplement

Accepted as of the date of this Supplement.

[Purchaser]

By: __________.

By:

Name:

Title:

------

**Information Relating to Additional Purchasers**

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>Name and Address of Additional Purchaser | &nbsp;&nbsp;Principal Amount <br>of Series 2016J <br>Notes to Be Purchased and Registered Note Number |
|  | &nbsp;&nbsp;RJ-[__] $ |

---

Schedule A

(to Supplement)

------

**Supplemental Representations**

Section 5*.* Representations and Warranties of the Company

*Section 5.1. Organization; Power and Authority*. Each of the Company and its Subsidiaries is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, has all requisite power and authority to carry on its business as now conducted and, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, is qualified to do business in, and is in good standing in, every jurisdiction where such qualification is required of the Company or such Subsidiary, as applicable.

*Section 5.2. Authorization, Etc*. The Transactions are within the Company's corporate powers and have been duly authorized by all necessary corporate action and, if required, by all necessary shareholder action. The Note Purchase Agreement and the Ninth Supplement have been duly executed and delivered by the Company and the Note Purchase Agreement as supplemented by the Ninth Supplement constitutes, and each of the other Note Documents to which it is a party when executed and delivered will constitute, a legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors' rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

*Section 5.3. Disclosure*. The Company has disclosed to the Series 2016J Additional Purchasers all agreements, instruments and corporate, limited liability company or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other information furnished by or on behalf of the Company to the Series 2016J Additional Purchasers in connection with the negotiation of the Note Purchase Agreement, the Ninth Supplement and the other Note Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished) when taken together with the Company's public filings contains any material misstatement of fact therein (or omits to state any material fact necessary to make the statements therein not misleading), in the light of the circumstances under which they were made; *provided* that, with respect to projected financial information, the Company represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time.

Since the date of the most recent Applicable Financial Statements, there has not been any event, development or circumstance that has had or could reasonably be expected to have a material adverse effect on (i) the business, Portfolio Investments and other assets, liabilities and financial condition of the Company and its Subsidiaries taken as a whole (excluding in any case a decline in the net asset value of the Company or a change in general market conditions or values of the Company's or any of its Subsidiaries' Portfolio Investments), or (ii) the validity or enforceability of any of the Note Documents or the rights or remedies of the Purchasers and the holders of the Notes thereunder.

Exhibit 1

(to Supplement)

------

*Section 5.4. Organization and Ownership of Shares of Subsidiaries*. (a) **Schedule 5.4** contains (except as noted therein) complete and correct lists (i) of the Company's Subsidiaries, showing, as to each Subsidiary, the correct name thereof, the jurisdiction of its organization, and the percentage of shares of each class of its capital stock or similar equity interests outstanding owned by the Company and each other Subsidiary (other than any tax blocker or investment held by such tax blocker), and (ii) of the Company's directors and senior officers.

(b) All of the outstanding shares of capital stock or similar equity interests of each Subsidiary shown in **Schedule 5.4** as being owned by the Company and its Subsidiaries have been validly issued, are fully paid and nonassessable and are owned by the Company or another Subsidiary free and clear of any Lien (except Permitted Liens, Liens created pursuant to the Security Documents or as otherwise disclosed in **Schedule 5.4**).

(c) Each Subsidiary identified in **Schedule 5.4** is a corporation or other legal entity duly organized, validly existing and, where legally applicable, in good standing under the laws of its jurisdiction of organization, and is duly qualified as a foreign corporation or other legal entity and, where legally applicable, is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which the failure to be so qualified or in good standing could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each such Subsidiary has the corporate or other power and authority to own or hold under lease the properties it purports to own or hold under lease and to transact the business it transacts and proposes to transact.

(d) No Subsidiary is a party to, or otherwise subject to any legal, regulatory, contractual or other restriction (other than the Note Purchase Agreement, the Ninth Supplement, the Senior Secured Credit Agreement, the agreements listed on **Schedule 5.4** and customary limitations imposed by corporate law or similar statutes) restricting the ability of such Subsidiary to pay dividends out of profits or make any other similar distributions of profits to the Company or any of its Subsidiaries that owns outstanding shares of capital stock or similar equity interests of such Subsidiary.

 *Section 5.5. Financial Statements; Material Liabilities*. The Company has heretofore delivered to each Purchaser the audited consolidated statement of assets and liabilities (or balance sheet) and statements of operations, changes in net assets and cash flows of the Company and its Subsidiaries as of and for the fiscal year ending on December 31, 2024; such financial statements present fairly, in all material respects, the consolidated financial position and results of operations and cash flows of the Company and its Subsidiaries as of such date in accordance with GAAP. The Company and its Subsidiaries do not have any Material liabilities that are not disclosed on such financial statements.

*Section 5.6. Compliance with Laws*. Each of the Company and its Subsidiaries is in compliance with all laws, regulations and orders of any Governmental Authority applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is subject

------

to any contract or other arrangement, the performance of which by the Company or any such Subsidiary could reasonably be expected to result in a Material Adverse Effect.

*Section 5.7. Governmental Authorizations, Compliance with Laws, Other Instruments, Etc*. The Transactions (a) do not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority, except for such as have been or will be obtained or made and are in full force and effect and are described in **Schedule 5.7**, (b) will not violate any applicable law or regulation or the limited liability company operating agreement, charter, by-laws or other organizational documents of the Company or any of its Subsidiaries or any order of any Governmental Authority, (c) will not violate or result in a default in any material respect under any indenture, agreement or other instrument binding upon the Company or any of its Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such Person, and (d) will not result in the creation or imposition of any Lien on any asset of the Company or any of its Subsidiaries.

 *Section 5.8. Litigation; Observance of Agreements, Statutes and Orders.* (a) There are no actions, suits, investigations or proceedings by or before any arbitrator or Governmental Authority now pending against or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries (i) as to which there is a reasonable possibility of an adverse determination and that if adversely determined could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect or (ii) that involve the Note Purchase Agreement, the Ninth Supplement, the Note Purchase Agreement as supplemented by the Ninth Supplement or the Transactions.

(b) Neither the Company nor any Subsidiary is in default under any term of any agreement or instrument to which it is a party or by which it is bound, or any order, judgment, decree or ruling of any court, arbitrator or Governmental Authority or is in violation of any applicable law, ordinance, rule or regulation of any Governmental Authority, which default or violation, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.

*Section 5.9. Taxes*. Each of the Company and its Subsidiaries has timely filed or caused to be filed all material Tax returns and reports required to have been filed and has paid or caused to be paid all material Taxes required to have been paid by it, except (a) Taxes that are being contested in good faith by appropriate proceedings and for which such Person has set aside on its books adequate reserves or (b) to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect. The charges, accruals and reserves on the books of the Company and its Subsidiaries in respect of Federal, state or other taxes for all fiscal periods are adequate in all material respects.

*Section 5.10. Title to Property; Leases*. Each of the Company and the other Obligors has good title to, or valid leasehold interests in, all its real and personal property material to its business, except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes.

------

*Section 5.11. Licenses, Permits, Etc.* Each of the Company and its Subsidiaries owns, or is licensed to use, all trademarks, tradenames, copyrights, patents and other intellectual property material to its business, and the use thereof by the Company and its Subsidiaries does not infringe upon the rights of any other Person, except for any such infringements that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.

*Section 5.12. ERISA*. (a) The execution and delivery of the Note Purchase Agreement or the Ninth Supplement and the issuance and sale of the Series 2016J Notes under the Note Purchase Agreement as supplemented by the Ninth Supplement will not involve any transaction that is subject to the prohibitions of section 406 of ERISA or in connection with which a tax could be imposed pursuant to section 4975(c)(1)(A)-(D) of the Code. The representation by the Company in the first sentence of this **Section 5.12(a)** is made in reliance upon and subject to the accuracy of such Purchaser's representation in **Section 6.2** as to the sources of the funds used to pay the purchase price of the Series 2016J Notes to be purchased by such Purchaser.

(b) No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events for which liability is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect.

*Section 5.13. Private Offering by the Company*. Neither the Company nor anyone acting on its behalf has offered the Series 2016J Notes or any similar Securities for sale to, or solicited any offer to buy any of the same from, or otherwise approached or negotiated in respect thereof with, any Person other than the Series 2016J Additional Purchasers, each of which has been offered the Series 2016J Notes at a private sale for investment. Neither the Company nor anyone acting on its behalf has taken, or will take, any action that would subject the issuance or sale of the Series 2016J Notes to the registration requirements of Section 5 of the Securities Act or to the registration requirements of any Securities or blue sky laws of any applicable jurisdiction.

*Section 5.14. Use of Proceeds; Margin Regulations*. The Company will apply the proceeds of the sale of the Series 2016J Notes for refinancing of existing debt and general corporate purposes and in compliance with all laws referenced in **Section 5.16**. Neither the Company nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the sale of the Series 2016J Notes hereunder will be used to buy or carry any Margin Stock, or to extend credit to others for the purpose of buying or carrying Margin Stock. After application of the proceeds of the sale of the Series 2016J Notes, not more than 25% of the value (as determined by any reasonable method) of the assets of the Company subject to any provision of the Note Purchase Agreement under which the sale, pledge or disposition of assets is restricted will consist of Margin Stock.

*Section 5.15. Existing Indebtedness; Future Liens*. (a) Part A of **Schedule 5.15** is a complete and correct list of each note, bond, certificate, credit agreement, loan agreement, indenture, note purchase agreement, guarantee, letter of credit or other arrangement providing for or otherwise relating to any Indebtedness or any extension of credit (or commitment for any extension of credit) to, or guarantee by, the Company or any of its Subsidiaries outstanding on the date of the Series 2016J Closing, and the aggregate principal or face amount outstanding or that

------

is, or may become, outstanding, the interest rate, collateral and related guaranties under each such arrangement is correctly described in Part A of **Schedule 5.15**.

(b) Part B of **Schedule 5.15** is a complete and correct list of each Lien securing Indebtedness of any Person outstanding or consented to on the date of the Series 2016J Closing covering any property of the Company or any Subsidiary Guarantor, and the aggregate Indebtedness secured (or that may be secured) by each such Lien and the property covered by each such Lien is correctly described in Part B of **Schedule 5.15**.

(c) Neither the Company nor any Subsidiary is a party to, or otherwise subject to any provision contained in, any instrument evidencing Indebtedness of the Company or such Subsidiary, any agreement relating thereto or any other agreement (including, but not limited to, its charter or other organizational document) which limits the amount of, or otherwise imposes restrictions on the incurring of, Indebtedness of the Company, except for the Senior Secured Credit Agreement (and the other documents related thereto) and except as specifically indicated in **Schedule 5.15**.

*Section 5.16. Foreign Assets Control Regulations, Etc*. (a) Neither the Company nor any Affiliated Entity is (i) a Person whose name appears on the list of Specially Designated Nationals and Blocked Persons published by the Office of Foreign Assets Control, United States Department of the Treasury (*"OFAC"*) (an *"OFAC Listed Person"*), (ii) an agent, department, or instrumentality of, or is otherwise beneficially owned by, controlled by or acting on behalf of, directly or indirectly, (x) any OFAC Listed Person or (y) any Person, entity, organization, foreign country or regime that is subject to any OFAC Sanctions Program, or (iii) otherwise blocked, subject to sanctions under or engaged in any activity in violation of other United States economic sanctions, including but not limited to, the Trading with the Enemy Act, the International Emergency Economic Powers Act, the Comprehensive Iran Sanctions, Accountability and Divestment Act (*"CISADA"*) or any similar law or regulation with respect to Iran or any other country, the Sudan Accountability and Divestment Act, any OFAC Sanctions Program, or any economic sanctions regulations administered and enforced by the United States or any enabling legislation or executive order relating to any of the foregoing (collectively, *"U.S. Economic Sanctions"*) (each OFAC Listed Person and each other Person, entity, organization and government of a country described in clause (i), clause (ii) or clause (iii), a *"Blocked Person"*). Neither the Company nor any Affiliated Entity has been notified that its name appears or may in the future appear on a state list of Persons that engage in investment or other commercial activities in Iran or any other country that is subject to U.S. Economic Sanctions.

(b) No part of the proceeds from the sale of the Series 2016J Notes hereunder constitutes or will constitute funds obtained on behalf of any Blocked Person or Canada Blocked Person or will otherwise be used by the Company or any Controlled Entity, directly or indirectly, (i) in connection with any investment in, or any transactions or dealings with, any Blocked Person or Canada Blocked Person, or (ii) otherwise in violation of U.S. Economic Sanctions or Canadian Economic Sanctions.

(c) Neither the Company nor any Affiliated Entity (i) has been found in violation of, charged with, or convicted of, money laundering, drug trafficking, terrorist-related activities or

------

other money laundering predicate crimes under the Currency and Foreign Transactions Reporting Act of 1970 (otherwise known as the Bank Secrecy Act), the USA PATRIOT Act, any similar provisions of the Criminal Code (Canada), any U.S. Economic Sanctions, any Canadian Economic Sanctions or any other United States or Canadian law or regulation governing such activities (collectively, *"Anti-Money Laundering Laws"*) or any U.S. Economic Sanctions violations or violations of Canadian Economic Sanctions Laws, (ii) to the Company's actual knowledge after making due inquiry, is under investigation by any governmental authority for possible violation of Anti-Money Laundering Laws or any U.S. Economic Sanctions violations or violations of Canadian Economic Sanctions Laws, (iii) has been assessed civil penalties under any Anti-Money Laundering Laws or any U.S. Economic Sanctions or Canadian Economic Sanctions Laws, or (iv) has had any of its funds seized or forfeited in an action under any Anti-Money Laundering Laws. The Company has established procedures and controls which it reasonably believes are adequate (and otherwise comply with applicable law) to ensure that the Company and each Controlled Entity is and will continue to be in compliance with all applicable current and future Anti-Money Laundering Laws and U.S. Economic Sanctions and Canadian Economic Sanctions Laws.

(d) (1) Neither the Company nor any Affiliated Entity (i) has been charged with, or convicted of bribery or any other anti-corruption related activity under any applicable law or regulation in a U.S. or any non-U.S. country or jurisdiction, including but not limited to, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and any similar provisions of the Criminal Code (Canada) (collectively, *"Anti-Corruption Laws"*) in the past five years, (ii) to the Company's actual knowledge after making due inquiry, is under investigation by any U.S. or non-U.S. Governmental Authority for possible violation of Anti-Corruption Laws, (iii) has been assessed civil or criminal penalties under any Anti-Corruption Laws in the past five years or (iv) has been or is the target of sanctions imposed by the United Nations, Canada or the European Union;

(2) To the Company's actual knowledge after making due inquiry, neither the Company nor any Affiliated Entity has, within the last five years, directly or indirectly offered, promised, given, paid or authorized the offer, promise, giving or payment of anything of value to a Governmental Official or a commercial counterparty for the purposes of: (i) influencing any act, decision or failure to act by such Governmental Official in his or her official capacity or such commercial counterparty, (ii) inducing a Governmental Official to do or omit to do any act in violation of the Governmental Official's lawful duty, or (iii) inducing a Governmental Official or a commercial counterparty to use his or her influence with a government or instrumentality to affect any act or decision of such government or entity; in each case in order to improperly obtain, retain or direct business or to otherwise secure an improper advantage in violation of any applicable law or regulation or which would cause any holder to be in violation of any Anti-Corruption Laws; and

(3) No part of the proceeds from the sale of the Series 2016J Notes hereunder will be used, directly or indirectly, for any improper payments, including bribes, to any Governmental Official or commercial counterparty in order to improperly obtain, retain or direct business or obtain any improper advantage. The Company has established procedures and controls which it reasonably believes are adequate (and otherwise comply with applicable law) to ensure that the

------

Company and each Affiliated Entity is and will continue to be in compliance with the Anti-Corruption Laws.

(e) Neither the Company nor any Affiliated Entity is (i) a Canada Blocked Person, (ii) an agent, department, or instrumentality of, or is otherwise controlled by or knowingly acting on behalf of, directly or indirectly, any such Person, or (iii) otherwise blocked, subject to sanctions under or engaged in any activity in violation of any Canadian Economic Sanctions Laws. Neither the Company nor any Affiliated Entity has been notified by a governmental authority in Canada that its name appears or has been proposed for inclusion on a list of Persons maintained by a governmental authority in Canada that engage in investment or other commercial activities in any country that is subject to Canadian Economic Sanctions Laws. Neither the Company nor any Affiliated Entity knowingly engages in any dealings or transactions with any Canada Blocked Person.

*Section 5.17. Status under Certain Statutes*. (a) The Company is a company that has elected to be regulated as a "business development company" within the meaning of the Investment Company Act and qualifies as a RIC.

(b) The business and other activities of the Company and its Subsidiaries, including the issuance of the Series 2016J Notes under the Note Purchase Agreement as supplemented by the Ninth Supplement, the application of the proceeds and repayment thereof by the Company and the consummation of the Transactions contemplated by the Note Documents do not result in a violation or breach in any material respect of the applicable provisions of the Investment Company Act or any rules, regulations or orders issued by the SEC thereunder.

(c) The Company is in compliance with its Investment Policies, except to the extent that the failure to so comply could not reasonably be expected to result in a Material Adverse Effect.

*Section 5.18. Series 2016J Notes Rank Pari Passu*. The obligations of the Company under the Note Purchase Agreement as supplemented by the Ninth Supplement and the Series 2016J Notes rank at least *pari passu* in right of payment with all other Senior Unsecured Indebtedness (actual or contingent) of the Company, including, without limitation, the Series 2016D Notes, the Series 2016E Notes, the Series 2016F Notes, the Series 2016G Notes, the Series 2016H Notes, the Series 2016I Notes and all other Senior Unsecured Indebtedness of the Company described in **Schedule 5.15** hereto.

*Section 5.19. Investments*. Set forth in **Schedule 5.19** is a complete and correct list of all Investments (other than Investments of the types referred to in clauses (b), (c) and (d) of **Section 10.4**) held by the Company or any Subsidiary Guarantor in any Person on the date of the Series 2016J Closing and, for each such Investment, (x) the identity of the Person or Persons holding such Investment and (y) the nature of such Investment. Except as disclosed in **Schedule 5.19**, as of the date of the Series 2016J Closing each of the Company and the Subsidiary Guarantors owns, free and clear of all Liens (other than Permitted Liens or Liens created pursuant to the Security Documents), all such Investments.

------

 *Section 5.20. Affiliate Agreements.* As of the date of the Series 2016J Closing, the Company has heretofore delivered (to the extent not otherwise publicly filed with the SEC) to each of the Purchasers true and complete copies of each of the Affiliate Agreements (including schedules and exhibits thereto, and any amendments, supplements or waivers executed and delivered thereunder). As of the date of the Series 2016J Closing, each of the Affiliate Agreements is in full force and effect.

------

## Exhibit 23.1

**Exhibit 23.1** 

November 4, 2025

SLR Investment Corp.

New York, New York

Re: Registration Statement No. 333-278755

With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated November 4, 2025 related to our review of interim financial information.

Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a registration statement prepared or certified by an independent registered public accounting firm, or a report prepared or certified by an independent registered public accounting firm within the meaning of Sections 7 and 11 of the Act.

/s/ KPMG LLP

New York, New York

------

## Exhibit 31.1

**EXHIBIT 31.1** 

**CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002** 

I, Michael S. Gross, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of SLR Investment Corp.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 4th day of November, 2025

---

| |
|:---|
| /s/ MICHAEL S. GROSS |
| **Michael S. Gross**<br>**Co-Chief Executive Officer** |

---

------

## Exhibit 31.2

**EXHIBIT 31.2** 

**CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002** 

I, Bruce J. Spohler, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of SLR Investment Corp.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 4th day of November, 2025

---

| |
|:---|
| /s/ BRUCE J. SPOHLER |
| **Bruce J. Spohler**<br>**Co-Chief Executive Officer** |

---

------

## Exhibit 31.3

**EXHIBIT 31.3** 

**CERTIFICATION OF CHIEF FINANCIAL OFFICER** 

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002** 

I, Shiraz Y. Kajee, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of SLR Investment Corp.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 4th day of November, 2025

---

| |
|:---|
| /s/ SHIRAZ Y. KAJEE |
| **Shiraz Y. Kajee**<br>**Chief Financial Officer** |

---

------

## Exhibit 32.1

**EXHIBIT 32.1** 

**CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)** 

In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2025 (the "Report") of SLR Investment Corp. (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, MICHAEL S. GROSS, the Co-Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | |
|:---|:---|
|  | /s/ MICHAEL S. GROSS |
| **Name:** | **Michael S. Gross**<br>**Co-Chief Executive Officer** |
| **Date:** | **November 4, 2025** |

---

------

## Exhibit 32.2

**EXHIBIT 32.2** 

**CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)** 

In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2025 (the "Report") of SLR Investment Corp. (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, BRUCE J. SPOHLER, the Co-Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | |
|:---|:---|
|  | /s/ BRUCE J. SPOHLER |
| **Name:** | **Bruce J. Spohler**<br>**Co-Chief Executive Officer** |
| **Date:** | **November 4, 2025** |

---

------

## Exhibit 32.3

**EXHIBIT 32.3** 

**CERTIFICATION OF CHIEF FINANCIAL OFFICER** 

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)** 

In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2025 (the "Report") of SLR Investment Corp. (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, SHIRAZ Y. KAJEE, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | |
|:---|:---|
|  | /s/ SHIRAZ Y. KAJEE |
| **Name:** | **Shiraz Y. Kajee**<br>**Chief Financial Officer** |
| **Date:** | **November 4, 2025** |

---

------